Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  1 of 113 22 Sep 2023 INITIUM  Protocol  
A Randomized Phase II, Open -label, Active -controlled, Multicenter Study 
Investigating the Efficacy and Safety of UV1 Vaccination in Combination with 
Nivolumab and Ipilimumab as First -line Treatment of Patients with 
Unresectable or Metastatic Melanoma  (UV1 -202)  
 
Protocol Number , Version and Date : 
UV1 -202, Version  5.0 (Final), 22 Sep 2023 
Study Phase : 
Phase II  
Sponsor Name and Legal Registered Address:  
Ultimovacs AS A 
Ullernchausséen 64, N-0379 Oslo, Norway  
 
Regulatory Agency Identifying Number s: 
Investigational New Drug:  17546  
EudraCT:    2019 -002026 -75 
 
 
Information described herein is confidential and may be disclosed only with the express written 
permi ssion of the Sponsor.  
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  2 of 113 22 Sep 2023 Sponsor:  
 
 
Øivind Foss, DrSc  
Head of Clinical Operations, Ultimovacs ASA   Date  
 
 
Kevin J. Carroll, Dr  
Consultant Statistician, KJC Statistics   Date  
 
 
Jens Bjørheim , MD, PhD  
Chief Medical Officer , Ultimovacs AS A  Date  
 
 
 
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  3 of 113 22 Sep 2023 Table of Contents  
 
Table of Contents  ................................ ................................ ................................ ............................  3 
List of In -text Tables and Figures  ................................ ................................ ................................ ... 7 
1 Synopsis  ................................ ................................ ................................ ................................ .... 8 
2 Introduction ................................ ................................ ................................ .............................  18 
2.1 Malignant Melanoma ................................ ................................ ................................ ........... 18 
2.2 Checkpoint Inhibitors for Advanced Malignant Melanoma  ................................ ................ 18 
2.2.1  Checkpoint Inhibitors Monotherapy  ................................ ................................ ...............  18 
2.2.2  Combination of Nivo lumab and Ipilimumab  ................................ ................................ . 19 
2.3 The UV1 Vaccine  ................................ ................................ ................................ ................ 20 
2.4 Clinical Data on UV1 Vaccination  ................................ ................................ ...................... 21 
2.5 Rationale for Combination of UV1 with Checkpoint Inhibitors  ................................ ......... 24 
2.6 Rationale for Dose and Administration Regimen  ................................ ................................ 25 
2.7 Rationale for Study Design  ................................ ................................ ................................ .27 
2.8 Benefit/Risk Assessment  ................................ ................................ ................................ .....28 
3 Objectives and Endpoints  ................................ ................................ ................................ ....... 30 
4 Study Design  ................................ ................................ ................................ ...........................  31 
4.1 Overall Design  ................................ ................................ ................................ ..................... 31 
4.2 Measures to Minim ize Bias: Randomization and Blinding  ................................ ................. 34 
5 Study Population  ................................ ................................ ................................ .....................  35 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................. 35 
5.2 Exclusion Criteria  ................................ ................................ ................................ ................ 36 
6 Treatments  ................................ ................................ ................................ ..............................  38 
6.1 Study Drugs  ................................ ................................ ................................ ......................... 38 
6.1.1  Sargramostim  ................................ ................................ ................................ ..................  38 
6.1.2  UV1  ................................ ................................ ................................ ................................  39 
6.1.3  Nivolumab  ................................ ................................ ................................ ......................  40 
6.1.4  Ipilimumab  ................................ ................................ ................................ .....................  40 
6.1.5  Administration of Study Drugs  ................................ ................................ ......................  40 
6.1.6  Preparation/Handling/Storage/Accountability  ................................ ...............................  41 
6.1.7  Treatment of Allergic Reactions to UV1 Vaccination  ................................ ....................  42 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  4 of 113 22 Sep 2023 6.1.8  Dose Modification  ................................ ................................ ................................ ..........  42 
6.1.9  Overdose  ................................ ................................ ................................ .........................  42 
6.2 Concomitant Medication  ................................ ................................ ................................ .....43 
6.2.1  Prohibited Medications During Induction Period  ................................ ...........................  43 
6.2.2  Permitted Medications During Induction Period  ................................ ............................  43 
6.2.3  New Anticancer Treatment  ................................ ................................ .............................  44 
6.3 Treatment After Progressive Disease  ................................ ................................ .................. 44 
7 Study Duration and Schedule of Activities  ................................ ................................ .............  45 
7.1 Screening  ................................ ................................ ................................ ............................. 50 
7.1.1  Screen Failures  ................................ ................................ ................................ ...............  50 
7.2 Induction Period  ................................ ................................ ................................ .................. 50 
7.2.1  Discontinuation of Induction Therapy  ................................ ................................ ............  50 
7.3 Follow -up Period  ................................ ................................ ................................ ................. 52 
7.3.1  Safety Follow -up Visit  ................................ ................................ ................................ .... 52 
7.3.2  Response Follow -up Visits  ................................ ................................ .............................  52 
7.3.3  Survival Follow -up Visits  ................................ ................................ ...............................  53 
7.4 Withdrawal of Consent  ................................ ................................ ................................ ........ 54 
7.5 Lost to Follow -up ................................ ................................ ................................ ................ 54 
7.6 End of Study  ................................ ................................ ................................ ........................ 55 
8 Study Assessments and Procedures  ................................ ................................ ........................  56 
8.1 Efficacy Assessments  ................................ ................................ ................................ .......... 56 
8.1.1  Assessment of Tumor Response  ................................ ................................ .....................  56 
8.2 Safety Plan and Assessmen ts ................................ ................................ ............................... 57 
8.2.1  Independent Data Monitoring Committee  ................................ ................................ ...... 58 
8.2.2  Physical Examinations  ................................ ................................ ................................ .... 59 
8.2.3  Vital Signs  ................................ ................................ ................................ ......................  59 
8.2.4  Eastern Cooperative Oncology Group  ................................ ................................ ............  59 
8.2.5  Clinical Safety Laboratory Assessments  ................................ ................................ ........  59 
8.2.6  Toxicity of the Study Drugs ................................ ................................ ............................  60 
8.3 Adverse Events  ................................ ................................ ................................ .................... 60 
8.3.1  Definitions  ................................ ................................ ................................ ......................  60 
8.3.2  Classification of Adverse Events  ................................ ................................ ....................  63 
8.3.3  Adverse Event Reporting and Follow -up ................................ ................................ ....... 65 
8.3.4  Expedited Reporting  ................................ ................................ ................................ ....... 67 
8.3.5  Regulatory Reporting Requirements for Investigator and Sponsor  ...............................  67 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  5 of 113 22 Sep 2023 8.3.6  Pregnancy  ................................ ................................ ................................ .......................  68 
8.4 Exploratory Assessments  ................................ ................................ ................................ .....69 
8.4.1  Biomarkers  ................................ ................................ ................................ .....................  70 
8.5 Extended Exploratory Cohort  ................................ ................................ .............................. 70 
8.6 Single Arm UV1 Cohort  ................................ ................................ ................................ ......70 
9 Statistical Methods ................................ ................................ ................................ ..................  71 
9.1 Statistical Hypothesis  ................................ ................................ ................................ .......... 71 
9.2 Sample Size Determination  ................................ ................................ ................................ .71 
9.3 Analysis Populations  ................................ ................................ ................................ ........... 72 
9.4 Statistical Analysis ................................ ................................ ................................ ............... 72 
9.4.1  General Considerations  ................................ ................................ ................................ .. 72 
9.4.2  Efficacy Analyses  ................................ ................................ ................................ ...........  72 
9.4.3  Safety Analyses  ................................ ................................ ................................ ..............  74 
9.4.4  Exploratory Analyses  ................................ ................................ ................................ ...... 74 
9.5 Timing of the Analyses  ................................ ................................ ................................ ........ 74 
10 Regulatory, Ethical, and Study Oversight Considerations ................................ ......................  76 
10.1  Regulatory and Ethical Considerations  ................................ ................................ ............... 76 
10.2  Financial Disclosure  ................................ ................................ ................................ ............ 76 
10.3  Informed Consent Process  ................................ ................................ ................................ ...77 
10.4  Data Protection  ................................ ................................ ................................ .................... 77 
10.5  Dissemination of Clinical Study Data  ................................ ................................ ................. 78 
10.6  Data Quality Assurance  ................................ ................................ ................................ .......78 
10.7  Source Documents  ................................ ................................ ................................ ............... 78 
10.8  Study and Site Closure  ................................ ................................ ................................ ........ 79 
10.9  Publication Policy  ................................ ................................ ................................ ................ 80 
10.10  Protocol Approval and Amendment  ................................ ................................ .................... 80 
10.11  Liability and Insuran ce ................................ ................................ ................................ ........ 80 
10.12  Access to Source Data  ................................ ................................ ................................ ......... 81 
Appendix  1 Clinical Laboratory Tests  ................................ ................................ ..........................  82 
Appendix  2 Extended Exploratory Cohort (N= approximately 40 patients)  ................................  84 
Appendix  3 Eastern Cooperative Oncology Group Performance Status Scale  ............................  90 
Appendix  5 Abbreviations  ................................ ................................ ................................ ............  95 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  6 of 113 22 Sep 2023 Appendix  7 Single Arm UV1 Cohort ................................ ................................ ..........................  101 
Appendix  8 Protocol Version Log  ................................ ................................ ...............................  103 
Declaration of the National Coordinating Investigator  ................................ ................................  112 
Declarati on of the Principal Investigator  ................................ ................................ .....................  113 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  7 of 113 22 Sep 2023 List of In -text Tables and Figures  
TABLES  
Table  1 Summary of Completed, Ongoing, and Planned Clinical Studies for UV1 
Vaccination  ................................ ................................ ................................ ............  22 
Table  2 Study Drugs (Induction Period)  ................................ ................................ ............  38 
Table  3 Instructions for Preparation of Sargramostim  ................................ .......................  39 
Table  4 Instructions for Preparation of UV1  ................................ ................................ ..... 39 
Table  5 Schedule of Activities – Experimental Arm ................................ ..........................  46 
Table  6 Schedule of Activities – Control Arm  ................................ ................................ ... 48 
Table  7 Local Laboratory Analysis (all patients, N=154)  ................................ ..................  82 
Table  8 Central Laboratory Sampling for Exploratory Analyses (all patients, N=154)  .... 83 
Table  9 Extended Exploratory Cohort Assessments – Experimental Arm  ........................  86 
Table  10 Extended Exploratory Cohort Assessments – Control Arm  ................................ .. 86 
FIGURES  
Figure  1 Estimated Timelines  ................................ ................................ ..............................  32 
Figure  2 Study Design  ................................ ................................ ................................ .........  32 
Figure  3 McBurney’s Point  ................................ ................................ ................................ . 41 
Figure  4 Time Periods for Reporting Adverse Events, Serious Adverse Events  .................  65 
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  8 of 113 22 Sep 2023 1 Synopsis  
INITIUM Protocol  
Protocol Title : 
A Randomized Phase  II, Open -label, Active -controlled, Multicenter Study Investigating the 
Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as 
First-line Treatment of Patients with Unresectable or Metastatic Melanoma  (UV1 -202) 
Protocol Number , Version:  
UV1 -202, Version 5.0 (Final ), 22 Sep 2023 
Study Phase: 
Phase II  
Study Sites: 
The study is planned to be conducted at 40 study sites in Europe  (approximately 16 sites) and the 
United States (approximately 24 sites). 
Number of Patients:  
A total of 154  patients will be randomized. It is estimated that approximately 200  patients will be 
screened to randomize 154  patients.  In addition , 20 patients will be enrolled in a single arm UV1  
cohort  for exploratory purposes only.  The single arm UV1 cohort is planned to start after 
154 patients have been randomized  in the main study .   
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  9 of 113 22 Sep 2023 Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To compare progression  free survival (PFS) of 
UV1 vaccination * in combination with 
nivolumab and ipilimumab  to that of nivolumab 
and ipilimumab   Primary  
• PFS per Response Evaluation Criteria in 
Solid Tumors ( RECIST ) 1.1 
Time from  randomization to progress ive 
disease (PD) or death from  any cause   
Secondary  
• To compare overall survival (OS) of UV1 
vaccination in combination with nivolumab and 
ipilimumab to that of nivolumab and ipilimumab  Secondary  
• OS 
Time from  randomization to death from  
any cause   
• To compare the objective response rate (ORR) of 
UV1 vaccina tion in combination with nivolumab 
and ipilimumab  to that of nivolumab and 
ipilimumab  • ORR per RECIST 1.1  
Proportion of patients with a best response 
of complete response (CR) or partial 
response (PR)   
• To compare duration of response (DOR) of UV1 
vaccination in combination with nivolumab and 
ipilimumab  to that of nivolumab and ipilimumab  • DOR per RECIST 1.1  
Time from  first CR  or PR to PD or death 
from  any cause   
• To compare the safety of UV1 vaccination in 
combination with nivolumab and ipilimumab to 
that of nivolumab and ipilimumab  • Adverse events  (AEs) , deaths, vital signs, 
laboratory assessments, and Eastern 
Cooperative Oncology Group ( ECOG ) 
performance  status  
Exploratory  
• To elucidate the immunological mechanisms 
underlying the interplay between immune 
activation provoked by UV1 vaccination and 
inhibi tion of tumor resistance mechanisms and 
peripheral immune tolerance induced by 
checkpoint blockade, and how biological factors 
affect the efficacy of the combination therapy  Exploratory  
• Change in immune - and tumor -related 
gene , cell , and protein profiles i n blood 
over time in both treatment arms (analysis 
of plasma proteins, cell -free plasma DNA , 
and cellular genomic DNA)  
• Other endpoints related to analysis 
conducted on biological material collected 
from the Extended Exploratory Cohort  
* UV1 vaccination includes sargramostim, used as a vaccine adjuvant, and UV1  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  10 of 113 22 Sep 2023 Study Design and Methodology  
This is a randomized, open -label, active -controlled , multicenter study to investigate efficacy and 
safety of UV1 vaccination in combination with nivolumab  and ipilimumab as first -line treatment 
of adult patients (≥18  years) with histologically confirmed unresectable metastatic melanoma.  
This study will consist of 3 phases : Screening, Induction period , and a Follow -up period . The 
Follow -up period includes safety, response , and survival follow -up visits.  
After a Screening period of up to 28 days, eligible patients will be randomized in a 1:1 ratio to 
receive induction therapy : UV1 vaccination in combination with nivolumab and ipilimumab  in 
an experimental arm , and nivolumab and ipilimumab in a control arm.  Randomization can occur 
after all Screening procedures have been completed (up to 3  days [from Day  -3 until Day  1] prior 
to first dosing on Day 1) and eligibility has been confirmed.  
Patients i n the experimental arm will receive 8  UV1 vaccination s over 4  cycles of nivolumab and 
ipilimumab. The UV1 vaccination will be administered  alone on Days 1, 3 to 7 (2 UV1 
vaccinations  within Day  3 to Day  7; consecutive dosing days not allowed ), and 26, and in 
combination with nivolumab and ipilimumab on Days 10, 31, 52 , and 73.  
Patients i n the control arm will receive 4  cycles of nivolumab and ipilimumab  on Days 1, 22, 43 , 
and 64.  
Patients in both arms will start maintenance therapy 6 weeks after last dose of induction therapy . 
The maintenance therapy is  nivolumab at a dose of 480  mg every 4  weeks (Q4W) according to 
the label . It is not allowed to use any other dose of maintenance t herapy (eg, 240  mg every 
2 weeks) . 
The study is event driven. The primary and secondary endpoints will be analyzed at the earliest 
of either  (hereinafter referred to as “PFS cut -off date”)  70 PFS events  reached across both 
treatment arms  or 18 months post last patient randomized , at which  time sponsor will notify the 
sites. From the PFS cut-off date , patients will be followed for a further 24 months for additional 
survival data; further analyses of OS data will be performed until defined end  of study to provide 
evidence supportive of PFS.  
All patients will be followed up until death or until the end of study (EOS) , whichever comes 
first. Estimated timelines at start of the study are outlined below.  
 
First Patient In   Last Patient In  70 PFS events reached   End of Study  
          
          
0 months   15 months  27 months   51 months  
The e stimated inclusion period is 15  months ; the e stimated time from last randomization to 70 
PFS events reached is 12  months ; the estimated time from 70 PFS events to EOS is 24  months  
and the t otal study duration is estimated to be 51 months  from first patient in . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  11 of 113 22 Sep 2023 The s tudy design and treatment are outlined below . 
 
 
 
 
 
 
 
 
 
 
The UV1 vaccination includes sargramostim , used as a vaccine adjuvant,  at a dose of 75  µg and 
UV1 at a dose of 300  µg. Sargramostim is a granulocyte -macrophage -colony -stimulating factor . 
Nivolumab and ipilimumab are dosed according to label in both treatment arms : induction 
therapy of nivolumab (1  mg/kg every 3  weeks [Q3W ]) and ipilimumab (3  mg/kg  every 3 weeks 
[Q3W ]), and maintenance therapy of nivolumab (480  mg every 4 weeks  [Q4W ]). 
Sargramostim and U V1 should be administered  intradermally  and injected at the same 
injection site  (McBurney’s point) each time, located 1/3 of the distance from the anterior 
superior iliac spine to the umbilicus  on the right side of the abdomen (or corresponding spot on 
the left side in case of appendectomy scar) . Sargramostim is administered 10  to 15 minutes prior 
to each UV1 treatment. Nivolumab and ipilimumab are administered intravenously, starting  at 
least 1  hour after the administration  of UV1.  
Following the last dose of induction therapy, the patient will then enter the Follow -up period and 
perform a safety follow -up visit 30  days post last dose of induction therapy.  
Tumor assessment will be done locally at the  study  site using RECIST 1.1 and immune Response 
Evaluation Criteria in Solid Tumors ( iRECIST ) criteria. Tumor imaging will be performed 
within 14 days prior to randomization and then on Week 12 and Week 19 post randomization. 
Subsequent response follow -up imaging will be performed every 8  weeks for 32  weeks and then 
every 12  weeks . 
Patients with PD per RECIST  1.1 will have a new scan 4 to 8 weeks later to confirm PD per 
iRECIST. Patients with immune unconfirmed PD per iRECIST (iUPD) , will continue at the 
Screening period         Induction period               Follow -up period   
 (Days -28 to -1)        (Days 1 to 73 / Days 1 to 64)                            (4 - 5 years)  
             
 
 
First-line 
unresectable IIIB-D 
or unresectable IV 
metastatic melanoma  
Experimental arm  
 
UV1 vaccination :  
Administ ered on Days 1, 3-7 (2 UV1 
vaccinations ), 10, 26, 31, 52, and 73  
 
Nivolumab and ipilimumab :  
Administered on Days 10, 31, 52 , and 
73 
All patients  
Safety follow -up 
Response follow -up 
Survival follow -up 
 
At the earliest  of either 70 PFS 
events reached  or 18 months 
post last patient randomized , 
all patients will be followed -
up for 2  years  
 
Nivolumab maintenance 
therapy ( 480 mg Q4W) 
according to label  
Rand  
1:1  
N = 154  
Control arm  
 
Nivolumab and ipilimumab :  
Administered on Days 1, 22, 43 and 64  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  12 of 113 22 Sep 2023 Investigator’s  discretion, with tumor imaging and treatment per protocol until  immune confirmed 
PD per iRECIST  (iCPD) , until 70 PFS events are reached  or until 18 months post last patient 
randomized (whatever comes first) . Patients with iCPD per iRECIST will be disconti nued from 
treatment and will proceed into the survival follow -up phase and be contacted per phone (or, at 
the investigator’s discretion visit the hospital)  every 12  weeks until the earliest of either 70 PFS 
events reached  or 18 months post last patient randomized . From the PFS cut-off date , the 
survival follow -up will continue in all patients every 6 months for 2 years.   
To reduce bias in evaluation of the efficacy endpoints, t umor evaluation for the statistical 
analysis of the efficacy endpoints  will be done by Blinded Independent Central Review ( BICR ) 
according to the RECIST  1.1 criteria. All images must be submitted to the central imaging 
vendor, but the results from the BICR will not be provided to the study site . Two independent 
radiologists will perform the central imaging review without knowledge of treatment 
assignments. If there are discrepancies between the 2 readers, a standardized procedure involving 
a third reviewer for adjudication will take place.  
From signing of the Informed Consent Form  (ICF) until the first dose of induction therapy , only 
AEs/serious A Es (SAEs)  caused by study -specific procedures should be reported. Non-serious 
AEs should be reported from the first dose of induction therapy until 30  days after the last dose 
of induction therapy, or until new anticancer treatment is initiated (whichever comes first). All 
SAEs should be reported from the first dose of induction therapy until  70 PFS events are 
reached , until 18 months  post last patient randomized or until new an ticancer treatment is 
initiated  (whichever comes first). Adverse events and SAEs that are ongoing beyond the required 
reporting timelines shall be followed up locally per institutional practice until resolution or 
stabilization or the patient is lost to fo llow up .  
During the study, a n Independent Data Monitoring Committee will monitor safety information to 
ensure patient safety . 
Patients at selected sites will have the option to be Included in the Extended Exploratory Cohort 
of the study. This cohort of approximately 40  patients, randomized in a 1:1 ratio to either of the 
2 treatment arms, will have additional sampling of blood, tissue, and feces for exploratory 
purposes. A biobank wi ll be established for current and future analysis of the samples collected.  
To support the Extended Exploratory Cohort of the study, an additional 20 patients will be 
enrolled  in a single arm UV1 cohort for collection of additional biological material  (Appendix  7 
Single Arm UV1 Cohort ). These patients will receive the same study treatment as patients in the 
experimental arm . 
Study Population  
Inclusion Criteria  
Patients are eligible for randomization if all of the following criteria are met:  
1. Male or female patients at least 18  years of age at the time of signing the ICF. 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  13 of 113 22 Sep 2023 2. Histologically confirmed diagnosis of unresectable stage IIIB -D, or unresectable stage  IV 
malignant melanoma. Patient must have at least 1  measurable lesion at Screening 
according to the RECIST  1.1 criteria.  
Note that lesions not measurable on compute d tomography  or magnetic resonance 
imaging ( MRI ) will be considered as non -measurable lesions.  
3. Eligible for combina tion treatment with nivolumab and ipilimumab . 
4. An ECOG performance status of 0 or 1 . 
5. Adequate organ function as indicated by the following laboratory values:  
Hematological  
a. Absolute neutrophil count ≥1,500/µL  
b. Platelet  count  ≥100 x 103/µL 
c. Hemoglobin ≥9 g/dL or ≥5.6  mmol/L  
Renal  
d. Creatinine ≤1.5 x upper limit of normal (ULN)  
Hepatic  
e. Total bilirubin ≤1.5 x ULN or  
direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5  ULN  
f. Aspartate aminotransferase/ glutamic -oxaloacetic transaminase  and alanine  
aminotransferase/ glutamic -pyruvic transaminase  ≤2.5 x ULN for patients without 
liver metastasis or ≤5 x ULN for patients with liver metastasis . 
6. Male patients who are sexually active with a female of childbearing potential must agree 
to use an adequate met hod of contraception prior to the first dose through 5 months  after 
the last dose of UV1  vaccination, nivolumab , or ipilimumab , whichever is administered 
last. The recommended method is using a male condom.  
7. Women  of childbearing potential (WOCBP) must have a negative urine or serum /plasma  
pregnancy test. If the urine test is positive or cannot be confirmed as negative, a 
serum /plasma  pregnancy test will be performed . The serum /plasma  pregnancy test must 
be negativ e for the patient to be eligible.  
8. WOCBP must use adequate contraception . Adequate contraception must be maintained 
throughout the study, starting with the first dose through 5 months  after the last dose of 
UV1  vaccination, nivolumab , or ipilimumab , whichever is administered  last. The 
acceptable contraceptive methods for WOCBP included in the study are: 
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal , or transdermal), progestogen -only hormonal 
contraception associated with inhibition of ovulation (oral, injectable , or implantable), 
Intrauterine device  (IUD) , Intrauterine hormone -releasing system  (IUS) , bilateral tubal 
occlusion, vasectomized  partner  (provided that the partner is the sole sexual partner of the 
WOCBP trial participant and that the vasectomized partner has received medical 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  14 of 113 22 Sep 2023 assessment of the surgical success) , or sexual abstinence  (if this  is the preferred and usual 
lifestyle of the subject)   
9. Written informed consent prior to any study -specific procedures . 
Exclusion Criteria  
Patients are not eligible for randomization if any of the following criteria a re met : 
1. Previous non -melanoma malignanc ies unless curatively -treated and complete remission 
was achieved at least 2  years prior to randomization. Patients with prior curatively -treated 
basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix , or 
carcinoma in situ of the breast, or other in situ cancers are allowed irrespective of time 
passed since curative treatment. Patients with prior completely resected malignant 
melanoma are also allowed . 
2. Known brain metastases or leptomeningeal metastases . If a patient experiences 
neurological symptoms indicative of brain metastases, a brain MRI should be performed.  
3. Diagnosis of uveal or ocular melanoma . 
4. Known history or any evidence of active, non -infectious pneumonitis . 
5. History of New York Heart Associat ion class 3 -4 congestive heart failure or history of 
myocardial infarction within 6 months of starting induction therapy . 
6. Active infection requiring systemic treatment . 
7. Diagnosis of immunodeficiency . 
8. Known history of severe hypersensitivity reactions to nivolumab, ipilimumab, 
sargramostim , or their excipients . 
9. Known h istory of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) . No HIV 
testing is required unless mandated by local health authority.  
10. History of or active hepatitis B ( hepatitis B surface an tigen  reactive) or  active  hepatitis C 
(hepatitis C virus antibody ). Testing must be performed to determine eligibility.  
11. Women who are breastfeeding . 
12. Prior systemic treatment for unresectable stage IIIB-D or unresectable stage IV malignant 
melanoma . Prior systemic BRAF/MEK inhibitors or immunotherapy as neoadjuvant or 
adjuvant or other setting treatment of stage I -IIIA, resectable III B-D, or resectable  IV if 
patient progressed earlier than 6 months after l ast dose of such treatment.  
13. Systemic cortico steroid treatment (doses exceeding 10  mg daily of prednisone or 
equivalent) or any other form of immunosuppressive treatment within 7  days prior to the 
first dose of induction therapy . Topical, ocular, intra-articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption) are allowed. Physiologic replacement 
doses of systemic corticosteroids , a brief course of corticosteroids for prophylaxis 
(eg, contrast dye allergy) or for tre atment of non -autoimmune conditions is permitted  even 
with >10  mg/day prednisone equivalents . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  15 of 113 22 Sep 2023 14. Receipt of  a live vaccine within 30 days prior to start of induction therapy . 
15. Recei pt of any other investigational treatment within 4 weeks of the first dose of induction 
therapy . 
16. Any medical, psychological, or social condition that would make it difficult for the patient 
to participate in the study and comply with the study procedures, restrictions , and 
requirements.  
Statistical Methods  
Statistical Hypothesis  
The primary endpoint is PFS. Under the null hypothesis, the PFS hazard ratio (HR)  for UV1 
vaccination in combination with  nivolumab and ipilimumab versus nivolumab and ipilimumab  is 
assumed to be unity. Under the alternative hypothesis, the PFS HR is assumed to be 0.60 or 
better, representing a beneficial effect on PFS for UV1 vaccination in combination with 
nivolumab and ipilimumab  compared to nivolumab and ipilimumab . 
Sample Size Determination  
To test the PFS null hypothesis with 80% power and a 1 -sided alpha level of 0.10, a total of 
70 PFS events are required. To generate the required 70  PFS events , 154 patients will be 
randomized over a 15 -month period and followed thereafter for a minimum of 12  months . This 
will give  a mean follow -up of PFS events of approximately 20  months . 
As of 1 9 September 2023, blinded event accrual stood  at 63 PFS events. A blinded examination 
of the overall PFS Kaplan Meier curve made as of 23 July 2023 , and then repeated as of 1 9 
September 2023 , showed strong evidence for a pla teau at 54 to 55% of subjects alive and without 
progression. Such a PFS curve plateau is not uncommon for IO therapies. In CheckMate 67, 
nivolumab plus ipilimumab, nivolumab alone and ipilimumab alone were evaluated in advanced 
melanoma (Hodi 2018). This s tudy formed the basis of the sample size calculations for the 
current study and showed a prolonged PFS tail for nivolumab plus ipilimumab plateauing at 
approximately 40% subjects alive and without progression. However, the blinded data realized 
thus far , has shown a higher plateau at 54 to 55% subjects alive and without progression . 
Specifically, there seems to be very little contribution to PFS events after 18 months in the study, 
with the PFS curve nearing asymptote. The plateau in the current study commences at 
approximately 21 months post first subject randomized with an estimated 56.02 % of subjects 
alive and without progression and persists  thereafter  for 15 months, out to 36 months at which 
time 54.32 % subjects are alive and w ithout progression, i.e. an increase in the progression rate of 
only 1.7% over 15 months. Based on the projected PFS curve, 70 PFS events are not expected to 
be reached until late 2028 at which time 69.3 events, 9 0% CI of (6 9.2, 72.3) , are expected.  
Given  the observed plateau in the accrual of PFS events, it has been decided to execute the 
primary analysis of PFS at the earliest of either 70 PFS events  reached across both treatment 
arms or 18 months post last patient randomized .   
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  16 of 113 22 Sep 2023 Timing of Analyses  
It sho uld be noted that this study is event driven so that the timing of the primary endpoint 
analysis is dependent upon the attainment of 70  PFS events and is not calendar based. Based on 
the assumptions supporting the sample size calculation  (Hodi, 2018) , it is expected that 70  PFS 
events will have accrued at around 27 months  after the first patient is randomized.  
However, a s of 1 9 September 2023, blinded event accrual stood  at 63 PFS events. A blinded 
examination of the overall PFS Kaplan Meier curve made as of 23 July 2023 , and then repeated 
as of 1 9 September 2023 , showed strong evidence for a plateau at 55% of subjects alive and 
without progression.  Given the observed plateau in the accrual of PFS events, it has been decided 
to execute the primary analysis of PFS at the earliest of either 70  PFS events  reached across both 
treatment arms or 18 months post last patient randomized .     
The secondary endpoints will also be analy zed at the earliest of  either  70 PFS events  reached 
across both treatment arms  or 18 months post last patient randomized . Follow -up for survival 
will continue for an additional 24 months after the PFS cut-off date  at which time 60 deaths are 
expected to have accrued.  
Primary Efficacy Analys es 
A Cox proportional hazards regression model  will be used to analyze PFS. The HR will be 
estimated from the model along with the associated 2 -sided confidence interval (CI) and 2 -sided 
p-value. The data will also be displayed using Kaplan -Meier  curves and median PFS times will 
be estimated. The PFS at 12  months will be estimated from the Kaplan -Meier  curves along with 
the associated 80% and 95% CI s. 
Note, patients who withdraw consent to follow -up may have missing PFS data. The impact of 
such patients on the analysis will be explored via imputation and possibly tipping point analyses. 
Full details will be provided in the Statistical Analysis Plan (SAP).  
Secondary Efficacy Analys es 
Overall Survival  will be analyzed in a fashion similar to that described for PFS  at the time of the 
PFS analys is. Patients who withdraw consent to follow -up may have missing OS data . The 
impact of such patients on the analysis will be explored via imputation and possibly tipping point 
analyses. Full details will be provided in the SAP.  Additionally, follow -up for survival will 
continue for a further 24 months after the PFS analysis at which time 60 deaths are expected to 
have accrued.  
Objective Response Rate  will be analyzed by exact logistic regression . Patients who have 
missing tumor assessment data leading to mi ssing objective response data will be included in the 
analysis as non -responders.  
Duration of Response will be analyzed via Cox regression modelling.  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
 
Version 5.0 (FINAL)  17 of 113 22 Sep 2023 Safety Analys es 
Adverse events will be summarized descriptively by treatment  group , in terms of body system 
and Medical Dictionary for Regulatory Activities  preferred term. A dverse event s will be 
summarized in terms of the number of patients and percentage of patients experiencing related 
AEs, SAEs , AEs leading to dose interruption, AEs  leading to withdrawal from randomized 
treatment , and AEs leading to death.  
Laboratory values, ECOG performance status , and vital signs will be summarized.  
Planned Timelines  
First patient in:      Q2 2020  
Last patient in:       H1 2022 
Primary endpoint rea d out:      H1 2024 
End of study:        H1 2026 
The First Patient In  is defined as the timepoint  when the first patient is randomized.   
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  18 of 113 22 Sep 2023 2 Introduction  
2.1 Malignant Melanoma  
Worldwide over 280,000  new cases of malignant melanoma were diagnosed in 2018, and it is 
estimated that more than 60,000  persons died from the disease.1  
There are 4 main subtypes of cutaneous melanomas: superficial spreading melanoma, nodular 
melanoma, lentigo malignant melano ma, and acral lentiginous melanoma. These can be 
clinically and histologically defined based on overall appearance, location , and histologic 
features of the melanocytes. The most common risk factors are of phenotypic (fair skin), genetic 
(inheriting melanocortin -1 receptor variant; presence  of high numbers of common naevi, large 
congenital naevi, multiple , and/or dysplastic naev i), and external (exposure to ultraviolet 
irradiation) types.  
Melanoma is categorized  into 5 stages: Stage 0 is in situ (intraepithelial) melanoma, Stages  I and 
II are localized invasive cutaneous disease, Stage III is regional  spread disease , and Stage IV is 
disease  with distant metastasis . Over 90% of new cases are diagnosed as primary tumo rs without 
any evidence of metastasis and surgical excision can be curative.  
The preferred treatment options for later stages of malignant melanoma include targeted therapy 
and immunotherapy. Targeted therapy is approved for patients with gene encoding B -Raf protein 
(BRAF ) mutations and includes BRAF/ mitogen -activated protein kinas e (MEK ) inhibitor 
combinations. Approved immune therapies include the anti -cytotoxic T -lymphocyte -associated 
protein -4 antibody ipilimumab and anti -programmed cell death 1 (PD -1) antibodies 
pembrolizumab and nivolumab.  
In September 2015, the Food and Drug Administration  (FDA ) granted accelerated approval of 
nivolumab in combination with ipilimumab in patients with BRAF V600 wild-type, unresectable , 
or metastatic melanoma. Positive  opinion from the Committee for Medicinal Products for 
Human Use for the combination recommending a change to the terms of the marketing 
authorization for nivolumab was received in April  2016.  
Many patients with unresectable or metastatic melanoma benefit from monotherapy or 
combination therapy with immune checkpoint inhibitors, but still many patients do not respond 
or become long -time survivors. Further therapeutic advances exploring additional 
immunotherap y combinations  are therefore warranted.  
2.2 Checkpoin t Inhibitors for Advanced Malignant Melanoma   
2.2.1 Checkpoint Inhibitors Monotherapy  
Ipilimumab monotherapy for advanced malignant melanoma gives a median progression free 
survival ( PFS) of 3 to 4 months and a median overall survival ( OS) of 6 to 20 months . 
2,3,4,5,6,7,8,9,10   
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  19 of 113 22 Sep 2023 In the Check Mate-066 study , nivolumab  monotherapy showed  a median PFS of 5.1 months  and a 
1-year OS rate of 72.9%. The median OS was not reached ; however, the study  demonstrated a 
statistically significant improvement in OS for the nivolumab arm compared with the 
dacarbazine arm in an interim analysis based on 47% of the total planned events for OS (hazard 
ratio [HR] for death, 0.42; 99.79% confidence interval [ CI], 0.25 to 0.73; p<0.001) .11 
Pembrolizumab demonstrate d a median PFS of 3  to 6 months, median OS of 13  to 15 months , 
and a 2-year survival of 36 % to 55%.11,12  
2.2.2 Combination of Nivolumab and Ipilimumab  
The combination of nivolumab and ipilimumab was approved based on study Check Mate-067 
([STUDY_ID_REMOVED]), a multicenter, double -blind study in which 945  patients with previously 
untreated, unresectable , or metastatic melanoma were randomized 1:1:1 into one of the following 
arms: nivolumab and ipilimumab, nivolumab, or ipilimumab. Patients receiv ed either nivolumab 
1 mg/kg with ipilimumab 3  mg/kg intravenously every 3  weeks (Q3W) for 4  doses, followed by 
nivolumab as a single agent at a dose of 3  mg/kg by intravenous infusion every 2  weeks (Q2W) 
(nivolumab plus ipilimumab arm) ; nivolumab 3  mg/kg b y intravenous infusion Q2W  (nivolumab 
arm) ; or ipilimumab 3  mg/kg intravenously Q3W  for 4  doses, followed by placebo Q2W  
(ipilimumab arm). Randomization was stratified by PD -L1 expression (≥5% versus  <5% tumor 
cell membrane expression) as determined by a c linical study assay, BRAF V600 mutation status, 
and M stage per the American Joint Committee on Cancer  staging system , 8th edition  (M0, M1a, 
M1b versus  M1c). Tumor assessments were conducted 12  weeks after randomization then every 
6 weeks for the first year, and every 12  weeks thereafter. The major efficacy outcome measures 
were Investigator assessed  PFS per Response Evaluation Criteria in Solid Tumors  (RECIST ) 
v1.1 and OS. Additional efficacy outcome measures were confirmed objective response rate  
(ORR ) and duration of response  (DOR ). 
The median PFS was 11.5  months (95%  CI, 8.9 to 16. 7) in the nivolumab plus ipilimumab 
group, 6.9 months (95% CI, 4.3 to 9.5) in the nivolumab group, and 2.9  months (95% CI, 2.8 to 
3.4) in the ipilimumab group. A signi ficant improvement in PFS was observed in the nivolumab 
plus ipilimumab group as compared with the ipilimumab group ( HR, 0.42; 95% CI, 0.31 to 0.57; 
p<0.0001). A significant improvement in PFS was also observed in the nivolumab group as 
compared with the i pilimumab group ( HR, 0.57; 95% CI, 0.43 to 0.76; p<0.0001). The HR for 
the comparison between nivolumab plus ipilimumab and nivolumab groups was 0.74 (95% CI, 
0.60 to 0.92).6 
The analysis results at 4  years of follow -up confirmed the improvement in PFS fro m the 
combination treatment over ipilimumab alone and showed a survival benefit of nivolumab plus 
ipilimumab or nivolumab alone over ipilimumab. At a minimum follow -up of 48  months from 
the date that the final patient was enrolled and randomi zed, median OS was not reached (95% CI , 
38.2 to not reached) in the nivolumab plus ipilimumab group, 36.9  months (28.3 to not reached) 
in the nivolumab group, and 19.9  months (16.9 to 24.6) in the ipilimumab group. The HR for 
death for the combination versus ipilimumab was 0.54 (95% CI , 0.44 to 0.67; p<0 .0001) and for 
nivolumab versus ipilimumab was 0.65 (0.53 to 0.79; p<0 .0001). Median PFS was 11.5  months 
(95% CI , 8.7 to 19.3) in the nivolumab plus ipilimumab group, 6.9  months (5.1 to 10.2) in the 
nivolumab g roup, and 2.9  months (2.8  to 3.2) in the ipilimumab group. The HR for PFS for the 
combination versus ipilimumab was 0.42 (95% CI , 0.35 to 0.51; p<0 .0001) and for nivolumab 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  20 of 113 22 Sep 2023 versus ipilimumab was 0.53 (0.44 to 0.64; p<0 .0001).6 At 5 years, the OS was 52% in the 
nivolumab  plus ipilimumab group and 44% in the nivolumab group, as compared with 26% in 
the ipilimumab group.13,14,15 Five-year PFS was 36%, 29%, and 8% in the nivolumab  plus 
ipilimumab, nivolumab, and ipilimumab groups, respectively. Among patients with tumors with 
BRAF mutations and those with tumors without BRAF mutations, OS at 5 years was 60% and 
48%, respectively, in the nivolumab  plus ipilimumab group , 46% and 43% in the nivolumab 
group , and 30% and 25% in the ipilimumab group.  
Despit e advances in the development of new treatment options, advanced malignant melanoma 
remains a condition with a large unmet medical need . 
2.3 The UV1 Vaccine  
UV1 is a therapeutic cancer vaccine consisting of 3 synthetically -produced peptides covering an 
epitope  rich sequence within the active site of the human telomerase reverse transcriptase  
(hTERT ).  
Role of Telomerase in Cancer Cell Pathogenesis  
Human telomerase reverse transcriptase  is one of 2 major components of the enzyme telomerase 
which catalyses  the sy nthesis and extension of telomeric deoxyribonucleic acid ( DNA ) in order 
to maintain telomere length.16  
Telomerase activity is associated with stem  cell proliferation, and telomerase is highly active in 
embryonal cells and less active in stem cells and germinal cells. During embryonic developme nt, 
telomerase activity decreases as cells differentiate17 and telomerase activity and hTERT 
messenger ribonucleic acid ( RNA ) are not detectable in t he majority of normal adult tissues, 
including cardiac/skeletal muscle, liver, prostate, breast, pancreas, brain, lung, and kidney.18  
Telomerase acti vation is the major mechanism implicated in human cell immortalization and 
cancer cell pathogenesis.16 In the absence of functional telomeres, chromosomes become highly 
unstable, and this can ultimately be lethal to the cell. Tumor  cells avoid this situation by turning 
on the expression of telomerase activity. Thus, immortalization involves the arrest of t he process 
of telomere shortening, and telomerase is the key enzyme in this process. Telomerase activity is 
present in approximately 100% of immortal cell lines and in >85% of human tumors  of various 
histological types.17,18 ,19 Telomerase is expressed in c ancer cells at every stage of tumor  
evolution, from the cancer stem cell to circulating tumor  cells. Due to its essential role for the 
immortality of tumor  cells and its universal expression by most human tumors , telomerase 
represents a unique cancer antig en as a basis for immunotherapy.20 Telomerase activity is 
reflected in the up -regulated expression of hTERT.21 
The UV1 Peptides  
The hTERT peptides composing the UV1 vaccine have been selected based on analyses of 
clinical and immunological response data from long -term cancer survi vors responding 
immunologically to an unrelated first -generation hTERT vaccine. It was shown that epitope 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  21 of 113 22 Sep 2023 spreading within hTERT and T-helper type  1 (Th1) reactivity ( ie, secretion of interferon gamma , 
tumor  necrosis  factor alpha , and interleukin -2) were a ssociated with prolonged survival. Based 
on these analyses, 3 long novel hTERT peptides associated with clinical benefit, shown to elicit 
strong CD4 T cell responses in blood from patients across several cancer types and predicted to 
contain multiple human  leukocyte antigen epitopes, were selected for the next -generation hTERT 
vaccine UV1.22,23  
The UV1 Vaccine  
The mode of action of UV1 is to activate the immune system to induce T cells that recognize 
hTERT . The efficacy of the vaccine is thought to be mediated through these T cells.   
Expression of telomerase is essential for unlimited growth and immortality of cancer cells (ie, 
the antigen is present throughout the tumorigenesis and the tumor cannot escape from 
dependence on telomerase ). 21 Due to the temporo -spatial  presence of the target, the CD4 T cells 
induced by UV1 can provide a pro -immunological environment in the tumor and tumor -draining 
lymph node, continuously over time, regardless of the genetic makeup of the individual tumor 
cell. The vaccine mediated  the CD4 immune response to optimize for priming of de novo 
immune responses (epitope spreading) and tumor cell killing in an otherwise highly dynamic 
tumor . 
UV1 is administered together with granulocyte -macrophage colony -stimulating factor 
(GM -CSF) as vaccine adjuvant. The GM -CSF used is sargramostim.  Peptide -based vaccines 
generally are poorly immunogenetic due to their small size. Adjuvants provide “danger signals” 
for cells of the innate immune system to present vaccine epitopes in the context of major 
histo compatibility complex  molecules, surface adherence molecules, and costimulatory 
molecules which are required for induction of a robust adaptive immune response. Sargramostim 
is selected as adjuvant  for UV1 since it is documented to favor  induction of pepti de-specific 
Th11 immune responses after intradermal  injections with peptides.24,25,26 UV1 vaccination refers 
to administration of both sargramostim and UV1.  
2.4 Clinical Data on UV1 Vaccination  
UV1 was brought into clinical development in 2013. Two dose -evaluation studies including 
40 patients with prostate cancer27 and non-small  cell lung cancer ( NSCLC )28 have completed 
treatment and patients are in follow -up for survival. One safety study combining UV1 
vaccination with ipilimumab in patients with melano ma has completed treatment of 1 2 patients. 
One safety study combining UV1 vaccination and pembrolizumab in patients with melanoma is 
ongoing  for safety follow -up, with  30 patients enrolled and treated . A tabulated summary of 
completed, ongoing , and planned  clinical studies is provided in  Table  1.  
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  22 of 113 22 Sep 2023 Table  1 Summary of Completed , Ongoing , and Planned Clinical Studies for UV1 
Vaccination  
As of November  2019, 72 patients have received  UV1 vaccinations in the context of clinical 
trials, and of these 68 patients have completed the UV1 vaccination therapy.  The completed 
studies have shown that UV1 is generally safe and well tolerated . Common adverse events ( AEs) 
related to UV1 include pru ritus, erythema, fatigue, diarrh oea, pain, and rash. Serious AEs were 
reported in 18% of the patients, and related SAEs in 10%. A few patients (7%) have reported 
serious allergic reactions to the UV1 vaccination . Four prostate cancer patients and 1 patient  with 
metastatic malignant melanoma experienced serious allergic reactions occurring within 3  to 
30 minutes after injection of 9 or more doses of UV1 and sargramostim . All events resolved 
without sequelae.  Protocol no. 
(EudraCT)  
/country  Study design  Study population  Enrolled/  
planned  Dose and  dosage regimen  
Completed studiesa) 
UV1/hTERT -
2012 -L 
(2012 -001852 -
20)/ 
Norway  Phase I/IIa open -
label, single -center 
dose-evaluation 
study of UV1  
Up to 10 -year 
follow -up Locally advanced 
and/or metastatic 
NSCLC with 
stable disease after 
radiation and/or 
chemotherapy  18 Dose:  
UV1 100/300/700 µg, sargramostim 75 µg 
(intradermal injection)  
Week  1: Three UV1 vaccinations (D1, 3, 5)  
Weeks  2, 3, 4, 6, 8, 10, 14, 18, 22, 26: One 
UV1 vaccination  
From Week 39: UV1 vaccination every 
3 months up to Week 91  
UV1/hTERT -
2012 -P 
(2012 -002411 -
26)/ 
Norway  Phase I/IIa 
open -label, 
single -center dose -
evaluation study of 
UV1  
Up to 10 -year 
follow -up Hormone -sensitive 
metastatic prostate 
cancer  22 Dose:  
UV1 100/300/700 µg, sargramostim  75 µg 
(intradermal injection)  
Week 1: Three UV1 vaccinations (D1, 3, 5)  
Weeks 2, 3, 4, 6, 8, 10, 14, 18, 22, 26: One 
UV1 vaccination  
From Week 52: UV1 vaccination every 
3 months up to Week 104  
UV1/hTERT -
MM 
(2013 -005582 -
39)/ 
Norway  Phase I/IIa, 
open -label, 
single -center study 
of UV1 and 
ipilimumab  
Up to 10 -year 
follow -up Unresectable or 
metastatic 
melanoma  12 Dose:  
UV1 300 µg, sargramostim  75 µg  
(intradermal injection)  
Ipilimumab according to label  
Week 1b): Three UV1 vaccinations (D1, 3, 5)  
Weeks 3, 4, 7, 10, 13, 17, 21: One UV1 
vaccination  
Weeks 2, 5, 8, 11: Ipilimumab  
Ongoing studies  
UV1/hTERT -
MM-103/ 
US Phase I open -label, 
multicenter study of  
UV1 and 
pembrolizumab  
2-year follow -up Unresectable or 
metastatic 
melanoma  30/ 
30 Dose: UV1 300 µg, sargramostim  37.5/75  µg 
(intradermal injection)  
Pembrolizumab according to label  
Week 1: Three UV1 vaccinations (D1, 3, 5)  
Weeks 2, 5, 8, 11, 14: One UV1 vaccination 
and pembrolizumab  
After Week 14: Pembrolizumab continued 
according to label  
a) Enrollment and UV1 treatment is completed and patients are in follow -up 
b) In the clinical study report, the first week of UV1 vaccination is referred to as “introduction week” and the week of first 
ipilimumab administration is “ Week 1”  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  23 of 113 22 Sep 2023 Across the three Phase I/IIa studies conducted wi th UV1  vaccination , vaccine -specific T  cells 
were induced in 78% (range 67 % to 91%) of the patients. This supports the universal utility of 
the vaccine across different individuals and cancer types, and thus pre -screen ing of patients for 
human leukocyte an tigen -type or other biomarkers before treatment with UV1 is not needed.  
In the study investigating the use of the UV1 vaccine in combination with ipilimumab in 
metastatic malignant melanoma patients, UV1 -specific immune responses were induced in 91% 
of the  patients. The vaccine -specific T  cells appeared more frequently and rap idly in this study 
than in the studies  investigating patients with prostate cancer and late -stage NSCLC, suggesting 
a synergistic effect of blocking of CTLA -4 and vaccination with UV1. Nine patients were 
evaluable for tumor response according to RECIST 1.1 . Of these, 3 patients obtained a partial 
response (PR) as best overall response, 3 achieved stable disease (SD), and 3 experienced 
progressive disease (PD). The median PFS was 6. 5 months and the 3 -year survival rate was 67% 
(8/12).  
The ongoing study comb ining UV1 and pembrolizumab in treatment of melanoma 
(UV1/hTERT -MM-103) has currently enrolled and treated 30 patients who are now in follow -up. 
Serious AEs  and AEs of special interest (AESIs) are reported expedited to the sponsor and are 
the basis for the  continuous safety assessment in this study. The collection of non -serious adverse 
is ongoing and will be reported when the study is completed, and all data have been finally 
verified. A thorough assessment of the safety profile of UV1 vaccination used in combination 
with pembrolizumab will include an evaluation of possible increase in frequency and severity of 
adverse reactions to pembrolizumab, the proportion of patients who have to terminate 
pembrolizumab treatment due to adverse reactions, and if the co mbination treatment enhances 
the UV1 related side effects.  
Up to the date of this protocol, the safety information available from study 
UV1/hTERT -MM-103 include nine serious adverse events (SAEs) for 7 patients (23.3%) in the 
study, the majority of which were considered unrelated to study treatment. One SAE of grade 3 
arthritis was assessed as possibly related to administration of UV1 vaccine and pembrolizumab, 
but the patient continued with treatment after resolution of the SAE . No AESIs (anaphylactic 
reaction, anaphylactic shock or hypersensitivity) have been reported among the  patients.  The 
number of UV1 vaccinations in this study is reduced to 8 compared to 12 to 18 in the completed 
Phase  I studies as a measure to reduce the risk for serious allergic re actions following UV1 
vaccination treatment.  
Based on the currently available safety information, study UV1/hTERT -MM-103 has not 
revealed any immediate safety hazard for the use of UV1 vaccination as add -on to treatment to 
pembrolizumab for patients with m alignant melanoma.  
Conclusion on the safety of UV1 vaccination in combination with checkpoint inhibitors  
With the safe treatment of 42 patients  with UV1 vaccination in combination with either 
ipilimumab or pembrolizumab the safety of the product does not preclude continued clinical 
development of UV1 vaccination in combination with CTLA -4 inhibitors or PD -1/PD -L1 
inhibitors.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  24 of 113 22 Sep 2023 2.5 Rationale for Combination  of UV1 with C heckpoint Inhibitors  
Checkpoint inhibition has become one of the main pillars in immune -based cancer therapies and 
involves inhibition of regulatory signalling  pathways which nor mally reduces or modulates 
T cell activation in order to promote immune tolerance and suppress auto immunity .29 Central to 
these processes are the CTLA -4 and PD -1 immune checkpoint pathways. These 2 pathways 
operate on different stages of an immune response. CTLA -4 mainly regulate activation of na ïve 
T cells in the lymph nodes, and PD -1 regulates previou sly activated T cells at the later stages of 
an immune response, primarily in the peripheral tissue.30   
The mode of action of checkpoint inhibitors is to block the interaction between PD -1 and 
CTLA -4 expressed on T  cells with their respective ligands, reducing negative effects on T cell 
activation and T effector mechanisms, and hence to promote T -cell-mediated immune activity.  
The immune c heckpoint inhibitor ipilimumab is a monoclonal antibody specific for CTLA -4. 
The proposed mechanism of action for ipilimumab is the disruption of the interaction of CTLA -4 
which is expressed in the cell surface of naïve T cells following stimulatory signal s, with B7 
co-stimulatory molecules (CD80 or CD86) expressed on antigen presenting  cells.31 The result is 
inhibition of the down -modulatory function of CTLA -4, and hence potentiation of a 
T-cell-mediated immune response.32 Ipilimumab  also interferes with t he negative action of 
regulatory T -cells. The combined effect is a release of pre -existing immune responses and 
generation  of a subsequent wave of secondary immune responses.  
Nivolumab is a monoclonal antibody specific for PD -1 which is expressed by T cel ls after 
persistent antigen exposure. PD -1 interacts with its ligand s, PD-L1 and PD -L2, which is 
normally expressed on a range of different types of leucocytes,  such as natural killer cells and 
macrophages  and plays a role in modulation of immune system re sponse . This interaction leads 
to inhibition of kinase -mediated signaling  pathways, and thus, inhibition of T -cell activation and 
response.  PD-L1 can be expressed on the surface of tumor cells as well and interaction between 
PD-1 on T cells and PD -L1 on tumor cells inhibits immune response against malignant cell.  
Blocking of the PD -1 receptor interaction with PD -L1 or PD -L2 reverse s this immune 
suppression and release s T-cell effector function .  
Blockade of both CTLA -4 and PD -1 aims to induce proliferation of a higher number of T cells 
early in an immune response,  and to restore immune responses of previously activated T cells 
that have become exhausted by chronic antigen stimulation. Combination therapy with 
nivolumab and ipil imumab in clinical studies has been shown to provide enhanced  clinical 
benefit compared to single -agent therapy with either nivolumab or ipilimumab.  
Efficacy of the combined treatment of ipilimumab and nivolumab depend s on the presence of a 
spontaneously induced T cell response against relevant tumor antigens. Patients who lack or have 
few tumor -specific T cells in their tumor  are less likely to obtain durable benefit from 
combination therapy with nivolumab plus ipilimumab. UV1  vaccination  has the potentia l to 
increase the efficacy of the combination therapy in patients where the immune response 
spontaneously primed by tumor  antigens is insufficient for induction of long -term clinical 
benefit . Vaccination with UV1 amplif ies the pool of hTERT specific tumor -reactive  CD4 T cells 
from the naïve  repertoire and has the potential to increase the breadth and diversity of the 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  25 of 113 22 Sep 2023 tumor -reactive  T cell response (epitope spread). Reciprocally, the efficacy of UV1 vaccination 
may be enhanced since the checkpoint inhibitors  can augment the clonal expansion and effector 
activity of UV1 -induced T cells that is otherwise restricted by intrinsic immune regulatory and 
tumor induced  suppressor mechanisms. The addition of UV1  vaccination  to checkpoint inhibitors 
thus have the poten tial to produce synergistic immunological activity which may transfer into 
increased clinical benefit compared to dual CTLA -4 and PD -1 checkpoint inhibitor therapy.  
2.6 Rationale for Dose  and Administration Regimen  
Three Phase I/I I studies investigating the use of UV1 vaccinations have been completed (n=52). 
One study  in NSCLC and one study in prostate cancer were dose-finding  studies comparing the 
safety of 100, 300 , and 700  µg UV1 using  75 µg sargramostim  per vaccination for up to  
18 vaccinations. No dose -limiting toxicities were observed in doses up to 700  µg. Signals of 
efficacy have been observed in all 3  studies in the form of vaccine -specific  immune responses 
and PFS and OS which compares favorably  to historical controls.  
Acro ss the 3 completed Phase I /II studies with UV1  vaccination , 78% (40/51) of the patients 
with samples available for analysis had detectable  vaccine -specific immune response. A highe r 
proportion of patients with vaccine -specific  immune response was seen in the group of patients 
receiving the 300  µg UV1 dose; 88% compared to 69% and 71% in the 100 and 700  µg groups, 
respectively. In the study where 300  µg UV1 was used in combination with ipilimumab in 
patients with melanoma, 91% o f the patients showed an immune response to UV1.  
No clear dose relationship was observed in the proportion of patients experiencing A Es, although 
a tendency towards a lower frequency of related AEs, injection site events , and Grade  3 events 
was observed i n the 300 -µg dose group. Across the 3 studies, a total of 17  SAEs were reported, 
and 9 patients (17%) had related SAEs. Three patients had events that were related to 
ipilimumab, and 6 patients (12%) experienced 6 SAEs  that were related to UV1 vaccination.  Of 
these, 5 events in 5 patients (10%) were serious allergic reactions: anaphylactic reaction, 
anaphylactic shock , and hypersensitivity. Three events of serious allergic reactions occurred in 
the 700  µg UV1 dose group, 2 in the 300  µg UV1 dose group , and none in the 100  µg UV1 dose 
group.  
Taken together, the data on efficacy in terms of vaccine -specific immune response and safety 
related to dose of UV1 from the completed Phase I/II studies with UV1 support the use of the 
300 µg UV1 dose for further clinical development of UV1.  
Across the 3 completed Phase I /II studies, UV1 was administered with 75  µg of the adjuvant 
sargramostim  per vaccination for up to 18  vaccinations. Localized dermal injection site reactions 
indicative of an inflammatory reaction to sargramostim  and hence recruitment of dendritic cells 
to the injection site were seen in 63% of patients and 78% developed a vaccine -specific immune 
response. This supports the use o f 75 μg sargramostim  per UV1 vaccination for the further 
clinical development of UV1.  
To reduce the risk for serious allergic reactions to UV1 and/or sargramostim , the number of 
vaccinations with UV1 and sargramostim  have been limited to 8  vaccinations over a period of 
73 days in the current protocol.  The serious allergic reactions observed in 5  patients (10%) 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  26 of 113 22 Sep 2023 occurred within 3  to 30 minutes after administration of the 9th or more vaccinations (>20  weeks 
of exposure). The immune response data from the comp leted study investigating the use of UV1 
with ipilimumab in patients with malignant melanoma support that 8  UV1 doses sufficed to 
generate a vaccine -specific  immune response. The patients in that study received an average of 
5.5 UV1 vaccinations (range  3 to 9), and 91% of the evaluable patients had immune  response 
within 12  weeks after first vaccination.  
In the current study , a dose of 75  µg sargramostim  will be injected  intradermally  10 to 
15 minutes prior to intradermal injection of UV1 at the same site.  
The 75  µg sargramostim  dose is the same dose that has been used in the 3 completed Phase I/II 
studies  with UV1 and in 10 out of 30  patients in the UV1/hTERT -MM-103 study.  
Patients in the experimental arm will receive 8  UV1 vaccinations over 4  cycles of nivolumab and 
ipilimumab. UV1 vaccination will be administered alone on Days  1, 3-7 (2 UV1 vaccinations 
within Day  3 to Day  7, consecutive dosing  days not allowed) and 26, and in combination with 
nivolumab and ipilimumab on Days  10, 31, 52 and 73.  The administration regimen for UV1 
vaccination during Days 1-10 is optimized for synergy with ipilimumab leading to effective 
priming and expansion of na ïve hTERT specific T cells in the local lymph node draining the 
vaccine injection site. At Days 26 and 73, the UV1 vaccinations are optimized for re -activation 
and effector activity of the vaccine induced T cells in the tumor micro -environment in synergy 
with nivolumab and ipilimumab.  
The proposed vaccine administration regimen for study UV1  202 is similar to the vaccination 
regimen used in the Phase  I studies UV1 -hTERT -L (NSCLC), UV1 -hTERT -P (prostate cancer) 
and UV1 -hTER -MM (malignant melanoma) respective ly. The Phase  I administration regimen 
was based on animal studies of immune responses to peptide vaccines using sargramostim as 
adjuvant .24,25 It was documented that an intradermal co -administration regimen with 3 injections 
of the UV1 peptides with sargramostim during Week  1, followed by regular vaccinations is 
effective for induction of a vaccine -specific immune responses. This regimen aims to provide a 
gradient of sargramostim over time to attract Langerhans cell s in the dermis to the vaccine 
injection site, allowing them to take up intact peptides while maturing into proper antigen 
presenting cells, migrate to the local lymph node and present the vaccine epitopes to na ïve T cell, 
thereby priming vaccine -specific T cells.  
Since CTLA -4 is expressed on the cell surface of T cells within 72 hours of activation and will 
limit clonal expansion and induce G1 arrest of proliferating T cells .32,33 The first ipilimumab dose 
was administered subsequent to three initial UV1 vaccinations in study UV1 -hTERT -MM. The 
following UV1 vaccinations were administered intermittent to the ipilimumab doses. UV1 
vaccination and ipilimumab administration was spaced in time to allow for CTLA -4 to be 
expressed in the cell membrane of clonally  expanded T cells primed and activated by UV1 
vaccinations before blocking of the signaling through CTLA -4 with ipilimumab. The 
vaccine -specific immune response in study UV1 -hTERT -MM appeared more frequently and 
rapidly than in the studies investigating th e use of UV1 vaccination as monotherapy ,27 supporting 
that ipilimumab act synergistically with UV1 to induce a vaccine -specific immune response. A 
similar regimen with spacing between UV1 vaccinations and administration of the first and 
second ipilimumab doses is proposed for the present study.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  27 of 113 22 Sep 2023 Nivolumab is administered every third week and will block signaling through PD -1 on 
tumor -specific T cells, t hus releasing the effector activity of T cells activated by UV1 vaccination 
and T cells spontaneously activated by antigens in the tumor. The UV1 vaccinations at Day s 52 
and 73 are administered concurrent with nivolumab and ipilimumab to optimize for boost ing of 
an ongoing vaccine -specific immune response and release of effector activity of T cells in the 
tumor and draining lymph nodes.  
2.7 Rationale  for Study Design  
Study UV1 -202 is a randomized, multicent er, open -label, active -controlled clinical study to 
document the efficacy and safety of adding UV1 vaccination to dual checkpoint blockade 
therapy with nivolumab plus ipilimumab.  
Primary Endpoint  
Progression free survival  is the primary endpoint of the study . In line with European Medicines 
Agency  and FDA a nticancer guidance, PFS is an acceptable primary endpoint in first-line 
metastatic disease, being reflective of clinical benefit. Progression free survival is considered an 
appropriate choice of endpoint especially when effective second -line therapies are available that 
would serve to confound subsequent OS outcome, as is the case in advanced malignant 
melanoma.  
Median PFS with nivolumab plus ipilimumab in unresectable or metastatic melanoma has been 
reported to be 11.5  months (95% CI, 8.9 to 16.5) in the nivolumab plus ipilimumab group.14 
Upon progression to more advanced melanoma, patients will likely receive subsequent effective 
anticancer treatment, including checkpoint monotherapy, chemotherapy , and targeted therapy, 
thus r uling out OS as a viable primary endpoint due to the diluting effect of these additional 
therapies.  
Progression free survival is appropriate for evaluating the effect of a therapeutic cancer vaccine. 
The expected mode of action for a therapeutic peptide c ancer vaccine is to induce proliferation of 
T cells recognizing epitopes within the vaccine peptides. The secondary effects of these T cells 
will depend on the individual patient’s  genetic, biochemical , and immunological status and may 
include increased fr equency of tumor  responses (increased ORR), prolonged DOR34, and 
increased frequency and duration of SD. Progression free survival , unlike DOR or ORR, as 
primary endpoints is suited to capture all tentative efficacy attributes of the vaccine. The study is 
therefore formally powered for analysis of PFS. O verall survival  will be analyzed  as supportive 
evidence.  
Treatment  Arms 
UV1 -202 is a randomized study with 2 arms, with the objective of documenting the add -on effect 
of UV1 vaccination to nivolumab and ipilimumab:  
• Experimental arm: UV1 vaccination in combination with nivolumab and ipilimumab  
• Control arm: nivolumab and ipilimumab  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  28 of 113 22 Sep 2023 A 2-armed study will provide dat a on the efficacy and safety of UV1 vaccination as add-on to 
nivolumab and ipilimumab in patients with unresectable stage III B-D or unresectable metastatic 
melanoma which will suffice for hypothesis generation.  
In addition to the 2 -armed part of the study , 20 patients will be enrolled in a single arm UV1 
cohort for collection of additional biological material  to support the Extended Exploratory 
Cohort of the study . The single arm UV1 cohort is intended  for exploratory purposes only  
(Appendix  7 Single Arm UV1 Cohort ). 
2.8 Benefit/Risk Assessment  
The clinical studies completed to date (n=52) have demonstrated that UV1 vaccination is 
generally well tolerated, both as monother apy and in combination with ipilimumab. There were  
no dose-limiting  toxicities observed in the 2 dose-finding studies completed, and no apparent 
dose relationships in the rate of patients experiencing the most common related A Es (injection 
site related  AEs). Anaphylactic reaction, anaphylactic shock, and hypersensitivity have been 
identified as AESIs  for UV1 vaccination based on 5  events in 5  patients included in the 
completed studies.  
Study UV1 /hTERT -MM-103, investigating the use of UV1 in combination with the anti -PD-1 
monoclonal antibody  pembrolizumab, is currently ongoing  for follow -up. 30 patients have been 
included and treat ed with UV1 and pembrolizumab. The combination of pembrolizumab and 
UV1 appears to be generally well tolerated . Nine serious adverse events (SAEs) for 7 patients 
(23.3%) in the study, the majority of which were considered unrelated to study treatment . 
To reduce the risk for AESIs, a maximum of 8  UV1 vaccinations will be administered t o the 
patients under the current protocol. Patients will remain at the study site for observation for at 
least 4  hours after each UV1 vaccination. Patients who develop serious allergic reactions during 
treatment with UV1 vaccinations will be discontinued f rom further UV1 vaccinations.  
No information on the effects of UV1 vaccination on fertility and reproduction is available, and 
patients of childbearing potential must agree to use an adequate method of contraception prior, 
during , and after completion of treatment with UV1 vaccination.  
Nivolumab and ipilimumab are approved for the patient population suggested in the current 
study, and the toxicity profile of the combination is well characterized. The toxicities reported in 
the studies investigating the use  of UV1 vaccination in combination with single agent  
ipilimumab and single agent  pembrolizumab in malignant melanoma have so far been modest. 
Since the use of UV1 vaccination combined with nivolumab and ipilimumab has not been 
investigated previously, the protocol specifies specific safety monitoring  for the study . 
The UV1 vaccine induces vaccine -specific  CD4 T cell response in the majority of patients across 
indications. The immunogenicity of the peptides in UV1 is further supported by data  from 
several long -term surviving patients with pancreatic cancer, lung cancer, and malignant 
melanoma treated with an earlier hTERT vaccine .28,29 The available clinical data on efficacy and 
reported AEs versus exposure from the completed and ongoing studies with UV1 indicates a 
favorable ris k/benefit profile for UV1 vaccination. The underlying scientific rationale for 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  29 of 113 22 Sep 2023 expected immunological synergy the use of UV1 vaccination in combination with nivolumab and 
ipilimumab justifies the present  clinical study . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  30 of 113 22 Sep 2023 3 Objectives  and Endpoints  
Objectives  Endpoints  
Primary  
• To compare progression  free survival ( PFS) of 
UV1 vaccination * in combination with 
nivolumab and ipilimumab  to that of nivolumab 
and ipilimumab   Primary  
• PFS per Response Evaluation Criteria in 
Solid Tumors ( RECIST ) 1.1 
Time from randomization to progressi ve 
disease ( PD) or death from any cause  
Secondary  
• To compare overall survival ( OS) of UV1 
vaccination in combination with nivolumab and 
ipilimumab to that of nivolumab and ipilimumab  Secondary  
• OS 
Time from randomization to death from 
any cause  
• To compare the objective response rate ( ORR ) of 
UV1 vaccination in combination with nivolumab 
and ipilimumab  to that of nivolumab and 
ipilimumab  • ORR per RECIST 1.1  
Proportion  of patients with a best  response 
of complete response (CR) or partial 
response ( PR) 
• To compare duration of response ( DOR ) of UV1 
vaccination in combination with nivolumab and 
ipilimumab  to that of nivolumab and ipilimumab  • DOR per RECIST 1.1  
Time from first CR or PR to PD or death 
from any cause  
• To compare the safety  of UV1 vaccination in 
combination with nivolumab and ipilimumab to 
that of nivolumab and ipilimumab  • Adverse events  (AEs) , deaths, vital signs, 
laboratory assessments, and Eastern 
Cooperative Oncology Group ( ECOG ) 
performance  status  
Exploratory  
• To elucidate the immunological mechanisms 
underlying the interplay between immune 
activation provoked by UV1 vaccination and 
inhibi tion of tumor resistance mechanisms and 
peripheral immune tolerance induced by 
checkpoint blockade, and how biological factors 
affect the efficacy of the combination therapy  Exploratory  
• Change in immune - and tumor -related  
gene , cell , and protein profiles in blood 
over time in both treatment arms (analysis 
of plasma proteins, cell -free plasma DNA , 
and cellular genomic DNA) .  
Other endpoints related to analysis  
conducted on biological material collected 
from the Extended Exploratory Cohort  
(refer  to Appendix  2). 
*UV1 vaccination includes sargramostim, used as a vaccine adjuvant, and UV1  
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  31 of 113 22 Sep 2023 4 Study Design  
4.1 Overall Design  
This is a randomized, open -label, active -controlled, multicenter study to investigate efficacy and 
safety of UV1 vaccination in combination with nivolumab and ipilimumab as first -line treatment 
of adult  patients  (≥18  years) with histologically confirmed unresectable metastatic melanoma . 
The study is planned to be conducted  at 40 study sites  in Europe  (approximately 16 sites)  and the 
United States (approximately 24 sites). 
This study will consist of 3 phases : Screening, Induction period , and Follow -up period. The 
Follow -up period includes safety, response , and survival follow -up visits . 
After a Screening period of up to 28 days, eligible patients will be randomized in a 1:1 ratio to 
receive induction therapy : UV1 vaccination in combination with nivolumab and ipilimumab  in 
an experimental arm , or nivolumab and ipilimumab in a control arm. Randomization can occur 
after all Screening procedures have been completed (up to 3  days [from Day  -3 until Day  1] prior 
to first dosing on Day  1) and eligibility has been confirmed.  It is estimated that approximately 
200 patients will need to be screened in order to randomize the required 154  patients.  
Patients in the experimental arm will receive 8  UV1 vaccinations over 4  cycles of nivolumab and 
ipilimumab. UV1 vaccination will be administered alone on Days  1, 3 to 7 (2 UV1 vaccinations  
within Day  3 to Day  7; consecutive dosing days not allowed ), and 26, and in combination with 
nivolumab and ipilimumab on Days  10, 31, 52 , and 73.  
Patients in the control arm will receive 4 cycles of nivolumab and ipilimumab on Days 1, 22, 43 , 
and 64 . 
Patients in both arms will start maintenance therapy 6 weeks after the last dose of induction 
therapy. The maintenance therapy is nivolumab at a dose of 480  mg every 4  weeks (Q4W) 
according to the label. It is not allowed to use any other dose of maintenance t herapy (eg, 240  mg 
Q2W ).  
The study is  event driven . The primary and secondary endpoints will be analyzed at the earliest 
of either 70 PFS events reached across both treatment arms  or 18 months post last patient 
randomized , at which time the sponsor will n otify the sites. From the PFS  cut-off date , patients 
will be followed for a further 24 months for additional survival data; further analyses of OS data 
will be performed  until defined end of study  to provide evidence supportive of PFS.   
All patients will be followed up until death  or until the end of the study ( EOS ), whichever comes 
first. Estimated timelines  at start of the study  are outlined in Figure  1. 
 
 
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  32 of 113 22 Sep 2023 Figure  1 Estimated Timelines  
First Patient In   Last Patient In  70 PFS events reached   End of Study  
          
          
0 months   15 months  27 months   51 months  
The estimated enrollment period is 15  months; the estimated time from last randomization to 70 
PFS events reached is 12  months; the estimated time from 70 PFS events to EOS is 24 months 
and the total study duration is estimated to be 51 months from first p atient in.  
The study design and treatment are outlined in  Figure  2.  
Figure  2 Study Design  
 
 
 
 
 
 
 
 
 
 
The UV1 vaccination includes sargramostim , used as a vaccine adjuvant,  at a dose of 75  µg and 
UV1 at a dose of 300  µg. Nivolumab and ipilimumab are dosed according to label  in both 
treatment arms : induction therapy of nivolumab (1  mg/kg Q3W) and ipilimumab (3  mg/kg  
Q3W ), and maintenan ce therapy of nivolumab (480  mg Q4W ). 
Sargramostim and UV1 should be administered  intradermal ly and injected at the same 
injection site (McBurney’s point) each time , located 1/3 of the distance from the anterior 
superior iliac spine to the umbilicus  on the  right side of the abdomen (or corresponding spot on 
the left side in case of appendectomy scar) . Sargramostim is administered 10  to 15 minutes prior 
to each UV1 injection. Nivolumab and ipilimumab are administered intravenously, starting  at 
least 1  hour after the administration  of UV1.  
Following the last dose of induction therapy, the patient will then enter the Follow -up period and 
perform a safety follow -up visit 30  days post last dose of induction therapy.  
Screening period         Induction period               Follow -up period   
 (Days -28 to -1)        (Days 1 to 73 / Days 1 to 64)                            (4 - 5 years)  
             
 
 
First-line 
unresectable IIIB-D 
or unresectable IV 
metastatic melanoma  
Experimental arm  
 
UV1 vaccination :  
Administ ered on Days 1, 3-7 (2 UV1 
vaccinations ), 10, 26, 31, 52, and 73  
 
Nivolumab and ipilimumab :  
Administered on Days 10, 31, 52 , and 
73 
All patients  
Safety follow -up 
Response follow -up 
Survival follow -up 
 
At the earliest of either 70 PFS 
events reached  or 18 months 
post last patient randomized , 
all patients will be followed -
up for 2 years  
 
Nivolumab maintenance 
therapy ( 480 mg Q4W) 
according to label  
Rand  
1:1  
N = 154  
Control arm  
 
Nivolumab and ipilimumab :  
Administered on Days 1, 22, 43 and 64  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  33 of 113 22 Sep 2023 Tumor assessment will be done locally at the study site using RECIST 1.1 and immune Response 
Evaluation Criteria in Solid Tumors ( iRECIST ) criteria. Tumor imaging will be performed within 
14 days prior to randomization and then on Week 12 and Week 19 post randomization. 
Subsequent response follow -up imaging will be performed every 8  weeks for 32  weeks and then 
every 12  weeks. Patients with PD per RECIST 1.1 will have a new scan 4 to 8 weeks later to 
confirm PD per iRECIST. Patients with immune unconfirmed PD per iRECIST (iUPD) will 
continue at the Investigator’s  discretion, with tumor imaging and treatment per protocol  until 
immune confirmed PD per iRECIST (iCPD) , until 70 PFS events are reached or until 18 months 
post last patient randomized (whatever comes first) . Patients wit h iCPD per iRECIST will be 
discontinued from treatment and will proceed into the survival follow -up phase and be contacted 
per phone (or, at the investigator’s discretion visit the hospital)  every 12  weeks until the earliest 
of either 70 PFS events reached  or 18 months post last patient randomized . From the PFS cut-off 
date, the survival follow -up will continue in all patients every 6 months for 2 years.  
To reduce bias in evaluation of the efficacy endpoints, t umor evaluation for the statistical 
analysis of the efficacy endpoints will be done by blinded independent central review (BICR) 
according to the RECIST  1.1 criteria. All images must be submitted to the central imaging 
vendor, but the results from the BICR  will not be provided to the study site . Two independent 
radiologists will perform the central imaging review without knowledge of treatment 
assignments. If there are discrepancies between the 2 readers, a standardized procedure involving 
a third reviewer for adjudication will take place.  
From signing of the Informed Consent Form (ICF) until the first dose of induction therapy , only 
AEs/SAEs  caused by study -specific procedures should be reported. Non-serious A Es should be 
reported from the first dose of induction therapy until 30  days after the last dose of induction 
therapy, or until new anticancer treatment is initiated (whichever comes first). All SAEs should 
be re ported  from the first dose of induction thera py until 70 PFS events are reached , until 18 
months post last patient randomized  or until new anticancer treatment is initiated (whichever 
comes first). Adverse events and SAEs that are ongoing beyond the required reporting timelines 
shall be followed up l ocally per institutional practice until resolution or stabilization or the 
patient is lost to follow up .  
During the study, a n Independent Data Monitoring Committee (I DMC ) will monitor safety 
information to ensure patient safety  (refer Section  8.2.1 ).  
Patients at selected sites will have the option to be included in the Extended  Exploratory Cohort 
of the study ( Appendix  2) provided that the cohort is still open for inclusion. This cohort of 
approximately 40  patients, randomized in a 1:1 ratio to either of the 2 treatment arms, will have 
additional  sampling of blood, tissue, and feces for exploratory purposes (see  Table  9 and 
Table  10). The biologic sampling will be in addition to blood samples planned for all patients in 
the study. Fecal samples will be collected in the Screening period while t umor biopsies 
(snap -frozen tissue and formalin fixated paraffin embedded  tissue) will be harvested in the 
Screening period and at the safety follow -up visit . In the experimental arm , delayed -type 
hypersensitivity (DTH) response will be  assessed at 5 timepoints during the study.  A biobank 
will be established for current and future analysis of the samples collected.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  34 of 113 22 Sep 2023 In addition to the 2 -armed part of the study, 20 patients will be enrolled in a single arm UV1 
cohort for collection of additional biological material to support the Extended Exploratory 
Cohort of the study. The single arm UV1 cohort is intended  for explor atory purposes only  
(Appendix  7 Single Arm UV1 Cohort ). 
Planned Timelines  
First patient in:      Q2 2020  
Last patient in:       H1 2022 
Primary endpoint read out:      H1 2024 
End of study:        H1 2026 
The First Patient In is defined as the timepoint  when the first patient is randomized.  
4.2 Measures to Minimize Bias: Randomization and Blinding  
Patients who satisfy all eligibility criteria will be randomly assigned by the central interactive 
web response system ( IWRS ; or equivalent) to receive induction therapy as either UV1 
vaccination in combination with nivolumab and ipilimumab in the experime ntal arm, or 
nivolumab and ipilimumab in the control arm. Randomization will be at a 1:1 ratio between the 
2 treatment arms.  
Randomization will be done  by the IWRS provider using a validated software. Randomization 
can occur after all Screening procedures  have been completed (up to 3  days [ from Day -3 until 
Day 1] prior to first dosing on Day 1) and eligibility has been confirmed, to prevent the 
Investigator’s  knowledge of treatment allocation influencing  the decision to include the patient.  
Given the stud y design, with visits occurring at different timepoints in the 2 treatment arms, 
neither patients nor Investigators will be blinded to the study treatment arms. To limit bias in 
evaluation of the efficacy endpoints , the statistical efficacy analyses will be based on tumor 
assessments by BICR . 
Patients in the single arm UV1 cohort will not be randomized and will therefore not be included 
in the data used for analysis of primary and secondary endpoints.  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  35 of 113 22 Sep 2023 5 Study Population  
The study population will consist of male and female patient s at least 18  years of age with a 
histologically confirmed diagnosis of unresectable stage  IIIB-D or unresectable  stage  IV 
metastatic melanoma . Patients  must provide written consent and  meet all the inclusion criteria 
and none of the exclusion criteria.  
Prospective approval of protocol deviations to the inclusion criteria , also known as protocol 
waivers or exemptions, will not be given . 
5.1 Inclusion Criteria  
To be eligible for randomization all of the following  criteria must be met: 
Age and Sex  
1. Male or female pa tient at least 18  years of age at the time of signing the ICF. 
Type of Patient  and Disease Characteristics  
2. Histologically confirmed diagnosis of unrese ctable  stage III B-D or unresectable stage  IV 
malignant melanoma . Patient must have at least 1  measurable lesion at Screening 
according to the RECIST  1.1 criteria . 
Note that lesions not measurable on a computed  tomography (CT) scan or a magnetic 
resonance imaging (MRI) will be considered as non -measurable lesions . 
3. Eligible for combination treatment with nivolumab and ipilimumab . 
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 . 
5. Adequate org an function as indicated by the following laboratory values : 
Hematological  
a. Absolute neutrophil count (ANC) ≥1 ,500/µL 
b. Platelet  count  ≥100 x 103/µL 
c. Hemoglobin ≥9 g/dL or ≥5.6  mmol/L  
Renal  
d. Creatinine ≤1.5 x upper limit of normal (ULN)  
Hepatic  
e. Total bilirubin ≤1.5 x ULN or  
direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5  ULN  
f. Aspartate aminotransferase/glutamic -oxaloacetic transaminase and alanine 
aminotransferase/glutamic -pyruvic transaminase  ≤2.5 x ULN for patients without 
liver metastasis or ≤5 x ULN for patients with liver metastas is. 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  36 of 113 22 Sep 2023 Male Patients:  
6. Male patients who are sexually active with a female of childbearing potential must agree 
to use an adequate method of contraception prior to the first dose  through 5  months after 
the last dose of UV1 vaccination, nivolumab, or ipilimumab , whichever is administered 
last. The recommended method is using a male condom.  
Female Patients:  
7. Women of childbearing potential (WOCBP) must have a negative urine or serum /plasma  
pregnancy  test. If the urine test is positive or cannot be confirmed as negative, a 
serum /plasma pregnancy test will be performed. The serum /plasma pregnancy test must 
be negative for the patient to be eligible.  
8. WOCBP (refer to Section  8.3.6 ) must use adequate contraception Adequate contraception 
must be maintained  throughout the study, starting with the first dose through 5  months 
after the last dose of UV1  vaccination, nivolumab , or ipilimumab , whichever is 
administered last. The acceptable contraceptive methods for WOCBP included in the 
study are:  
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibiti on of ovulation (oral, intravaginal, or transdermal), progestogen -only hormonal 
contraception associated with inhibition of ovulation (oral, injectable, or implantable), 
Intrauterine device (IUD), Intrauterine hormone -releasing system (IUS), bilateral tuba l 
occlusion, vasectomized partner (provided that the partner is the sole sexual partner of the 
WOCBP trial participant and that the vasectomized partner has received medical 
assessment of the surgical success), or sexual abstinence (if this is the preferre d and usual 
lifestyle of the subject)  
Informed Consent  
9. Written informed consent prior to any study -specific procedures.  
5.2 Exclusion Criteria  
Patients  are not eligible for randomization if any of the following criteria are met : 
Medical Conditions  
1. Previous non -melanoma malignancies unless curatively  treated and complete remission 
was achieved at least 2  years prior to randomization. Patients with prior curatively -treated 
basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix , or 
carcinoma in situ of the breast, or other in situ cancers are allowed irrespective of time 
passed since curative treatment. Patients with prior completely resected malignant 
melanoma are also allowed . 
2. Known brain metastases or leptomeningeal metastases. If a patient experiences 
neurological symptoms indicative of brain metastases, a brain MRI should be performed.  
3. Diagnos is of uveal  or ocular melanoma . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  37 of 113 22 Sep 2023 4. Known history or any evidence of active, non -infectious pneumonitis . 
5. History of New York Heart A ssociation class 3 -4 congestive heart failure or history of 
myocardial infarction within 6 months of starting study treatment . 
6. Active infection requiring systemic treatment . 
7. Diagnosis of immunodeficiency . 
8. Known h istory of severe hypersensitivity reactions to nivolumab, ipilimumab, 
sargramostim , or their excipients . 
9. Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). No HIV 
testing is required unless mandated by local health authority.  
10. History of or active hepatitis B ( hepatitis B surface antigen  reactive) or active hepatitis C 
(hepatitis C virus antibody ). Testing must be performed to determine eligibility.  
11. Women who are breastfeeding . 
Prior/Concomitant Therapy  – Also Prohibited During the Induction Therapy  
12. Prior system ic treatment for unresectable stage III B-D or unresectable stage  IV malignant 
melanoma . Prior systemic  BRAF/MEK inhibitors or immunotherapy as neoadjuvant or 
adjuvant or other setting treatment of stage  I-IIIA, resectable III B-D, or resectable  IV if 
patient progressed earlier than 6  months  after last dose of such treatment.   
13. Systemic cortico steroid treatment (doses exceeding 10  mg daily of prednisone or 
equivalent) or any other form of immunosuppressive treatment within 7  days prior to the 
first dose of induction therapy . Topical, ocular, intra -articular, intranasal, and inhalational 
corticosteroids (with minimal systemic absorption) are allowed. Physiologic replacement 
doses of systemic corticosteroids , a brief course of c orticosteroids for prophylaxis ( eg, 
contrast dye allergy) or for treatment of non -autoimmune conditions is permitted  even 
with >10  mg/day prednisone equivalents . 
14. Receipt of  a live vaccine within 30  days prior to the start of  induction therapy . 
Prior/Concur rent Clinical Study  Experience  
15. Receipt of any other investigational therapy within 4  weeks of the first dose of study 
treatment . 
Other Exclusions  
16. Any medical, psychological, or social condition that would make it difficult for the patient 
to participate in the study and comply with the study procedures, restrictions , and 
requirements . 
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  38 of 113 22 Sep 2023 6 Treatments  
6.1 Study Drugs  
Table  2 Study Drugs  (Induction Period ) 
 Investigational Medicinal Products  Non-Investigational Medicinal Products  
Study drug name:  Sargramostim  UV1  Nivolumab  Ipilimumab  
Dosage Formulation:  Reconstituted for 
injection  Reconstituted for 
injection  Reconstituted 
according to the 
prescribing 
information  Reconstituted 
according to the 
prescribing 
information  
Dose Strengths/  Dosage 
Levels:  75 µg 300 µg 1 mg/kg  3 mg/kg  
Route of 
Administration:  Intradermal injection  Intradermal injection  Intravenous infusion  Intravenous infusion  
Dosing Instructions:  75 µg administrated in a 
volume of 150  µL 300 μg administered 
in a volume of 100  μL 1 mg/kg  according to 
the prescribing 
information  3 mg/kg  according to 
the prescribing 
information  
Packaging and Labeling:  Lyophilized 
sargramostim provided 
in a glass vial.  
 
Labelled according to 
GCP /GMP and local 
regulations  Lyophilized UV1 
provided in a glass 
vial.  
 
 
Labelled according to 
GCP/GMP and local 
regulations  According to the 
prescribing 
information  According to the 
prescribing 
information  
Storage conditions:  Lyophilized:  
2ºC to 8ºC  
 
Reconstituted:  
2ºC to 8ºC   
(maximum 6  hours)  
Do not freeze or shake  Lyophilized:  
2ºC to 8ºC  
 
Reconstituted:  
2ºC to 8ºC   
(maximum  6 hours ) According to the 
prescribing 
information  According to the 
prescribing 
information  
Manufacturer:  Partner Therapeutics, 
Inc. Corden Pharma SpA  Bristol -Myers Squibb  Bristol -Myers Squibb  
Abbreviations: GCP = Good Clinical Practice ; GMP = Good Manufacturing Practice ; N/A = not applicable.  
6.1.1 Sargramostim  
Sargramostim will be used as an adjuvant to UV1 in this study.   
Lyophilized sargramostim vials must be stored refrigerated (2 °C to 8°C)  and protected from 
light.  
Lyophilized sargramostim (250  µg) should be reconstituted with 0.5  mL water for injection to a 
concentration equal to 500  µg/mL giving a clear liquid ready for use. The volume to be 
administered is 150  μL, giving a dose of 75  μg. See also Table  3.  
Reconstituted sargramostim must be stored at 2 ºC to 8ºC for a maximum of 6  hours prior to 
administration. Discard unused  portion of  reconstituted sargramostim . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  39 of 113 22 Sep 2023 Table  3 Instructions for Preparation of Sargramostim  
Dose of Sargramostim 
per injection  Package Format  Content  Water  Concentration  Volume 
injected  
75 µg Lyophilized sargramostim 
glass vial  250 µg 0.5 mL 500 µg/mL  150 µL 
Sargramostim is not approved as a vaccine adjuvant to UV1 and is considered an investigational 
medicinal product (IMP) in this study.  
6.1.2 UV1  
UV1 is produced by lyophilization of a sterile aqueous solution of drug substances. No 
additional excipients are present in the UV1 product.  
Lyophilized UV1 vials must be stored refrigerated (2 °C to 8°C)  and protected from light . The 
vials may also be sto red at room temperature (≤27ºC) for a maximum of 3 days to cover 
short -term excursions.  
Lyophilized UV1 (0.9  mg) should be reconstituted with 0.3  mL water for injection to a 
concentration equal to 3.0  mg/mL giving a clear liquid ready for use. The volume to be 
administered is 100  μL, giving a dose of 300  μg. See also Table  4.  
Reconstituted UV1 must  be stored at 2°C to 8ºC for a maximum of 6  hours  prior to 
administration. Excursions up to room temperature (≤27ºC) are allowed  for a maximum of 
1 hour in total.  Unused portion of reconstituted UV1  should be discarded .  
Table  4 Instructions for Preparation of UV1  
Dose of UV1 per 
injection  Package Format  Content  Water  Concentration  Volume 
injected  
300 µg Lyophilized  UV1  
glass vial  0.9 mg 0.30 mL 3.0 mg/mL  100 µL 
UV1 is not approved as a therapeutic cancer vaccine and is considered an IMP in this study.  
6.1.2.1  UV1 Used for Delayed -type Hypersensitivity  Testing  
For patients who are participating in the Extended Exploratory Cohort, and who are randomized 
to the experimental arm, a DTH skin test will be performed as described in  Appendix  2 and at 
timepoints described in  Table  9.  
For the DTH testing, 20  μL of the  reconstituted  UV1 solution should be injected (intradermally) 
without sargramostim in the skin of the anterior forearm . For the visits where both UV1 
vaccination and DTH testing are performed, the UV1 solution prepared for the vaccination 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  40 of 113 22 Sep 2023 should also be used for the DT H testing. The injection for the DTH  testing should be done prior 
to the UV1 vaccination.  
6.1.3 Nivolumab  
Nivolumab will be reconstituted according to the prescribing information /product characteristic . 
Patients will receive a n induction therapy dose of 1 mg/kg, administered intravenously.  
Six weeks following the last dose of induction therapy, patients will receive maintenance therapy 
at a dose of 480  mg Q4W  according to the label . It is not allowed to use any other dose of 
maintenance therapy  (eg, 240  mg Q2W ).  
Nivolumab is to be used according to the prescribing information and is a non -investigational 
medicinal product (NIMP) in this study.  
6.1.4 Ipilimumab  
Ipilimumab will be reconstituted according to the prescribing information. Patients will re ceive 
an induction therapy dose of 3  mg/kg, administered intravenously.  
Ipilimumab is to be used according to the prescribing information and is a NIMP in this study.  
6.1.5 Administration of Study Drugs  
The administration of study drugs should be done as the las t procedure at each applicable study 
visit per the schedule of activities  (Table  5 and Table  6). 
Sargramostim and UV1 should be administered  intradermally  in an area corresponding to 
McBurney’s point (Figure  3) on the right side of the abdomen (or corresponding spot on the left 
side in case of appendectomy scar). It is important that both injections are strictly intradermal . 
The utmost care must be taken so no material is administered subcutaneously. When done 
correctly, a small bleb should appear following the injection. An injection too superficial will 
result in loss of volume from the injection site during injection or after withdrawal of the needle. 
All 16  injections (8  sargramostim  and 8  UV1) should be injected at the exact same site . 
Permanent marker -pens may be used to ensure that the same site is utilized each time.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  41 of 113 22 Sep 2023 Figure  3 McBurney’s Point 
 
Administration of UV1 should be done 10 to 15 minutes  after  the administration of 
sargramostim. The UV1 is to be administrated at the exact same site as the sargramostim.   
Allergic reactions may occur after sargramostim and UV1 injections. Therefore, patients should 
remain at the site for observation for at least 4 hours after each UV1  injection . 
Nivolumab and ipilimumab are administered intravenously  according  to the label and 
administration is to be started  at least 1  hour after the injection of UV1.  
Patients in the experimental arm will receive 8  UV1 vaccinations over 4  cycles of nivolumab and 
ipilimumab. The UV1 vaccination will be administered alone on Days 1, 3 to 7 (2 UV1 
vaccinations) , and 26, and in combination with nivolumab and ipilimumab on Days 10, 31, 52 , 
and 73.  
Patients in the control arm will receive 4  cycles of nivolumab and ipilimumab, on Days 1, 22, 43 , 
and 64.  
The administration of sargramostim, UV1, nivolumab , and ipilimumab must be recorded in the 
patients’ medical files and the appropriate section of the electronic Case Report Form ( eCRF ). 
The r eason for dose interruption, reduction, or omission will also be recorded in  the medical files 
of patient and later in the eCRF. This information will be used to assess compliance with 
treatment.  
Following the induction therapy , patients in both treatment arms will start maintenance therapy 
and receive nivolumab at a dose of 480 mg Q4W  according to the label . It is not allowed to use 
any other dose of maintenance therapy (eg, 240  mg Q2W ). Nivolumab is the standard of care and 
should be monitored according to the  institutional practice (including routine blood sampling).  
6.1.6 Preparation/Handling/Storage/Accountabi lity 
Unless stated otherwise, s argramostim , nivolumab , and ipilimumab should be stored and handled 
according to the prescribing information. All handling of study drug should be compliant with 
normal  handling of sterile products for injection . 

Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  42 of 113 22 Sep 2023 UV1 and sargramostim will be supplied to the study sites by the Sponsor . Nivolumab and 
ipilimumab will be sourced locally by the study sites . 
The Investigator or designee must maintain accurate records of study drugs received from the 
Sponsor , and documentatio n of preparation and administration of sargramostim, UV1, 
nivolumab , and ipilimumab. Drug name, dose, and batch number/study treatment ID (if required)  
will be documented for all study drugs administered.  
Only patients randomized in the study may receive s tudy drug and only site staff authorized by 
the Investigator may supply or administer the study drug (s). All study drugs must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area with access 
limited to the Investigato r and authorized site staff.  
The Investigator or designee must maintain a log to confirm appropriate temperature conditions 
have been maintained during storage for all study drugs received by the Sponsor  and any 
discrepancies must be reported and resolved before use of the study drug. 
The Investigator  or designee is responsible for study drug accountability, reconciliation, and 
record maintenance ( ie, receipt, reconciliation, and final disposition records).  
Where appropriate facilities and procedures for drug destruction exist and prior approval from 
the site monitor has been received, site personnel will account for appropriate destruction.  
6.1.7 Treatment of Allergic Reactions to UV1 Vaccination  
Investigators are advised to follow the standard t reatment of anaphylaxis and allergies per local 
guidelines.  
6.1.8 Dose Modification  
Dose modification  of sargramostim or UV1 is not allowed in this study. Nivolumab and 
ipilimumab should be dosed according to the label.  
6.1.9 Overdose  
There is no information on over dose of UV1 vaccination, but the distribution route and 
degradation of the UV1 vaccination suggest s that there would be few  consequences , if any. 
Therefore, in the event of an overdose, the patient should be observed for any reactions and 
treated symptomat ically.  
There is no information on overdos e with ipilimumab and nivolumab, given either as 
monotherapies or concomitantly. In case of overdosage, patients must be closely monitored for 
signs or symptoms of adverse reactions  and appropriate symptomatic treatment instituted . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  43 of 113 22 Sep 2023 6.2 Concomitant Medication  
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the patient is receiving at the time of randomization  or receives 
during the study must be recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency . 
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy.  
All ongoing and new medications will be recorded fro m 28 days prior to randomization , until 
30 days after the last dose of induction , or until new anticancer treatment is initiated (whichever 
comes first).  Ongoing and new medications shall also be recorded in connection with any SAEs.  
6.2.1 Prohibited Medications During Induction Period  
The following medications and vaccinations are not allowed during the Induction period:  
• Immunosuppressive agents  
• Systemic corticosteroids >10  mg daily prednisone equivalent (except as stated in 
Section  6.2.2 ) 
• Any concurrent anticancer therapy ( ie, chemotherapy, hormonal therapy, immunotherapy, 
radiation therapy , or investigational agents for treat ment of cancer). Radiation therapy to 
a symptomatic lesion may be allowed after consultation with the sponsor.  Supportive care 
for disease -related symptoms , including bisphosphonates and denosumab , may be offered 
to all patient s in the study . 
• Live vaccines  within 30  days prior to the first dose of induction therapy  and while 
participating in the study. Examples of live vaccines include, but are not limited to, 
measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 flu, rabies, BCG, 
and typhoid v accine . 
• Other  investigational agents . 
6.2.2 Permitted Medications During Induction Period  
Patient s are permitted to use topical, ocular, intra -articular, intranasal, and inhalational  
corticosteroids (with minimal  systemic absorption). Physiologic replacement doses of systemic 
corticosteroids , a brief course of corticosteroids for prophylaxis ( e.g. contrast dye allergy) or for 
treatment of non -autoimmune conditions is permitted  even with >10  mg/day prednisone 
equivalents . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  44 of 113 22 Sep 2023 6.2.3 New Anticancer Treatment  
Details of any new anticancer treatments , from the time of the last dose of induction therapy until 
the earliest of either 70 PFS events reached or 18 months post last patient randomize d, must be 
recorded in the eCRF . The r eason for end of treatment for IMP and NIMP (nivolumab and 
ipilimumab) must be recorded.  
6.3 Treatment  After Progressive Disease  
Clinical evidence  indicates that some patients treated with immune system -stimulating agents 
may develop PD by conventional resp onse criteria  (ie, pseudo -progression per iRECIST ), before 
demonstrating clinical overall responses and/or SD. This may be explained by:  
• Enhance d inflammation within tumors leading to increased tumor size which would 
appear as an enlarged index lesion and as newly visible small non -index lesions. Over 
time, both the malignant and inflammatory portions of the mass may then decrease 
leading to overt  signs of clinical improvement.  
• Initially , the kinetics of tumor growth may outpace anti -tumor immune activity. With 
sufficient time, the anti -tumor activity will dominate and become clinically apparent.  
For patients who have initial radiological evidence of PD by RECIST  1.1 or iUPD (per 
iRECIST) , it is at the discretion of the Investigator to keep the patient on induction/maintenance 
therapy (in the absence of clinical deterioration) until repeat imaging is obtained 4 to 8 weeks 
afterwards (iRECIST -based management). The decision to continue induction /maintenance 
therapy should only be made if the patient  is assessed to be clinically stable, deriving clinical 
benefit , and tolerating the treatment . 
At a minimum, patients must meet the f ollowing criteria for continu ing induction/maintenance 
therapy after PD per RECIST 1.1/iUPD is identified:  
• Absence of worsening symptoms and signs (including worsening of laboratory values)  
• No decline in ECOG performance status  
• Absence of rapid PD or of progressive tumor at critical anatomical sites ( eg, cord 
compression) requiring urgent alternative medical intervention.  
If repeat imaging fails to demonstrate iCPD  (by iRECIST ) and the patient continues to be 
clinically stable, induction/maintenance therapy  should continue per protocol.  
If repeat imaging demonstrate s iCPD , induction/maintenance therapy  should be discontinued.  
The continuation/discontinuation of nivolumab as maintenance therapy will be recorded in the 
patients’ me dical file and in the eCRF.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  45 of 113 22 Sep 2023 7 Study Duration and Schedule of Activities  
This study will consist  of 3 phases : Screening, an Induction period , and a Follow -up period. The 
Follow -up period includes safety , response , and survival follow -up visits.  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  46 of 113 22 Sep 2023 Table  5 Schedule of Activities – Experimental Arm 
 Screening  Induction period  Follow -up period  
Visit/Cycle   V1 
 V2 + 3  
 V4 
C1 V5 
 V6 
C2 V7 
C3 V8 
C4 Safety follow -
up Response follow -up 
 Survival follow -upa 
 Survival follow -
upa 
 
Visit window   0 0 ± 2d ± 2d ± 2d ± 2d ± 2d +7d ±1w ±1w +2w 
Days/Weeks  D -28 to -1 D1 D3-7 D10 D26 D31 D52 D73 30 days post 
last dose of 
induction 
therapy  10w post last dose of   
induction therapy  
then every 8w for 32w.  
Subsequent visits every 12w until 
iCPD per iRECIST or PFS  cut-off 
date reached  Every 12w from 
iCPD per iRECIST 
until PFS cut-off date 
reached  From time of  the 
PFS cut-off d ate 
reached:  
Every 6 months for  
2 years  UV1 vaccinations  
Consecutive 
dosing days not 
allowed  
Signed consent  X             
Eligibility criteria  X             
Medical history  X             
Vital signs & ECOG  X X   X  X X X X    
Physical examination  X         X    
Local lab analysis (all patients)b  
• Hematology & chemistrym X X   X X X X X X    
• Hepatitis B & C virus  X             
• Pregnancy testc X    X  X X X X    
Central lab sampling (all 
patients)d  X     X X  X X (2nd visit only)    
Randomizatione  X            
Treatment:   
• UV1 vaccination   X X X X X X X X  
• Nivolumab      X  X X X Nivolumab 480 mg Q4W according to label (maintenance therapy)f 
• Ipilimumab      X  X X X  
Adverse Eventsg X X X X X X X X X X X X  
Concomitant medicationh X X X X X X X X X X    
Subsequent anticancer treatment           X X X  
Survival status             X X 
Tumor imagingi FIRST tumor imaging during Screening at Day -14 to -1 
SECOND tumor imaging at Week  12 and THIRD tumor imaging at Week  19 post randomization  
SUBSEQUENT tumor imaging every 8  weeks for 32  weeks and then every 12  weeks until PD per iRECIST or until PFS cut-off date  is reached  (whichever comes first)  
ADDITIONAL tumor imaging if premature treatment discontinuation due to any cause  
Extended Explora tory Cohort (40  patients)j 
Signed consent (exploratory 
cohort)  X             
Fecal sample  X             
Tumor biopsy (FFPE & 
snap-frozen)k X         X    
DNA & SNP   X            
PBMC  
  X     X   X X (2nd visit only)    
DTHl 
  X     X X  X X (2nd visit only)   
   
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  47 of 113 22 Sep 2023  
Abbreviations : AE = adverse event;  C = cycle; D/d = day; DNA = deoxyribonucleic acid; DTH = delayed -type hypersensitivity;  ECOG = Eastern Cooperative Oncology Group ; FFPE  = formalin fixed, 
paraffin embedded; ICF = Informed Consent Form; iCPD = immune confirmed progressive disease; iRECIST =  immune Response Evaluation Criteria in Solid Tumors ; PFS = Progression Free 
Survival; PBMC = peripheral blood mononuclear cell; Q4W = every 4  weeks; SAE = serious adverse event;  SNP = single nucleotide polymorphisms ; V = visit; w = week.  
a Patients with iCPD per iRECIST will be discontinued from treatment and will proceed into the survival follow -up phase and be contacted per phone  (or, at the Investigator’s discretion visit the 
hospital) every 12  weeks until PFS cut-off date is reached  (earliest of either 70 PFS events or 18 months post last patient randomized) . From the PFS cut-off date , the survival follow -up visits will 
continue every 6 months for 2 years.     
b Local lab analysis for verification of eligibility criteria is required during Screening at Day -14 to -1. See Table  7 for protocol -required safety laboratory assessments . 
c WOCBP require negative pregnancy test within 72 hours prior to randomization , at Days 10 , 31,52, 73  and at the safety follow -up visit. Additional pregnancy tests according to local regulations for 
treatment of nivolumab and ipilimumab, if required .  
d See Table  8 for collection of samples for exploratory analysis.  
e Patients can be randomized up to 3  days ( from Day -3 until Day  1) prior to first dosing on Day  1 but only after all Screening assessments  are completed .   
f Patients will start maintenance therapy 6 weeks after last dose of induction therapy.  
g From signing of the ICF until the first dose of induction therapy only AEs/SAEs caused by study -specific procedures should be reported. All non-serious AEs should be reported from the first dose of 
induction therapy  until 30  days after the last dose of induction therapy, or until new anticancer treatment is initiated (whichever comes first). All SA Es should be reported from the first dose of 
induction therapy until the PFS cut-off date is reached  or until new anticancer treatment is initiated (whichever comes first).  
h All ongoing and new medications will be recorded from 28  days prior to randomization, until 30  days after the last dose of ind uction, or until new anticancer treatment is initiated (whichever comes 
first). Ongoing and new medications shall also be recorded in connection with any SAEs.  
i Tumor imaging should be performed regardless of treatment stop or delays and within a visit wi ndow of ± 7  days. Tumor imaging will be performed using CT/MRI scans of the chest, abdomen, and 
pelvis. CT scans are the required modality for measurable disease unless a patient has a clinical condition (e .g. severe contrast allergy) or the lesions are be tter visualized through the use of MRI. 
The same imaging technique has to be used in a patient throughout the study. If an unscheduled CT/MRI is performed during the  study, subsequent protocol planned CTs/MRIs should be performed 
unless the time interval b etween the CTs/MRIs is <4 weeks.   
j A cohort of approximately 4 0 patients  at selected sites will be asked to volunteer for additional biological sampling and analysis. See Table  9 and Table  10 for collection of samples and DTH for the 
Extended Exploratory Cohort . 
k If the patient has only one target lesion, the biopsy should be taken either subsequent or at least 7 days prior to the scree ning imaging scan . 
l UV1 without sargramostim injected intradermally in the skin of the anterior forearm. Patient will measure an d record the skin reaction 48±4 hours after the injection.  
m It is recommended to have blood sampling on day of treatment.  If the sampling was not done on the day  of treat ment  and the most current Liver Function Test (LFT) results warrant a safety concern , 
the site must repeat the LFT panel on the day of treatment  and review the results prior to study drug administration.    
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  48 of 113 22 Sep 2023 Table  6 Schedule of Activities – Control Arm 
Extended Exploratory Cohort ( 40 patients)j 
Signed consent (exploratory cohort)  X        
Fecal sample  
 X        
Tumor biopsy (FFPE & snap -frozen) k X     X   
DNA & SNP   X       
PBMC   X  X  X X (2nd visit only)    Screening  Induction therapy  Follow -up period  
Visit/Cycle   V1 
C1 V2 
C2 V3 
C3 V4 
C4 Safety 
follow -up  Response follow -up Survival follow - upa 
 Survival follow - upa 
 
Visit window   0 ± 2d ± 2d ± 2d +7d ±1w ±1w +2w 
Days/Weeks  D -28 to -1  D1 D22 D43 D64 30 days post 
last dose of 
induction 
therapy  10w post last dose of 
induction therapy  
then every 8w for 
32w. Subsequent 
visits every 12w until 
iCPD per iRECIST  or 
PFS cut-off date 
reached  Every 12w from iCPD per 
iRECIST  
until PFS cut-off date  reached  From time of thePFS cut-off date 
reached:  
Every 6 months for  
2 years  
Signed consent  X         
Eligibility criteria  X         
Medical history  X         
Vital signs & ECOG  X X X X X X    
Physical examination  X     X    
Local lab analysis (all patients)b   
• Hematology & chemistryl) X X X X X X    
• Hepatitis B & C virus  X         
• Pregnancy test c X X X X X X    
Central lab sampling (all patients)d  X  X X X X (2nd visit only)    
Randomizatione  X        
Treatment:   
• Nivolumab   X X X X Nivolumab 480 mg Q4W according to label (maintenance therapy)f 
• Ipilimumab   X X X X  
Adverse Eventsg X X X X X X X X  
Concomitant medicationh X X X X X X    
Subsequent anticancer treatment       X X X  
Survival status         X X 
Tumor imagingi FIRST tumor imaging during Screening at Days -14 to -1 
SECOND tumor imaging at Week  12 and THIRD tumor imaging at Week  19 post randomization  
SUBSEQUENT tumor imaging every 8  weeks for 32  weeks and then every 12  weeks until PD per iRECIST  or until the PFS cut-off date is reached  (whichever comes 
first)  
ADDITIONAL tumor imaging if premature treatment discontinuation due to any cause  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  49 of 113 22 Sep 2023 Abbreviations : AE = adverse event; C = cycle; D/d = day; DNA = deoxyribonucleic acid; ECOG = Eastern Cooperative Oncology Group ; FFPE = formalin fixed, paraffin embedded; ICF = Informed 
Consent Form; iCPD = immune confirmed progressive disease; iRECIST = immune Response Evaluation Criteria in Solid Tumors ; PFS = Progression Free Survival; PBMC = peripheral blood 
mononuclear cell; Q4W = every 4  weeks; SAE = serious adverse event; SNP = single nucleotide polymorphisms; V = visit; w = week.  
a Patients with iCPD per iRECIST will be discontinued from treatment and will proceed into the survival follow -up phase and be contacted per phone (or, at the Investigator’s discretion visit the 
hospital) every 12  weeks until  PFS cut-off date  is reached  (earliest of either 70 PFS events or 18 months post last patient randomized) . From the PFS  cut-off date , the survival follow -up visits will 
continue every 6 months for 2 years.    
b Local lab  analysis for verification of eligibility criteria is required during Screening at Day -14 to -1. See Table  7 for protocol -required safety laboratory a ssessments . 
c WOCBP require negative pregnancy test within 72 hours prior to randomization , at Days 1, 22, 43 , 64 and at the safety follow -up visit. Additional pregnancy tests according to local regulations for 
treatment of nivolumab and ipilimumab, if required .  
d See Table  8 for collection of samples for exploratory analysis.  
e Patients can be randomized up to 3  days ( from Day -3 until Day  1) prior to first dosing on Day 1 but only after all Screening assessments are completed .  
f Patients will start maintenance therapy 6 weeks after last dose of induction therapy.  
g From signing of the ICF until the first dose of induction therap y only AEs/SAEs caused by study -specific procedures should be reported. All non -serious AEs should be reported from the first dose of 
induction therapy  until 30  days after the last dose of induction therapy, or until new anticancer treatment is initiated ( whichever comes first). All SAEs should be reported from the first dose of 
induction therapy until  the PFS cut-off date is reached  or until new anticancer treatment is initiated (whichever comes first).   
h All ongoing and new medications will be recorded from 28  days prior to randomization, until 30  days after the last dose of induction, or until new anticancer treatment is initiated (whichever comes 
first). Ongoing and new medications shall also be recorded in connection with any SAEs.  
i Tumor im aging should be performed regardless of treatment stop or delays and within a visit window of ± 7  days. Tumor imaging will be performed using CT/MRI scans of the chest, abdomen, and 
pelvis. CT scans are the required modality for measurable disease unless a  patient has a clinical condition (e .g. severe contrast allergy) or the lesions are better visualized through the use of MRI. 
The same imaging technique has to be used in a patient throughout the study. If an unscheduled CT/MRI is performed during the  study, subsequent protocol planned CTs/MRIs should be performed 
unless the time interval between the CTs/MRIs is <4 weeks .  
j A cohort of approximately 4 0 patients at selected sites will be asked to volunteer for additional biological sampling and analysis. A separate ICF will be used for the Extended Exploratory Cohort and 
will be different than the main study. See Table  9 and Table  10 for collection of samples for the Extended Exploratory Cohort . 
k If the pa tient has only one target lesion, the biopsy should be taken either subsequent or at least 7 days prior to the screening imag ing scan . 
l It is recommended to have blood sampling on day of treatment.  If the sampling was not done on the day of treatment and the most current Liver Function Test (LFT) results warrant a safety concern, 
the site must repeat the LFT panel on the day of treatment  and review the results prior to study drug administration .  
 
 
 
 
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  50 of 113 22 Sep 2023 7.1 Screening  
Within  28 days prior to randomization, potential patients will be evaluated to determine if they 
fulfill the eligibility criteria  described in Section  5.1 and Section  5.2. Procedures conducted as 
part of the patient’s routine clinical management ( eg, blood count) obtained before signing of the 
ICF may be utilized for Screening or Baseline purposes provided the procedure met the 
protocol -specified criteria and was performed within the timeframe defined in the schedule of 
activities ( Table  5 and Table  6). 
7.1.1 Screen Failures  
Screen failures are defined as patients who consent to participate in the clinical study but who are 
not subsequently randomiz ed. A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure patients to meet the consolidated standards of reporting 
trials publishing requirements and to respond to queries from regulatory authorities. Min imal 
information includes demographics, screen failure details, eligibility criteria, and any AEs caused 
by study -specific procedures.  
Individuals who do not meet the criteria for randomization (screen failures) may be re -screened  
once . Re-screened patient s should be assigned a new screening number and be re -consented.  
The Investigator  must account for all patients screened and randomized. A patient participation 
log is to be completed with the patient’s screening number, randomization number (if patient is  
randomized), date of consent, and date of the initial administration of induction therapy . If a 
patient is not randomized, the reason for exclusion from the study will be documented in the 
eCRF.  
7.2 Induction Period  
Patients who satisfy all eligibility criteria will be randomized in a 1:1 ratio between the 
2 treatment arms and start treatment with induction therapy:   
• Experimental arm: UV1 vaccination in combination with nivolumab and ipilimumab  
• Control arm: nivolumab  and ipilimumab . 
The combination of nivolumab and ipilimumab as induction therapy is admin istered Q3W  for 
4 doses. Patients randomized to the experimental arm will undergo  4 additional visits to receiv e 
single doses with UV1  vaccination .  
7.2.1 Discontinuation of Induction Therapy  
If, during the Induction period, both nivolumab and ipilimumab are temporarily discontinued  for 
patients randomized to the experimental arm , study visits and treatment with UV1 vaccination 
should also be temporarily di scontinued. However, UV1 vaccination at visit 5 (monotherapy) can 
be administered if the patient would have been considered eligible to receive nivolumab and 
ipilimumab at that time point.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  51 of 113 22 Sep 2023 If, during the Induction period , nivolumab and ipilimumab are permanently discontinued, study 
visits and treatment with UV1 vaccination  should  be permanently discontinued.  If the decision to  
permanently  discontinue induction therapy is done during a scheduled study visit, the procedures  
and assessments applicable for that visit should be performed.  However, if it’s been > 30 days 
since last induction dose, the safety follow -up visit should be performed instead . If the decision 
to permanently  discontinue induction therapy is done between two scheduled study visits, the 
next visit will be the safety follow -up visit  which shall be  performed 30 -37 days after the last 
induction dose.  If it’s been > 37 days since last induction dose, the safety follow -up visit should 
be performed as soon as pos sible . 
If the UV1 vaccination is discontinued, nivolumab and ipilimumab  induction therapy may 
continue as scheduled  in the protocol . With the exception of the DTH  testing, all study 
procedures and assessments described in the schedule of activities  will be performed . 
Discontinuation of induction therapy does not represent withdrawal from the study. All patients 
that permanently discontinue all induction therap ies prior to completion of the Induction period 
(Day s 1 to 73 in the experimental  arm and Days 1 to 64 in the control arm) will attend the safety 
follow -up visit and continue in the study for the determination of PD and survival . 
UV1 vaccination will be discontinued if any of the following situations occur:  
1. Patient requests to stop UV1 vaccination, nivolumab and ipilimumab  
2. Any clinical AE, laboratory abnormality, intercurrent illness which, in the opinion of the 
Investigator , indicates that continuation with UV1 vaccination is not in the best interest of the 
patient  
3. Patient starts another anticancer treatment while receiving UV1 vaccination,  nivolumab , and 
ipilimumab  
4. Pregnancy  
5. At the discretion of the Investigator  
6. Termination of the study by the Sponsor . 
Adverse events associated with nivolumab and/or ipilimum ab and/or UV1 vaccine exposure may 
represent an immunologic etiology. These A Es may occur shortly after the first dose or several 
months after the last dose of treatment. Nivolumab and/or ipilimumab must be withheld for 
moderate or severe drug -related toxi cities and severe or life -threatening A Es.  
Patients who develop serious allergic reactions during treatment with sargramostim  and/or UV1 
will be discontinued from further vaccinations independently of the deemed relatedness to 
sargramostim or UV1. Treatme nt with nivolumab and ipilimumab may continue at the 
Investigator ’s discretion.  
Permanent Discontinuation of  Induction  Therapy Due to Safety Reasons  
If due to safety reasons , all induction therapies are discontinued,  the patient will complete the 
safety follow -up visit 30  to 37 days after the last dose of induction therapy. Thereafter, the 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  52 of 113 22 Sep 2023 patient will continue with the response follow -up visits ( 10 weeks post last dose of induction 
therapy ).  
Permanent Discontinuation of  Induction Therapy Due to Progressive Disease   
If, during  the Induction period , a patient has PD confirmed by a repeat CT /MRI  scan according 
to iRECIST  (iCPD) , all induction therapy will be discontinued  and the patient will complete  the 
safety f ollow -up visit 30 to 37 days after the last dose of induction therapy. Further anticancer 
treatment will be given at the Investigator ’s discretion.  If anticancer treatments other than 
nivolumab are planned to start prior to 30  days after the l ast dose of induction therapy , the safety 
follow -up visit will be performed as soon as possible following the confirmed PD. The patient 
will thereafter continue into the survival follow -up. 
Permanent Discontinuation  of Induction Therapy Due or Patient Decision or Investigator ’ s 
Discretion  
Patients taking part in the study can request to stop treatment with all induction therap ies or 
decision to stop can be done at the Investigator ’s discretion. If either occurs , the pa tient will be 
asked to complete  the safety follow -up visit 30  to 37 days after the last dose of induction therapy . 
The patient should be encouraged to continue the study as scheduled thereafter. If this is not 
accepted by the patient, he/she should be asked for acceptance to continue in the survival 
follow -up and be contacted by phone (or, at the investigator’s discr etion visit the hospital).   
7.3 Follow -up Period  
Six weeks after last dose of induction therapy, patients in both treatment arms will start 
maintenance therapy and receive nivolumab at a dose of 480 mg Q4W  according to the label . It 
is not allowed to use any other dose of maintenance therapy  (e.g. 240 mg Q2W ). 
The Follow -up period includes a safety follow -up visit, response follow -up visits , and survival 
follow -up visits as described below. All patients should be followed for the intended duration of 
the study on an intent -to-treat basis for confir mation of PD and OS, regardless of the receipt of 
any new anticancer treatment.  
7.3.1 Safety Follow -up Visit  
The safety follow -up visit should be conducted 30  to 37 days after the last dose of induction 
therapy . If anticancer treatments other than nivolumab are planned to start prior to 30  days after 
the last dose of induction therapy, the safety follow -up visit will be performed before the 
initiation of new anticancer treatment if possible.  
7.3.2 Response Follow -up Visits  
Patients who complete the Induction period and/or who discontinue the Induction period  for 
other reasons than confirmed PD will continue with response follow -up visits (after the 
completion of the safety follow -up visit) and should be assessed with imaging and assessments 
according to the schedule of activities for monitoring of disease status.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  53 of 113 22 Sep 2023 The first response follow -up visit should occur 10 weeks post last dose of induction therapy. 
Subs equent response follow -up visit s will be performed every 8  weeks for 32  weeks and then 
every 12  weeks thereafter . Every effort should be made to collect information regarding disease 
status until confirmed PD (iCPD) per iRECIST , until 70 PFS events are reached or until 18 
months post last patient randomized (whichever comes first).  If required, images may be 
requested by BICR also after local iRECIST progression.  
Handling  Progressive Disease During the Response Follow -up Period  
If, during the response Follow -up period  a patient has iCPD  confirmed  by 2 scans , 4 to 8 weeks 
apart according to iRECIST criteria , the patient will continue with survival follow -up visits and 
will be contacted by phone (or, at the investigator’s discretion visit the hospital) every 12  weeks 
until the earliest of either 70 PFS events reached  or 18 months post last patient randomized . 
From the PFS cut-off date  is reached , survival follow -up visits will continue  every 6 mon ths for 
2 years.  
If PD is not confirmed  according to iRECIST criteria, patient should continue with the response 
follow -up visits and imaging schedule according to Table  5 and Table  6.  
Handling  Complete Response During the Response Follow -up Period  
If, during the response Follow-up period a patient has complete response ( CR) according to 
RECIST 1.1 , the patient will be treated according to the Investigator ’s discretion. Patients who 
stop anticancer treatment while in CR will continue to undergo tumor imaging as scheduled in 
the study protocol. In the event of disease recurrence, any anticancer treat ment  including 
nivolumab  may be resumed at the Investigator ’s discretion.  
7.3.3 Survival Follow -up Visits  
Patients who ha ve confirmed iCPD according to iRECIST will continue with survival follow -up 
visits  and be contacted per phone (or, at the investigator’s discretion visit the hospital) every 
12 weeks for survival status , assessment of SAEs and new anticancer treatments until  the earlie st 
of either 70 PFS events reached  across both treatment arms or 18 months post last patient 
randomized .  
From the PFS cut-off date is reached , the survival follow -up visits will continue every 6  months 
for 2 years  and only survival status will be collected . Detailed visit instructions will be provided 
by the sponsor at this time.  
The Sponsor  may request survival status to be collected at additional timepoints during the study.  
For example, updated survival status may be requested prior to a n IDMC  review.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  54 of 113 22 Sep 2023 7.4 Withdrawal  of Consent  
• A patient may withdraw consent from the study at any time at his/he r own request. 
Although a patient  is not obliged to give his/her reason(s) for withdrawing prematurely 
from a study , the Investigator  should make a reasonable effort to ascertain the reason(s), 
while fully respecting the patient’s  rights . 
• If the patient wi thdraws consent for disclosure of future information, the Sponsor  may 
retain and continue to use any data collected before such a withdrawal of consent. 
Survival status post withdrawal of consent can still be obtained from publicly available 
sources such a s national cancer registries.  
• If a patient withdraws consent from the study, he/she may request destruction of any 
samples taken and not tested, and the Investigator  must document this in the medical 
records.  
If Withdrawal of Consent Occurs During the Induction Period  
If possibl e, the procedures for the safety follow -up visit should be performed at the time of 
withdrawal . If the withdrawal takes place between 2 study visits , the patient should be asked to 
attend the safety follow -up visit as soon as pos sible. Any DTH registration card should be 
returned. The patient will no longer receive induction therapy or be followed at scheduled 
protocol visits.  
If Withdrawal of Consent Occurs During the Follow -up Period   
If possible, t he procedures for the applicable visit where withdrawal takes place should be 
performed. If withdrawal takes place between 2 study visits, the patient should be asked to attend 
the next visit as soon as possible. Any DTH registration card should be returne d. The patient will 
no longer be followed a t scheduled protocol visits.  
7.5 Lost to Follow -up 
A patient  will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  A patient is not considered lost to follow -up 
until the study is declared stopped.  
The following actions must be taken if a patient  fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact the patient  and reschedule the m issed visit as soon as 
possible and counsel the patient  on the importance of maintaining the assigned visit 
schedule and ascertain whether  the patient  wishes to and/or should continue in the study  
or not . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  55 of 113 22 Sep 2023 • In cases in which the patient  is deemed lost to fol low-up, the Investigator  or designee 
must make every effort to regain contact with the patient  (where possible, 3 telephone 
calls and , if necessary , a certified letter to the patient ’s last known mailing address or 
local equivalent methods). These contact attempts should be documented in the patient ’s 
medical record . 
• For lost to follow -up patients, survival status can still be obtained from publicly available 
sources such as national cancer registries.  
7.6 End of Study  
The primary and secondary endpoint analysis will be conducted at the earliest of either 70 PFS 
events reached across both treatment arms or 18 months post last patient randomized . From  the 
PFS cut-off date is reached, all pa tients  will have survival follow -up visits every 6 months for 2 
years. The EOS is defined as the date of the last survival follow -up visit of the last patient 
undergoing the study.   
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  56 of 113 22 Sep 2023 8 Study Assessments and Procedures  
• Study procedures and their timing are su mmarized in the schedule of activities (Table  5 
and Table  6). Adherence to th e study design requirements is essential and required for 
study conduct.  
• Protocol waivers or exemptions are not allowed with the exception of immediate safety 
concerns . These should be discussed with the Sponsor  immediately upon occurrence or 
awareness to determine if the patient  should continue or discontinue study treatment . 
• All screening evaluations must be completed and reviewed prior to randomization to  
confirm that  potential patients meet all eligibility cr iteria. The Investigator  will maintain a 
screening log to record details of all patient s screened and to confirm eligibility or record 
reasons for sc reening failure, as applicable.  
• The maximum amount of blood collected from each patient  over the duration o f the 
study, including  any extra assessments that may be required , is estimated to be 30  mL for 
local analysis and 95 mL for exploratory analysis . Patients who volunteer to take part in 
the extended exploratory sampling ( Section 8.5) will have approximately 326 mL extra 
volume of blood collected.  
• Repeat  or unscheduled samples may be taken for safety reasons or for tec hnical issues 
with the samples.  
8.1 Efficacy Assessments  
8.1.1 Assessment of Tumor Response  
8.1.1.1  Tumor Imaging  
Tumor imaging will be performed  as detailed in the schedule of activities (Table  5 and Table  6) 
and should not be adjusted for dosing delays.  It is important that patients are assessed according 
to the intended scanning schedule to prevent bias in analysis that may occur if one treatment arm 
is assessed differently compared to the other.  If an unscheduled CT/MRI is performed during the 
study, su bsequent protocol planned CTs/MRIs should be performed unless the time interval 
between the CTs/MRIs is <4  weeks.  
Mandatory tumor imaging consists of:  
• Contrast enhanced CT or MRI of chest, abdomen , and pelvis  and all other known sites of 
disease . The CT s cans are the preferred modality for measurable disease unless a patient 
has a severe iodine contrast allergy or other clinical condition that precludes optimal CT 
imaging, or the lesions are better visualized through the use of MRI. An MRI is the 
preferred  modality for central nervous system ( CNS ) imaging in the case of suspected 
new CNS involvement . For a given patient, the same imaging modality should be used 
throughout the entire study to allow for comparability of lesions over time  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  57 of 113 22 Sep 2023 • A CT or MRI of other body regions where lesions are present or suspected and can be 
visualized on CT or MRI (does not apply to superficial skin lesions). Once a lesion has 
been identified  and documented with CT/MRI scanning , follow -up CT/MRI scans must 
be co nsistently repeated at all subsequent tumor assessment timepoints  
• Digital  photography and documentation with label and ruler of all skin lesions   
All scheduled tumor images will be submitted for BICR. In addition, images that are obtained at 
an unscheduled  timepoint and which relate to tumor assessment should also be submitted for 
BICR. Further details on tumor imaging and data transfer will be provided in a  separate Imaging 
Guidance document.  
8.1.1.2  Tumor Assessments  
Tumor assessments will be performed by the loc al Investigator /site and by BICR according to 
RECIST  1.1. In addition, the Investigator will evaluate new lesions and any potential PD by  
iRECIST  (Appendix  4). For this protocol, target skin lesions are considered measurable only if 
measurable on CT or MRI. Measurable lesions that have previously been irradiated will not be 
considered target lesion s unless size increase has been observed  following  completion of 
radiation t reatment . 
As a clarification to RECIST  1.1, the following applies if a lesion is resected  or receive s any 
form of treatment  or local therapy  during the study : 
• The procedure itself, the pathology result (positive, negative, non -evaluable  [NE] ), and 
all post -procedure lesion assessments should  always be recorded in the eCRF  
• Subsequent assessments for  such patients will be NE until PD has been  determined from 
the nadir  
Patients with PD per RECIST  1.1 and unconfirmed PD ( iUPD ) per iRECIST will have a new 
scan 4 to 8  weeks later to confirm PD per iRECIST (iCPD). A detailed description of response 
criteria is given in Appendix  4.  
If confirmatory scan performed 4  to 8 weeks after iUPD does not confirm progression, further 
scans continue as originally planned.  
Patient treatment will be determined by the Investigator . The BICR will perform  assessments for 
statistical endpoint analysis only and will not interfere with Investigator  assessments or treatment 
decisions.  Treatment should continue until iCPD has been confirmed . 
8.2 Safety Plan and Assessments  
The administration of  study treatment will be performed in a setting with emergency medical 
facilities and staff who are trained to monitor for and respond to medical emergencies.  Eligibility 
criteria were selected to guard the safety of patients in this study . During the stud y, patients will 
be closely monitored for the development of any AEs, including signs or symptoms of 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  58 of 113 22 Sep 2023 autoimmune conditions.  Patients receiving UV 1 injections will be observed in study site  for 
4 hours following each treatment with UV1 and sargramostim.  
Planned timepoints for all safety assessments are provided in the schedule of activities . Adverse 
event s will be reported throughout the study as described in Section  8.3. Any clinically 
significant abnormalities persisting at  the PFS cut-off date reached  will be followed by the 
Investigator  until resolution or until a stable clinical status  is reached but wil l not be recorded in 
the eCRF ; however, clinically significant abnormalities should be noted in the patient’s medical 
file. 
8.2.1 Independent Data Monitoring Committee  
During the course of the study, a n IDMC will monitor safety information to ensure patient safety. 
The primary responsibility of the IDMC is to safeguard the interests of patients in the study. The 
IDMC will provide recommendations regarding stopping, modifying , or continuing the trial.  The 
IDMC will consist of medical and statistical experts  and provide their recommendations  to the 
Sponsor . The safety and well -being of the study patients are the most important considerations.  
An organizational IDMC meeting will be held and an IDMC charter developed prior to the first 
patient screened in the study . The first operational IDMC meeting will take place approximately 
three weeks after the first 6  patients (3 in experimental and 3 in control arm ) have completed  the 
first treatment cycle  (defined as until planned start of C2 dosing)  of ipilimumab and nivolumab 
+/- UV1  and will include a safety review of all the included patients. The second IDMC meeting 
will take place  approximately three weeks  after the f irst 6 (3+3) patients have finished or 
discontinued  the second cycle  (defined as until planned start of C3 dosing) , and the third meeting 
will take place approximately seven weeks after the 6 (3+3) patients have finished or 
discontinued  planned cycle 4 .  
The safety data of all inclu ded patients will be reviewed at each meeting. Subsequent meetings 
will be held every 3 months until  the PFS cut -off date is reached  or until last dose of induction 
therapy  in the single arm UV1 cohort, whichever c omes  later. 
The IDMC’s assessment will be based on accumulated listings of the safety data collected in the 
study  (ie, AEs, SAEs, hematology and chemistry data, withdrawals due  to AEs , and treatment 
termination caused  by AEs, etc). 
8.2.1.1  Study Stopping Rules 
A decision to stop the study  on the basis of safety findings will be  done in accordance with the 
IDMC Charter for the study.  Conditions that may warrant halting of the study include, but are not 
limited to the following:  
• The discovery of an unexpected, significant,  or unacceptable risk to the patients  
• Subsequent discovery of a detrimental impact on efficacy of UV1 resulting in a negative 
risk/benefit balance  
• Cancellation of drug development  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  59 of 113 22 Sep 2023 8.2.2 Physical Examination s 
• Height will be measured at Screening only . 
• Weight  should be measured using the same scale for a patient . 
• A physical examination of the skin, cardiac, pulmonary, abdomen , and peripheral lymph 
node status will be conducted . 
• Investigators should pay special  attention to clinical signs relate d to previous serious 
illnesses . 
• Clini cally significant findings  observed by the Investigator  or symptoms reported 
spontaneously by the patient during the physical ex amination will be reported  as AEs and 
in accordance with Section  8.3.3 . 
8.2.3 Vital Signs  
• Temperature, pulse rate and blood pressure will be assessed.  
• Blood pressure will be assessed in the seated  position  (after 5  minutes of rest)  with a 
completely automated device . Manual techniques will be used only if an automated 
device is not available . 
8.2.4 Eastern Cooperative Oncology Group  
The ECOG performance status  will be measured as indicated in the schedule of activities. See 
Appendix  3 for the ECOG performance status scale.  
8.2.5 Clinical Safety Laboratory Assessme nts 
Refer to  Appendix  1 Clinical Laboratory Tests  for the list of clinical laboratory tests to be 
performed and to the schedule of activities for the timing and frequency . 
The Investigator  must review the laboratory report, document this revi ew, and report any 
clinically relevant changes in the AE section of the eCRF . Abnormal laboratory findings should 
be reported  as AEs if they are clinically significant  (ie, medical intervention or corrective action , 
such as transfusions, initiation of antibiotics , other treatment regimens, or hydration , is required ) 
or the abnormality  is deemed clinically significant by the treating physician  due to any other 
reason . The laboratory reports must be filed with the source documents.  Laborator y values must 
be graded using National Cancer Institute Common Terminolo gy Criteria for Adverse Events  
version 5.0. 
All abnormal laboratory tests with values considered clinically significant  should be followed up 
per institutional practice . Every attempt should be made to perform repeat assessment until the 
values return to normal or baseline or if a new baseline is established, as determined by the 
Investigator .  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  60 of 113 22 Sep 2023 8.2.6 Toxicity of the Study Drugs  
There are no data on the toxicity of the combined therapy with all 4 study drugs in the present  
study.  The combined toxicity of ipilimumab and nivolumab is known through several studies and  
is mentioned in the respective prescribing information.  If a patient receiving ipilimumab  and/or 
nivolumab  develops suspected immune AEs, this must be handled according to the 
label/ prescribing information  for the relevant study drug(s) . Further, both the IMP s and NIMPs  
may give general symptoms like fatigue. Please refer to the Investigator’s Brochure ( IB)/label  for 
the IMP/study drug for further information.  
8.3 Adverse Events  
8.3.1 Definitions  
8.3.1.1  Definition of AE 
An AE is any untoward medical occurrence in a subject  or clinical study patient, temporally 
associated with the use of a study treatment, whether or not considere d related to the medicinal 
product.  
Examples of e vents meeting the AE definition:  
• Any unfavorable laboratory test abnormality  (hematology, clinical chemistry, or 
urinalysis) or other unfavorable safety assessment  abnorma lity (eg, electrocardiogram , 
radiolo gical scans, vital signs measurements), including those that worsen from Baseline, 
will be considered an AE. An unfavorable laboratory test abnormality may be one which 
requires medical intervention, requires action on the study  drug(s) or is considered on e at 
the discretion of the Investigator.  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition  
• New conditions detected or diagnosed after study treatment administration  even though it 
may have been present before the start of the study  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se should  not be reported as an AE 
unless it is an intentional overdose taken with possible suicidal/self -harming intent. In 
that case , the overdose should be reported as an AE regardless of sequelae.  
• “Lack of efficacy ” or “failure of expected pharmacological action ” per se should not be 
reported as an AE. Such instances will be captured in the efficacy assessments. However, 
the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy should be 
reported as an  AE if they fulfill the definition of an AE.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  61 of 113 22 Sep 2023 8.3.1.2  Events Not Meeting the AE Definition  
The following are examples of events that do not meet the definition of an AE. These events 
should not be reported  as AEs, unless  there is evidence suggesting a causal relationship between 
the study treatment  and the event:  
• The disease being studied. This includes signs, symptoms, clinically significant abnormal 
laboratory findings , or other abnormal safety assessments that are associated with the 
underlying disease, unless  more severe than e xpected for the patient’s condition . 
• Progression from the disease being studied. This inclu des AEs definitely related to 
disease progression . 
• Death from the disease being studied . 
• Elective medical or surgical procedure ( eg, endoscopy, appendectomy). Note: The 
condition that leads to the procedure is the AE (or part of medical history) . 
• Situations in which an untoward medical occurrence did not occur, but the patient was 
hospitalized (social and/or convenience admission to a hospital) . 
• Minor laboratory deviations outside of normal ranges and a nticipated day -to-day 
fluctu ations of pre -existin g disease(s) or condition(s) present or detected at the start of the 
study that do not worsen . 
• Pregnancy, unless there is a suspicion that the study intervention may have interfered 
with the effectiveness  of a contraceptive medication . All pregnancies must be reported in 
a pregnancy report form and should follow the procedures outlined in Section  8.3.4 . 
• Elective abortions without complications . 
• Hospitalization for normal delivery of a healthy newborn . All pregnancy outcomes must 
be reported in a pregnancy outcomes form and should follow the procedures outlined in 
Section  8.3.4 . 
8.3.1.3  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious ness 
conditions are met . 
An SAE is defined as any untoward medical occurrence that, at any dose:  
1. Results in death  
2. Is life -threatening  
The term ‘life-threatening ’ in the definition of ‘serious ’ refers to an event in which the patient 
was at risk of death at the time of the event. It does not refer to an event  that hypothetically 
might have caused death, if it were more severe.  
3. Requires inpatient hospitalization or prolongation of existing hospit alization  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  62 of 113 22 Sep 2023 In general, hospitalization signifies that the patient has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment 
that would not have been appropriate in the physician’s off ice or outpatient setting. 
Complications that occur during hospitalization are AE s. If a complication prolongs 
hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to 
whether ‘hospitalization ’ occurred or was neces sary, the AE should be considered serious.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
Baseline is not considered an AE.  
4. Results in persistent disability/incapacity  
The term ‘disability ’ means a substantial d isruption of a person’s ability to conduct normal 
life functions.  
This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental 
trauma ( eg, sprained ankle) which may interfere with or prevent everyday life functions but 
do not constitute a substantial disruption  
5. Is a congenital anomaly/birth defect  
6. Other situations 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the patient or may 
require medical or surgical intervention to prevent one o f the other outcomes listed in the 
above definition. These events should usually be considered serious.  
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dysc rasias or convulsions that 
do not result in hospitalization, or development of drug dependency or drug abuse.  
8.3.1.4  Potential Drug Induced Liver Injury (DILI)  
All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs.  
Potential d rug induced liver injury is defined as:  
7. ALT or AST elevation > 3 times upper limit of normal (ULN), AND  
8. Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated alkaline 
phosphatase), AND  
9. No other immediately apparent possible causes of ALT or AST elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre -existing chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  63 of 113 22 Sep 2023 8.3.1.5  Definition of Adverse Event of Spec ial Interest  
Adverse events of special interest are events of scientific and medical interest specific to the 
further understanding of the safety of UV1 vaccination. An AESI may be serious or non -seriou s. 
For all A ESIs, the Investigator  should provide a description of the event, including but not 
limited to time of onset, treatment given , and outcome.  Events falling under the AESI definition 
is an AESI regardless of the investigator’s assessment of relatedness to a study drug , and 
regard less of which treatment arm the patient is randomized to.  
Adverse events of special interest  include  any of the following events occurring on the same day 
of sargramostim, UV1, nivolumab or ipilimumab administration : 
• Anaphylactic  shock  
• Anaphylactic reactio n 
• Hypersensitivity  (allergic reactions except local injection site reactions) . 
8.3.1.6  Definition of Suspected Unexpected Serious Adverse Reaction  
A suspected unexpected serious adverse reaction (SUSAR) is an SAE that is not expected, and 
for which there is a reasona ble possibility that the study treatment caused the event . 
For UV1 and sargramostim, the  reference safety information section in the  UV1 IB is the 
reference document for what is considered to be expecte d SAEs. All clinical data in the IB are 
for use of the UV1 vaccination  (ie, the combination of UV1 and sargramostim ). An event that is 
expected for the UV1 vaccination is considered as expected for both UV1 and sargramostim.  
The causality assessment for SUSARs is the same as for other events, as described in 
Section  8.3.2.2 . 
8.3.2 Classification of A dverse Events  
8.3.2.1  Severity and Grade  
The National Cancer I nstitute  Common Terminology Criteria for Adverse Events  version 5.0 
criteria will be used to gr ade AEs. 
The Investigator  will assess severity  for each AE and assign it to one of the following categories:  
• Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
• Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age 
appropriate instrumental Activities of Daily Living ( ADL )*.  
• Grade 3: Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation  of hospitalization indicated; disabling; limiting self -care 
ADL**.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  64 of 113 22 Sep 2023 • Grade 4: Life -threatening consequences; urgent intervention indicated.  
• Grade 5 : Death related to AE.  
Activities of Daily Living:  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
**Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.  
8.3.2.2  Caus ality  
The Investigator  is obligated to assess the causal relationship between each study treatment and 
an AE. The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Causality must be reported as one of the following:  
1. Definitely : The AE is definitely related to the study treatment.  
2. Probably : There is high degree of certainty that the AE is related to the study treatment.  
3. Possibly : The AE could be related to either the study treatment or to concurrent 
disease/ medication . 
4. Unlikely : There is high degree of certainty that the AE is NOT related to the study treatment . 
5. Not related : The AE is clearly due to other causes (eg, concurrent medication, underlying 
disease, etc.).   
If causality is assessed as definitely, probably , or possibl y related , the event will be considered as 
related for regulatory reporting purposes.  
The Investigator  will use clinical judgment to determine the relationship  between an event and 
the study drugs. For an event to be assess ed as related there should be a reasonable possibility 
that the drug caused the event. ‘Reasonable possibility ’ means that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
Alterna tive causes, such as underlying disease(s), concomitant medication, and other risk factors, 
as well as the temporal relationship of the event to study treatment administration must be 
considered and investigated.  
The Investigator  should also consult the IB and/or product information in their assessment.  
For each AE, the Investigator  must document in the medical records or other source data that 
he/she has reviewed each AE and has provided an assessment of causality.  
There may be situations in which an SAE has occurred , and the Investigator  has minimal 
information to include in the initial report to the Sponsor . However, it is very important that the 
Investigator  always assesses causality for every event , with the currently available information,  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  65 of 113 22 Sep 2023 before the initial transmission of the SAE data to the Sponsor . The Investigator  may change 
his/her opinion of causality in light of follow -up information and send an SAE follow -up report 
with the updated causality assessment.  
8.3.3 Adverse Event Reporting  and Follow -up 
8.3.3.1  Reporting 
Adverse events will be reported by the patient (or, when appropriate, by a caregiver, surrogate, or 
the patient ’s legally authorized representative). Care will be taken not to introduce bias when 
detect ing A Es. Open -ended and non -leading verbal questioning of the patient is the preferred 
method to inquire about AE  occurrence  (for example, “Have you experienced any new or 
changed symptoms since we last asked/since your last visit?” ). 
From signing of the ICF until the first dose of induction therapy , only AEs/SAE s caused by 
study -specific procedures should be reported. All non -serious AEs should be reported from the 
first dose of induction therapy until 30  days after the last dose of induction therapy, or until new 
anticancer treatme nt is initiated (whichever comes first).  
All SAEs should be reported  from the first dose of induction therapy until  70 PFS events are 
reached , until 18 months post last patient randomized  or until new anticancer treatment is 
initiated (whichever comes fir st).  
The time periods for reporting of AEs and SAEs are outlined in  Figure  4.  
Figure  4 Time Periods for Reporting A dverse Ev ents, Serious Adverse Events 
 
Signing of 
ICF 1st dose 
induction 
therapy  30 days post last dose 
induction therapy  Earliest of 70 PFS events ,  
18 month post last patient 
randomized  
or start of  
new anticancer treatment  
         
         
Only AEs/SAEs 
related to study 
procedures          
        
All non -serious AEsa         
        
All SAEsb         
        
 
a All non -serious AEs should be reported until 30 days after the last dose of induction therapy, or until new anticancer treatment is i nitiated 
(whichever comes first)  
b All SAEs should be reported until 70 PFS events are reached , until 18 months post las t patient randomized  or until new anticancer treatment 
is initiated (whichever comes first)  
 
When an AE occurs, it is the responsibility of the Investigator  to review all documentation 
(eg, hospital progress notes, laboratory, and diagnostics reports) related to the event.  
The Investigator  will then record all relevant AE information in the eCRF.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  66 of 113 22 Sep 2023 It is not acceptable for the Investigator  to send photocopies of the patient’s medical records to 
the site monitor/ Contract Research Organization ( CRO )/Sponsor  in lieu of completion of the AE 
eCRF page.  
There may be instances when copies of medical records for certain cases are requested by the site 
monitor/CRO/ Sponsor . In this case, all patient identifiers, with the exception of the screening 
and/or ra ndomization number, will be blinded on the copies of the medical records before 
submission.  
The Investigator  should  attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not  the individual 
signs/symptoms) will be documented as the AE.  
Investigators are not obliged to actively inquire about AEs after the patient has been withdrawn 
from the study. However, if the Investigator  learns of any SAE, including a death, at any time 
after a patient has been discharged from the study, and considers the event to be related to the 
induction therapy or study participation, the Investigator  must promptly report to the Sponsor . 
Medical history will include all active conditions and any condition considered to be clinically 
significant by the Investigator . Medical history including demographic information (birth date, 
race, gender, etc.), current and historical medical conditions,  cancer history (malignant 
melanoma, melanoma mutations , and other cancer types) , and relevant surgical procedures must 
be collected at the Screening visit. Medical history will be recorded up until the first dose of 
induction therapy; however, AEs that oc cur between the time of signature of the ICF and the first 
dose of induction therapy that are believed to be at least possibly caused by  study -specific 
procedures ( ie, blood draws, imaging, biopsies , or other study procedures) will be reported as 
AEs as in dicated.  
8.3.3.2  Follow -up 
After the initial detection of an AE, the Investigator  is required to proactively follow each patient 
at subsequent visits/contacts. Adverse events and SAEs that are ongoing beyond the required 
reporting timelines shall be followed up lo cally per institutional practice until resolution or 
stabilization or the patient is lost to follow up . 
The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the Sponsor  to 
elucidate the nature and/or causality of the AE as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with other 
health care professionals.  E.g. if an Adverse Event is classified as an AESI CTCAE grade ≥ 3, a 
plasma sample (from ≥ 5 mL whole blood) should be collected the sa me day as the event and 
stored for shipment to sponsor upon request.   
New or updated information will be reported in the eCRF  until 70 PFS events are reached  or 
until 18 months post last patient randomized (whichever comes first) . 
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  67 of 113 22 Sep 2023 8.3.4 Expedited Reporting  
Certain events require immediate reporting to allow the Sponsor  to take appropriate measures to 
address potential new risks in a clinical study . The Investigator  must report such events to the 
Sponsor  immediately ; under no circumstances should reporting take place more than 24  hours 
after the Investigator  learns of the event. The following events must be report ed by the 
Investigator  to the Sponsor  within 24  hours after learning of the event, regardless of relationship 
to study drug:  
• Serious AEs 
• Pregn ancies  
If only limited  information is initially available, follow -up report ing is required.  
The minimum information required for an initial report is:  
• Name of person sending the report ( ie, name, address of Investigator ) 
• Participant identification (screening/randomization number, initials, NOT participant 
name)  
• Protocol number  
• Description of SAE  
• Causalit y assessment ; please refer to Section  8.3.2.2 . 
Howe ver, as far as possible all information  on the SAE form should be covered in the initial 
report . 
If an on going SAE changes in its intensity or relationship to study drug or if new information 
becomes available, follow -up SAE report ing should be sent to the Sponsor  within 24  hours . 
8.3.5 Regulatory Reporting Requirements  for Investigator and Sponsor  
Prompt notification of SAEs (within 24  hours) by the Investigator  to the Sponsor  is essenti al so 
that legal obligations and ethical responsibilities towards the safety of patients and the safety of a 
study drug under clinical investigation are met.  
The Sponsor  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation. The Sponsor  
will comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Boards (IRB)/Independent Et hics Committees (IEC), 
and Investigator s. This includes annual safety updates.  
Suspected unexpected serious adverse reaction s have additional reporting requirements. The 
Sponsor  will report SUSARs as described below.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  68 of 113 22 Sep 2023 • If the SUSAR is fatal or life -threate ning, regulatory authorities and IRBs /IECs will be 
notified within 7  calendar days after the Sponsor  learns of the event. Additional follow -up 
(cause  of death, autopsy report, and hospital report) information will be reported within 
an additional 8  days (15  days total).  
• If the S USAR  is not fatal or life -threatening but is otherwise serious, regulatory 
authorities and IRBs/ IECs will be notified within 1 5 calendar days after the Sponsor  
learns of the event.  
The Sponsor  will prepare Investigator  safety reports for SUSAR s according to local regulatory 
requirements and forward  to Investigator s as necessary.  
Only SUSARs related to the IMPs  (UV1 and sargramost im) will be expeditiously reported by the 
Sponsor . 
An Investigator  who receives an Investigator  safety report describing an SAE or other specific 
safety information ( eg, summary or listing of SAE) from the Sponsor  must  file it along with the 
IB and notify the IRB/IEC, if appropriate according to local requirements.  
8.3.6 Pregnancy  
Details of all pregnancies in female patients and female partners of male patients will be 
collected after the start of induction therapy and until  5 months  after the last dose of UV1 
vaccination, nivolumab , or ipilimumab (whichever comes last). For male patients, this still 
applies if their partners become pregnant within 5 months  after the last dose of UV1 vaccination, 
nivolumab , or ipilimumab (whi chever is administered  last.) The pregnancy and outcome of 
pregnancy should be monitored.  
The Sponsor  has a responsibility to monitor the outcome of pregnancies where there has been 
maternal exposure to the study drug. 
All pregnancies must be reported by the Investigator  to the Sponsor  in a pregnancy report form 
within 24  hours after becoming aware of the pregnancy and should follow the procedures 
outlined in Section  8.3.4 . The Investigator  must follow -up and document the course and outcome 
of all pregnancies even if the patient was discontinued from the study or if the study has ended.  
All pregnancy outcomes must be reported by the Investigator  to the Sponsor  in a pregnancy 
outcome report form within 30  days after he or she has gained knowledge of the outcome . 
Elective abortions without complications should not be handled as AEs. The outcome of all 
pregnancies (spontaneous miscarriage, elective termination, normal birth , or congenital 
abnormality) must be followed up and documented even if the patient was disc ontinued from the 
study.  
Pregnancy alone is not regarded as an AE unless there is a suspicion that the study intervention 
may have interfered with the effectiveness of a contraceptive medication.  
Any pregnancy complication should  be reported as an AE. Hosp italization for normal delivery of 
a healthy newborn should not be considered an SAE.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  69 of 113 22 Sep 2023 Any SAE that occurs during pregnancy and abnormal pregnancy outcomes (eg, maternal serious 
complications, spontaneous or therapeutic abortion, ectopic pregnancy, stillbir th, neonatal death, 
congenital anomaly, or birth defect ) should be reported even if they occur outside the normal 
SAE reporting period. These events must be reported within 24  hours in accordance with the 
procedure for reporting SAEs.  
Woman of Childbearing  Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered WOCBP:  
1. Premenarchal  
2. Premenopausal female with one of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bi lateral oophorectomy  
NOTE: Documentation can come from the site personnel’s review of the patient’s medical 
records, medical examination, or medical history interview.  
Post-menopausal female  
• A post -menopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the post -menopausal 
range may be used to confirm a post -menopausal state in women not u sing hormonal 
contraception or hormonal replacement therapy (HRT).  However, in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non -estrogen hormonal highly effective con traception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of post -menopausal status before study randomization.  
8.4 Exploratory Assessments  
Blood samp les for exploratory analysis of immune -related gene profiling and immune - and 
tumor -related protein and gene profiles will be collected from all patients . In the experimental 
arm, collection will be done  on Days 1, 31 , and 52; and in the control  arm on Days 1, 43 , and 64. 
Collection will also be done in both treatment arms on the safety follow -up visit and 18  weeks 
post last dose of induction therapy  (2nd response follow -up visit) . Assessments related to these 
samples are described in Table  8. 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  70 of 113 22 Sep 2023 8.4.1 Biomarkers  
Blood samples for DNA and RNA isolation will be collected from all patients.  Analys is of DNA 
and RNA isolated from blood will include , but is not limited to , analys is of the T cell receptor 
repertoire,  analysis of  circulating tumor DNA , and analysis of microRNA s. Blood samples may 
be also used to isolate and analyze circulating tumor cells.  
Blood samples will be stored, and analysis may  be performed on biomarker variants thought to 
underlie  the interplay between immune activation provoked by vaccination with UV1 and 
inhibition of tumor resistance mechanisms and peripheral immune tolerance induced by 
checkpoint blockade . Analys es may include but  are not limited to levels of antibodies specific for 
vaccine peptides,  tumor -specific antigens, cytokines, chemokines, and inflammatory factors.  
Assessments of potential biomarkers may be used to  evaluate their association with observed 
clinical re sponses to UV1 vaccination in combination with nivolumab and ipilimumab, or 
nivolumab and ipilimumab alone . 
The final disposition of samples will be conducted per local regulations.  
Samples may be stored for a maximum of 5 years (or according to local regu lations) following 
the last patient’s last visit for the study at a facility selected by the Sponsor  to enable further 
analysis of biomarker responses . 
8.5 Extended Exploratory Cohort  
A cohort of approximately 4 0 patients at selected sites will be asked to volunteer for additional 
biological sampling and analysis. Extended  blood sampling, tumor biopsy collection, fecal 
sampling , and DTH testing (only for experimental arm) will be conducted on patients in the 
Extended Exploratory Cohort. Expl oratory assessments related to the biological samples 
collected from this cohort of patients with rationale  and objectives are described in  Appendix  2. 
The samples collected in the Extended Exploratory Cohort will be in addition to those required 
elsewhere per protocol for all patients.  
8.6 Single Arm UV1 Cohort  
To support the Extended Exploratory Cohort of the study, an additional 20 patients at selected 
sites will be enrolled in a single arm UV1 cohort for collection of additional biological material .  
(Appendix 7).  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  71 of 113 22 Sep 2023 9 Statistical Methods  
The statistical considerations summarized in this section outline the plan for data analysis of this 
study. Any deviation s from the planned analyses will be described in the Statistical Analysis Plan 
and justified in the final integrated study report.  
9.1 Statistical Hypothes is 
The primary endpoint is PFS. Under the null hypothesis, the PFS HR  for UV1 vaccination in 
combination with  nivolumab and ipilimumab versus nivolumab and ipilimumab  is assumed to be 
unity. Under the alternative hypothesis, the PFS HR is assumed to be 0.60 or better, representing 
a beneficial effect on PFS for UV1 vaccination in combination with nivolumab and ipilimumab  
compared to nivolumab and ipilimumab . 
9.2 Sample Size Determination  
To test the PFS null hypothesis with 80% power and a 1 -sided alpha level of 0.10, a total of 
70 PFS events are required.  Hodi et al (2018) 14 provides data on PFS with nivolumab and 
ipilimumab  in patients with advanced melanoma.  Assuming a similar shape of the PFS curve for 
nivolumab and ipilimumab  is observed in the current study, 154 patients randomized over a 
15-month period and followed thereafter for a minimum of 12  months will give  a mean 
follow -up of PFS events of approxim ately 20  months.  Follow -up for survival will continue for an 
additional 24 months after the PFS analysis at which time 60 deaths are expected to have 
accrued; this many deaths, an observed OS HR of 0.60 would reach p<0.025 1 -sided.  
As of 1 9 September 2023,  blinded event accrual stood  at 63 PFS events. A blinded examination 
of the overall PFS Kaplan Meier curve made as of 23 July 2023 , and then repeated as of 1 9 
September 2023 , showed strong evidence for a plateau at 54 to 55% of subjects alive and without 
progression. Such a PFS curve plateau is not uncommon for IO therapies. In CheckMate 67, 
nivolumab plus ipilimumab, nivolumab alone and ipilimumab alone were evaluated in advanced 
melanoma (Hodi 2018). This study formed the basis of the sample size calculat ions for the 
current study and showed a prolonged PFS tail for nivolumab plus ipilimumab plateauing at 
approximately 40% for subjects alive and without progression. However, the blinded data 
realized thus far has shown a higher plateau at 54 to 55% for subjects alive and without 
progression . 
Specifically, there seems to be very little contribution to PFS events after 18 months in the study, 
with the PFS curve  nearing asymptote . The plateau in the current study commences at 
approximately 21 months post f irst subject randomized with an estimated 5 6.02% of subjects 
alive and without progression and persists thereafter  for 15 months, out to 36 months at which 
time 54. 32% subjects are alive and without progression, i.e. an increase in the progression rate of 
only 1.7% over 15 months. Based on the projected PFS curve, 70 PFS events are not expected to 
be reached by late 2028  at which time 69.3 events, 9 0% CI of (6 9.2, 72.3) , are expected.   
Given the observed plateau in the accrual of PFS events, it has been de cided to execute the 
primary analysis of PFS at the earliest of either 70 PFS events reached across both treatment 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  72 of 113 22 Sep 2023 arms or 18 months post last patient randomized . An analysis with slightly fewer PFS events has 
negligible impact on the observed HR to reach a given level of statistical significance.  
9.3 Analys is Populations  
For purposes of analysis, the following analysis populations are defined:  
Analysis populations  Descri ption  
Intention -to-treat (ITT) 
population  All randomized patients. Efficacy data in this population will be 
summarized by randomized treatment. The primary PFS and secondary 
OS analysis will be assessed in the ITT  population. Patients will be 
analyzed by the treatment arm to which they are randomi zed. 
Response evaluable 
population  All randomized patients with measurable disease by RECIST 1.1. The 
secondary endpoint analys es of ORR and DOR will be assessed using 
the response evaluable population. Patients will be analyzed by the 
treatment arm to which they are randomized.  
Safety population  All randomized patients who receive at least one dose (or partial dose) 
of induction therapy. Patients will be assessed by the treatment 
received, based on the first dose of study drug.  
9.4 Statistical Analys is 
9.4.1 General Considerations  
Demographic data and disease -related baseline characteristics will be summarized using 
descriptive statistics (count and percent, mean, median, standard deviation, minimum, and 
maximum). All patient, efficacy , and safety data will be summarized. In addition to the 
summarized analysis plan outlined below, a Statistical Analysis Plan (SAP) will be written and 
finalized prior to the first planned data analysis. The SAP will provide a detailed and expanded 
descript ion of the statistical methods outlined in this protocol. Additional analyses, such as in 
important subgroups, will also be described in the SAP.  
9.4.2 Efficacy Analyses  
9.4.2.1  Primary Efficacy Analys es 
Progression Free Survival   
Progression free survival  is defined as time from randomization to progression (by BICR) or 
death from  any cause, whichever occurs first.  A Cox proportional hazards regression model will 
be used to analyze PFS on an ITT basis. Patients who have not progressed or died will be 
censo red at their last follow -up tumor assessment. The model will include a single covariate for 
randomized treatment and covariates for baseline ECOG (0 versus  1) score.  The HR will be 
estimated from the model along with the associated 2 -sided CI and 2 -sided p -value. The data will 
also be displayed using Kaplan -Meier  curves and median PFS times will be estimated.  The PFS 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  73 of 113 22 Sep 2023 at 12  months will be estimated from the Kaplan -Meier  curves along with the associated  80% and  
95% Cis. 
Sensitivity Analyses of the Progression Free Survival  
Several sensitivity analyses will be performed on the primary endpoint:  
i. As per FDA guidance, a sensitivity analysis will be performed in patients who started any 
subsequent anticancer treatment without a prior reported progression. Patients will be 
censored at the last evaluable tumor assessment prior to initiation of the subsequent 
anticancer treatment; and  
ii. A log rank test on PFS as determined by BICR . The 2-sided p -value will be extracted and 
presented  alongside the results of the Cox analysis; and  
iii. A Cox regression analysis on PFS as determined by the local Investigator ’s review; and  
iv. A log rank test on PFS as determined by the local Investigator ’s review. The 2 -sided 
p-value will be extracted and prese nted alongside the results of the Cox analysis.  
Additional sensitivity analyses may be specified in the SAP.  
9.4.2.2  Secondary Efficacy Analys es 
Overall Survival  
Overall survival  is defined as the time from randomization to death from  any cause. Overall 
survival  will be analyzed in a fashion similar to that described for PFS. Overall survival  data at 
the time of the PFS analysis and with an additional  follow -up thereafter will be analyzed until 
defined end of study to provide evidence supportive of PFS.  
Objective Response Rate  
Objective response rate is defined as the proportion of patients with a best response of CR or PR 
(by BICR ). The ORR will be analyzed by exact logistic regression. The model will include a 
single covariate for randomized treatment and  covariates for baseline ECOG (0 versus  1) score. 
The exact odds ratio  will be estimated from the model along with the associated 80% and 95% 
Cis and 2 -sided p -value. Exact Clopper -Pearson 2-sided 80% and 95% confidence limits will be 
calculated for the proportion of patients with ORR in each arm.  
Duration of Response  
Duration of response  is defined as the time from first CR or PR (by BICR ), whichever is 
recorded first, to progression (by BICR ) or death from  any cause , whichever occurs first . The 
DOR will  be analyzed via Cox regression modelling with a fixed effect term for randomized 
treatment. The HR will be estimated from the model along with the associated 80% and 95% CI 
and 2 -sided p -value. The data will also be displayed using Kaplan -Meier curves; me dian DOR 
and the 80% and 95% C is will be estimated from the Kaplan -Meier  curve by treatment arm. 
Since DOR is assessed in responding patients only, a supportive analysis will be performed 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  74 of 113 22 Sep 2023 based on the expected duration of response as per Ellis et al (2008)32 as this analysis includes all 
randomized patients, including those who did not respond.  
9.4.3 Safety Analyses  
Adverse events will be classified using the latest version of the Medical Dictionary for 
Regulatory Activities (MedDRA) classification system. Treatment -emergent AEs (TEAEs) will 
be summarized . A TEAE is defined as an AE that was not present prior to first study tr eatment 
but appeared following treatment, or was present at treatment initiation but worsened during 
treatment. An AE that was present at treatment initiation but resolved and then reappeared while 
the patient was on treatment is a TEAE (regardless of the intensity of the AE when the treatment 
was initiated). For simplicity, TEAEs will be referred to as AEs in this protocol. Adverse events 
will be summarized descriptively by treatment  arm, in terms of body system and MedDRA 
preferred term. Patients with mul tiple occurrences of the same AE will only be counted once at 
the maximum severity/grade for each preferred term, system organ class, and overall. A dverse 
events  will be summarized in terms of the number and percentages of patients experiencing 
related A Es, SAEs , AEs leading to dose interruption, A Es leading to withdrawal from 
randomized treatment , and A Es leading to death.  In the event that a patient experiences repeated 
episodes of the same AE, the patient  will be counted once within each system organ class and 
similarly counted once within each preferred term and the event with the highest severity grade 
and/or strongest causal relationship to each treatment will be used for incidence tabulations.  
Laboratory values and change from Baseline will be summarized using descriptive statistics at 
scheduled visits by treatment. Shift tables of the worst on -study laboratory toxici ty relative to 
Baseline will be presented by treatment arm. Patient listings of Grades ≥3  laboratory toxicities 
will be provided.  
Vital signs and ECOG performance status (observed and change from Baseline) will be 
summarized using descriptive statistics by timepoint and treatment.  
9.4.4 Exploratory Analyses  
Biomarkers and parameters for immunological mode of action ( eg, T-cell response) wi ll be 
summarized per timepoint with descriptive statistics. The potential relationship between 
exploratory biomarkers and treatment response/immune response will be summarized using 
cross -tabulation (biomarker measured as present Yes/No) and level of bioma rker (mean, standard 
deviation, median, minimum , and maximum) for each response group (biomarkers measured on 
continuous scales).  
9.5 Timing of the Analyses  
This study is event driven so that the timing of the primary endpoint analysis is dependent upon 
the attainment of 70  PFS events and is not calendar based. Based on the assumptions supporting 
the sample size calculation  (Hodi, 2018) , it is expected that 70  PFS events will have accrued at 
around 27  months after the first patient is randomized.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  75 of 113 22 Sep 2023 However, a s of 19 September 2023, blinded event accrual stood  at 63 PFS events. A blinded 
examination of the overall PFS Kaplan Meier curve made as of 23 July 2023 , and then repeated 
as of 1 9 September 2023 , showed strong evidence for a plateau at 54-55% of subjects a live and 
without progression.  Given the observed plateau in the accrual of PFS events, it has been decided 
to execute the primary analysis of PFS at the earliest of either 70 PFS events reached across both 
treatment arms or 18 months post last patient rand omized . Follow -up for survival will continue 
for an additional 24 months after the PFS cut-off date , at which time 60 deaths are expected to 
have accrued.  
The secondary endpoints will also be analyzed at the earliest of either 70 PFS events reached 
across both treatment arms  or 18 months post last patient randomized . 
In addition, overall survival will be analyzed until defined end of study .  
 
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  76 of 113 22 Sep 2023 10 Regulatory, Ethical, and Study Oversight Considerations  
10.1 Regulatory and Ethical Considerations  
• This study will be conducted in accordance with Good Clinical Practice (GCP) as defined 
by the International Conference of Harmonisation (ICH), ethical principles derived from 
the Declara tion of Helsinki, the General Data Protection Regulation, the United States 
Code of Federal Regulations (CFR) Title 21, European regulation No 536/2014 , and other 
applicable laws and regulations.  
• The study will be conducted in compliance with the protocol  and amendments, as 
applicable . 
• The protocol, protocol amendments, ICF, and other relevant documents ( eg, 
advertisements) will receive  required regulatory authority approval and IRB/IEC 
approval/favorable opinion before the study is initiated.  
• Any substantial amendments to the protocol will require regulatory authority approval 
and IEC/IRB approval /favorable opinion  before implementation of changes made to the 
study design, except for changes necessary to eliminate an immediat e hazard to study 
patient s. 
• The Investigator  will ensure that : 
o Written and dated appro val/favorable opinion from the IRB/IEC for the protocol, 
ICF, and other relevant documents have been obtained before study initiation  
o The IRB/IEC has been provided with a copy of the IB 
o Written summaries of the status of the study are provided to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/ IEC 
o The IRB/IEC is notified of SAE s and other significant safety findin gs as required 
by IRB/IEC procedures  
o Overall conduct of the study at the site and adherence to national and international 
regulations, IRB/IEC  requirements , and all other applicable local regulations  are 
followed . 
10.2 Financial Disclosure  
Investigators and sub -Investigator s will provide the Sponsor  with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor  to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1  year after completion of the study.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  77 of 113 22 Sep 2023 10.3 Informed Consent Process  
• The Investigator  or his/her representative will explain the n ature of the study to the 
patient  or his/her legally authoriz ed representative and answer all  questions regarding the 
study.  
• Patient s must be informed that their participation is voluntary. Patient s or their legally 
authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health 
Insurance Portability and Accountability Act requirements, the Europea n Union  General 
Data Protection Regulation , IRB/IEC  requirements, and applicable laws regulations.  
• The medical record must include a statement that written informed consent was obtained 
before the patient  was randomized  in the study and the date the writte n consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
• Patient s must be re -consented to the most current version of the ICF(s) during th eir 
participation in the study.  
• A copy of the ICF(s) must be provided to t he patient  or the patient ’s leg ally authorized 
representative.  
• Prior to any study -specific procedu res being performed, all patients must sign the ICF. 
Patients that decide to take part in the extended exploratory analyses  need to sign a 
separate ICF (Appendix  2).  
• After the patient has signed the ICF, the site will enter information into the IWRS, or 
equivalent , which wil l assign a unique screening number. Once assigned, a screening 
number cannot be re -used for any reason.  
Patient s who are rescreened are required to sign a new ICF  and will receive a new screening 
number . 
If a protocol amendment is required, the ICF may need to be revised to reflect the changes to the 
protocol. If the ICF is revised, it must be reviewed and approved by the appropriate IEC/ IRB and  
signed by all patient s subsequently screened  in the study as well as those currently randomized  in 
the study.  
10.4 Data Protection  
• Participants will be assigned a unique identifier by interactive web response system . Any 
patient  records or datasets that are tra nsferred to the Sponsor  will contain the identifier 
only; patient names or any information which would make the patient  identi fiable will 
not be transferred.  
• The patient  must be informed that his/her personal study -related data will be used by the 
Sponsor  in accordance with relevant data protection law s. The level of disclosure must 
also b e explained to the patient . 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  78 of 113 22 Sep 2023 • The patient  must be informed that his/her medical record s may be examined by study 
monitors,  quality assurance auditors , and  other authorized personnel appointed by the 
Sponsor , by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.  
10.5 Dissemination of Clinical Study Data  
When the Clinical Study Report  is completed, the Sponsor  will provide the major findings of the 
study to the Investigator . A summary of the study results will also be posted in a publicly 
accessible database ( eg, www.ClinTrials .gov). The results may also be submitted for publication.  
10.6 Data Quality Assurance  
• All patient  data relating to the study will be recorded in an eCRF  unless transmitted to the 
Sponsor  or designee electronically ( eg, laboratory data). The Investigator  is responsible 
for verifying that data  entries are accurate and correct by electronically signing t he eCRF.  
• The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
• The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct a ccess to source data documents.  
• The Sponsor  or designee is responsible for the data management of this study including 
quality checking of the data.  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of patient s are being pr otected; and that the 
study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all appl icable regulatory requirements.  
• Once the eCRF clinical data have been submitted to the central server at the independent 
data center, corrections to the data fields will be captured in an audit trail. The reason for 
change  and the name of the person who performed the change, together with the time and 
date, will be logged to provide an audit trail.  
• If additio nal corrections are needed, the responsible monitor or data manager will raise a 
query in the eCRF . The appropriate staff at the study site will answer queries sent to the 
Investigator . The name of the staff member responding to the query, and time and dat e 
stamp will be captured to provide an audit trail.  
• The specific procedures to be used for data entry and query resolution using the eCRF 
will be provided to study si tes in a training manual. In addition, site personnel will 
receive training on the eCRF.  
10.7 Source Documents  
• Source documents provide evidence for the existence of the patient  and substantiate the 
integrity of the data collected. Source documents are filed at the Investigator ’s site.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  79 of 113 22 Sep 2023 • Data reported in the eCRF  that are transcribed from source documents must be consistent 
with the source documents , or the discrepancies must be explained. The Investigator  may 
need to request previous medical records or transfer records, depending on the study. 
Also, current medic al records must be available.  
The study site will maintain a n Investigator  site file containing , at a minimum, the IB, protocol 
and any amendments, drug accountability records, correspondence with the IEC/IRB, the 
identification of all participating patien ts, study -specific source documents, source workshee ts, 
all original signed and dated IC F forms, and detailed records of drug disposition to enable 
evaluations or audits from regulatory authorities and the Sponsor  or its designees.  
The Investigator  will retain the Investigator  site file to be maintained until at least 2  years after 
the last approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region or at least 2  years have elap sed since the 
formal discontinuation of clinical development of the investigational product.  
No data should be destroyed without the agreement of the Sponsor . Should the Investigator  wish 
to assign the study records to another party or move them to another location, the Sponsor  must 
be notified in writing of the new responsible person and/or the new location.  
Patients’ medical records and other original data will be archived in accor dance with the 
archiv ing regulations or facilities of the investigational site.  
10.8 Study and Site Closure  
For reasonable cause, the Sponsor  may terminate a study site or the entire study prematurely. 
When feasible, a 30 -day written notification will be given.  Conditions that may warrant 
termination include, but are not limited to:  
• The discovery o f an unexpected, significant, or unacceptable risk to the patients  
• Difficulties in the screening and/or randomization of patients  – individual sites or entire 
study ma y be closed/terminated based on this criterion  
• Insufficient adherence to protocol requirements (non -compliance)  – individual sites may 
be closed based on this criterion  
• Cancellation of drug  development . 
Should this be necessary, the Sponsor  will arrange discontinuation procedures. In terminating the 
study, the Sponsor  will ensure  that adequate consideration is given to the protection of the 
patients’ interests.  
Regardless of the reason for termination, all data available for the patient at t he time of 
discontinuation of follow -up must be recorded in the eCRF. In terminating the study, the 
Investigator  will ensure that adequate consideration is given to the protection of the patients’ 
interests.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  80 of 113 22 Sep 2023 10.9 Publication Policy  
• The results of this study may  be published and/or presented at scientific meetings. If this 
is foreseen, the Investigator  agrees to submit manuscripts or abstracts to the Sponsor  
before submission. This allows the Sponsor  to protect proprietary information and to 
provide comments.  
• The Sponsor  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor  will generally 
support publication of multicenter studies only in their entirety and not as individual site  
data. In this case, a coordinating Investigator  will be designated by mutual agreement.  
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  
• All data generated from this study are the property of the Sponsor  and will be held in 
strict confidence along with all information furnished by the Sponsor . Independent 
analysis and/or publication of these data by the Investigator (s) or any member of thei r 
staff is not permitted without the prior, written consent of the Sponsor . Written 
permission to the Investigator  will be contingent on the review by the Sponsor  of the 
manuscript and will provide for nondisclosure of Sponsor  confidential or proprietary 
information. In all cases, the parties agree to submit all manuscripts or abstracts to all 
other parties 30 days prior to submission. This will enable all parties to protect 
proprietary information and to provide comments based on information that may not y et 
be available to other parties.  
10.10  Protocol Approval and Amendment  
Before the start of the study, the study protocol and/or other relevant documents will be reviewed 
and/or approved by the IRB /IEC , and of regulatory authorities  in accordance with local legal 
requirements . The Sponsor  must ensure that all ethical and legal requirements have been met 
before the first patient performs any study -specific procedures.  
This protocol is to be followed exactly. To alter the protocol, ame ndments must be written, 
receive approval from the appropriate personnel, and receive IRB/IEC/ regulatory authority 
approval prior to implementation (if appropriate). In the United States : The protocol 
amendment(s) will be submitted to the Investigational N ew Drug  under which the study is being 
conducted.  
Admi nistrative changes may be made without the need for a formal amendment. All amendments 
will be distributed to all protocol recipients, with appropriate instructions.  
10.11  Liability and Insurance  
The Sponsor  will take out reasonable third -party liability insurance cover in accordance with all 
local legal requirements. The civil liability of the Investigator , the persons instructed by him or 
her, and the study site , practice, or institute in which they are empl oyed and the liability of the 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  81 of 113 22 Sep 2023 Sponsor  with respect to financial loss due to personal injury and other damage that may arise as a 
result of the carrying out of this study are governed by the applicable law.  
The Sponsor  will arrange for patients participating in this study to be insured against financial 
loss due to personal injury caused by the pharmaceutical products being tested or by medical 
steps taken in the course of the study.  
10.12  Access to Source Data  
On behalf of the Sponsor , a study monitor will contact and visit the Investigator  at the study 
center prior to entry of the first patient and at appropriate intervals during the study until after the 
last patient is completed. The monitor will also perform a study closu re visit.  
In accordance with ICH GCP guidelines, the Investigator  must ensure provision of sufficient 
time, reasonable space, and adequate qualified personnel for the monitoring visits. The visits are 
for the purpose of verifying adherence to the study pro tocol and the completeness, consistency, 
and accuracy of data entered on the eCRF and other documents.  
The Investigator  will make all source data ( ie, the various study records, the eCRFs, laboratory 
test reports, other patient records, drug accountabilit y forms, and other pertinent data) available 
for the monitor and allow access to them throughout the entire study period. Monitoring is done 
by comparing the relevant site records of the patients with the entries on the eCRF ( ie, source 
data verification).  It is the monitor’s responsibility to verify the adherence to the study protocol 
and the completeness, consistency, and accuracy of the data recorded on the eCRFs.  
By agreeing to participate in the study, the Investigator  agrees to cooperate with the moni tor and 
to ensure that any problems detected in the course of the monitoring visits are resolved. 
Representatives from the Sponsor  may also contact and visit the Investigator s and monitor data 
during the study.  
 
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  82 of 113 22 Sep 2023 Appendix  1 Clinical Laboratory Tests  
• Local laboratory analysis (all patients) are detailed in Table  7. 
• Central laboratory sampling for e xploratory analysis (all patients) are detailed in  Table  8.  
• Extended Exploratory Cohort assessments (approximately 4 0 patients) are detailed in  
Appendix  2, Table  9, and Table  10. 
• Additional tests may be performed at any time during the study as determi ned necessary 
by the Investigator  or required by local regulations.  
• Blood samples must be collected prior to administration of treatment.  
Table  7 Local Laboratory Analysis (all patients , N=154 ) 
Laboratory 
Assessments  Parameters  
Hematology  
 Red blood cell ( RBC ) Count  
Hemoglobin  
Hematocrit  
White blood cell ( WBC ) Count  
Platelet Count  
Absolute neutrophil count  RBC Indices:  
Mean corpuscular 
volume  
Mean corpuscular 
hemoglobin  WBC count with Differential:  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Clinical 
Chemistry  from 
serum  or plasma1 
 Blood urea nitrog en 
(BUN )/Urea *  
Potassium  
Total and direct bilirubin  
Creatinine  
Sodium  
Albumin  
Chloride  Glucose (non-fasting ) 
Calcium  
Alkaline phosphatase  
Aspartate aminotransferase (AST /GOT ) 
Alanine aminotransferase (ALT /GPT ) 
Lactate dehydrogenase  
Uric acid  
Thyroid panel (TSH and fT4) 
Other Screening 
Tests  • Hepatitis B surface antigen and hepatitis C virus antibody  
• Human chorionic gonadotropin pregnancy test (for women of childbearing potential)2 
NOTES:  
1 All events of ALT or AST 3 × upper limit of normal (ULN) AND  bilirubin 2 × ULN, which may indicate severe liver injury 
(possible Hy’s Law), must be reported as a serious adverse  event . 
2 Local urine testing will be standard for the protocol unless serum or plasma testing is required by local regulation or  Institutional 
Review Board /Independent Ethics Committee . If the urine test is positive or cannot be confirmed as negative, a s erum or plasma 
pregnancy test will be required.  
*Assessment of urea to be performed by  sites where laboratories are not using BUN . 
Total amount of blood for local analysis will be approximately 30 mL per patient.  
Investigators must document their review of each laboratory safety report.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  83 of 113 22 Sep 2023 Table  8 Central Laboratory Sampling for Exploratory Analys es (all patients , N=154 ) 
Treatment arm  Visits  Laboratory a ssessments  Volume of blood 
collected   
Experimental arm  • Day 1  
• Day 31  
• Day 52 
• Safety Follow -up  
• 18 weeks post last 
dose of induction 
therapy  (2nd response 
follow -up visit)  • Blood for immune -related gene profiling  
based on cell -free plasma DNA and 
cellular genomic DNA  
• Blood for generation of plasma  95 mL blood over 
5 visits  
Control arm  • Day 1  
• Day 43  
• Day 64  
• Safety Follow -up  
• 18 weeks post last 
dose of induction 
therapy  (2nd response 
follow -up visit)  • Blood for immune -related gene profiling  
based on cell -free plasma DNA and 
cellular genomic DNA  
• Blood for generation of plasma  95 mL blood over 
5 visits  
 Total blood volume   95 mL blood / 
patient  
 
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  84 of 113 22 Sep 2023 Appendix  2 Extended Exploratory Cohort ( N= approximately 4 0 patients)  
Background  
As part of the development and evaluation of the UV1 vaccine, a cohort of approximately 
40 patients at selected sites will be asked to volunteer for additional biological sampling and 
analys is. The patients will have to sign a separate Informed Consent Form (ICF) to enro ll in this 
part of the study . The analysis of the samples will aim to reveal how changes in biological 
markers, including tumor mutational burden (TMB), and T-cell receptor ( TCR ) repertoire 
diversity reflect the efficacy of the treatments. The goal is to further elucidate and characterize 
the immunological mechanisms induced with UV1 in combination with nivolumab and 
ipilimumab in blood and tumor.  
Research Objectives  and Assessment s 
A biobank will be established for current and future analysis of the samples collected. The 
specific research objectives include, but are not restricted to  investigate if : 
• UV1 vaccination in addition to ipilimumab and nivolumab: induce a broader repertoi re of 
TCR specificities i ncluding epitopes not included in the UV1 vaccine compared to 
ipilimumab and nivolumab.   
• UV1 vaccination in addition to ipilimumab and nivolumab : induces changes in the 
post-treatment TMB from the pre -treatment TMB compared to ipilimumab and 
nivolumab .  
• UV1 vaccination in addition to ipilimumab and nivolumab: induces changes in the 
post-treatment immune cell infiltrate of the  tumor from the pre -treatment immune cell 
infiltrate compared to ipilimumab and nivolumab.  
• UV1 vaccinatio n in addition to ipilimumab and nivolumab: induces vaccine -specific 
immune responses in blood.  
• The microbial composition in feces pre-treatment affects response to treatment with UV1 
vaccination in addition to ipilimumab and nivolumab compared to ipilimumab and 
nivolumab . 
• UV1 vaccination in addition to ipilimumab and nivolumab: induces delayed -type 
hypersensitivity ( DTH ) responses .  
Exploratory Endpoints  
• Correlation in the change in TCR repertoire in bloo d over time to clinical response in 
both treatment arms.  
• Correlation between vaccine -specific immune response in blood and clinical response in 
the UV1 in addition to ipilimumab and nivolumab arm.  
• Correlation between DTH and clinical response in the UV1 in addition to ipilimumab and 
nivolumab ar m. 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  85 of 113 22 Sep 2023 • Change in the post -treatment TMB from pre -treatment TMB in both treatment arms.  
• Change in composition of the immune cell infiltrate of the tumor post -treatment 
compared to pre -treatment in both treatment arms.  
• Correlation of m icrobiologic composition of fecal samples to response to treatment in 
both treatment arms.  
Target Population  
Selected study sites  that have the necessary laboratory facilities to collect and handle the 
requested lab samples can take part in the extended laboratory cohort part of t he study. Patients 
eligible for the study will be offered to take part in the Extended Exploratory Cohort until the 
needed number of patients in the cohort is reached.   
Discontinuation from Extended Exploratory Cohort  
Patients can withdraw their extended e xploratory cohort consent at any time without this 
affecting their care and treatment. These patients can continue in the main part of the study. In 
case of withdrawal of extended exploratory cohort consent, the patient can request all samples 
collected un der this consent to be destroyed. Results from samples already analyzed will not be 
deleted.  
Sample Collection  and Assessments  
The sample collection and assessments in the Extended Exploratory Cohort will be done in 
addition to those requested elsewhere pe r protocol. In the experimental arm these will be done 
during the Screening period, and at Days  1, 31, and 52 . In the control arm these will be done 
during the Screening period , and at Days  1 and 43. In both treatment arms sample  collection and 
assessment will also be done at the safety follow -up visit and 18 weeks post last dose of 
induction therapy. Sample type and assessments are described in  Table  9 and Table  10 below.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  86 of 113 22 Sep 2023 Table  9 Extended Exploratory Cohort Assessments – Experimental Arm 
Visit  Assessment  Volume of tissue collected   
Screening  Fecal sample  
Tumor biopsy (FFPE biopsy ) 
Tumor biopsy (Snap -frozen biopsy)  Dedicated sample card  
At the pathologist’s decision (one biopsy)  
At the pathologist’s decision (two snap -frozen)  
Day 1 Whole blood for DNA  
SNP sample  
Whole blood for PBMC  
DTHa 3 mL blood  
3 mL blood  
80 mL blood  
Not applicable  
Day 31  Whole blood for PBMC  
DTHa 80 mL blood  
Not applicable  
Day 52  DTHa Not applicable  
Safety follow -up Whole blood for PBMC  
Tumor biopsy (FFPE biopsy)  
Tumor biopsy (Snap -frozen biopsy)  
DTHa 80 mL blood  
At the pathologist’s decision (one biopsy)  
At the pathologist’s decision (two snap -frozen)  
Not applicable  
18 weeks post  last dose 
of induction therapy  
(2nd response follow -up 
visit)  Whole blood for PBMC  
DTHa 80 mL blood  
Not applicable  
Total blood volume   326 mL blood / patient  
Abbreviations: DNA = deoxyribonucleic acid; DTH = delayed -type hypersensitivity; FFPE = formalin fixed, paraffin 
embedded ; PBMC = peripheral blood mononuclear cell; SNP = single nucleotide polymorphisms .  
a UV1 without sargramostim  intradermally in the skin of the anterior forearm . Patient will measure and record the skin reaction 
48±4 hours after the injection . 
Table  10 Extended Exploratory Cohort Assessments – Control Arm 
Abbreviations:  DNA = deoxyribonucleic acid; FFPE = formalin fixed;  paraffin embedded ; PBMC = peripheral blood 
mononuclear cell; SNP = single nucleotide polymorphisms .  Visit  Assessment  Volume of tissue collected   
Screening  Fecal sample  
Tumor biopsy (FFPE biopsy)  
Tumor biopsy (Snap -frozen biopsy)  Dedicated sample card  
At the pathologist’s decision (one biopsy)  
At the pathologist’s decision (two snap -frozen)  
Day 1 Whole blood for DNA  
SNP sample  
Whole blood for PBMC  3 mL blood  
3 mL blood  
80 mL blood  
Day 43  Whole blood for PBMC  80 mL blood  
Safety follow -up Whole blood for PBMC  
Tumor biopsy (FFPE biopsy)  
Tumor biopsy (Snap -frozen biopsy)  80 mL blood  
At the pathologist’s decision (one biopsy)  
At the pathologist’s decision (two snap -frozen)  
18 weeks post last 
dose of induction 
therapy  (2nd response 
follow -up visit)  Whole blood for PBMC  80 mL blood  
Total blood volume   326 mL blood / patient  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  87 of 113 22 Sep 2023 Sample Processing , Shipping , and Storage  
The study site s will receive a sampling kit and lab oratory  manual with instructions on sample 
collection and processing.  Details on storage conditions will be provided in the lab oratory  
manual.  
Assessments  
In the future, additional genes, biomarkers , and analysis methods of interest will most likely be 
identified. It is therefore important not to restrict the utilization of this biologic material to 
current knowledge and retain the possibility of conducting other investigations as well. However, 
based  on current knowledge, it is planned to utilize the material in the manner  described in the 
following sections.  
Whole Blood for DNA  
Exome sequencing of deoxyribonucleic acid (DNA) will be performed on blood samples 
collected before initiation of UV1 vaccination. The DNA from normal cells will serve as a basis 
for comparison to DNA sequence from tumor tissue, allowing to detect tumor -specific DNA 
alterations.  
Use/Analysis  of DNA  
• Genetic variation may impact a patient ’s response to therapy. Variable res ponse to therapy 
may be due to  genetic determinants that impact drug absorption, distribution, metabolism, 
and excretion; mechanism of action of the drug; disease etiology; and/or molecular 
subtype of the disease being treated. Therefore, where local regul ations and Institutional 
Review Board /Independent Ethics Committee  allow, a blood sample will be collected for 
DNA analysis.  
• DNA samples will be used for research related to sargramostim and/or UV1 or metasta tic 
malignant melanoma . Genetic  research may con sist of the analysis of one or more 
candidate genes or the analysis of genetic markers throughout the genome in relation to 
sargramostim and/or UV1 . 
• DNA samples will be analyzed as described in Section 8.4.1 . Additional analyses may be 
conducted if it is hypothesized that this may help further understand the clinical data  or 
help resolve  issues with the clinical data.  
• The s amples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to sargramostim and/or UV1  or study treatment  of this class to 
understand study disease or related conditions.  
• The results of genetic analyses will be re ported in a separate study addendum.  
• The Sponsor  will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  88 of 113 22 Sep 2023 • The samples will be retained while research on sargramostim and/or UV1  or study 
treatment s of this clas s or indication continues but no longer than 5 years or other period 
as per local requirements . 
Whole Blood for Analyses of Single Nucleotide Polymorphisms  (SNPs)  
Whole blood for analyses of SNPs will be taken prior to initiation of study treatment. Genomic 
DNA will be extracted and subsequently assessed for SNPs and other genetic variations in 
candidate genes that may predispose patients to benefit from the addition of UV1 vaccination to 
nivolumab and ipilimumab), or adverse events. Such g enes include, but are not limited to 
hTERT, PD -1, PD -L1, PD -L2 and CTLA -4. Additional use of these data may include correlative 
analysis aimed at identifying genotypic associations with clinically relevant biomarkers 
identified by other methodologies.  
Whol e Blood for Peripheral Blood Mononuclear Cells  (PBMCs)  
Whole blood samples will be taken prior to initiation of study treatment and at designated 
timepoints for PBMC  preparation . These samples may be used for immunophenotyping or 
characterization of the im mune cell subsets in the periphery, including, but not limited to, T -cells, 
B cells, natural killer  cells, myeloid -derived suppressor cells, or subpopulations of the 
aforementioned immune cell types. Additionally, these samples may be used for human 
leukoc yte antigen  typing, cytokine -release analyses, for functional immune cell tests , and 
characterization of the immune reactivity against tumor antigen.  
Tumor Tissue Specimens  
Tumor biopsies (formalin fixed, paraffin embedded [FFPE ]) will form the basis for i n situ 
characterization of the tumor and the tumor -microenvironment, including the tumor -infiltrating 
immune cells. The FFPE biopsies and snap -frozen biopsies will be used for DNA/RNA 
extraction and sequencing aiming at characterizing the immune contexture  of the tumor, and to 
identify tumor -specific somatic mutations.  
The biopsies should be collected from the same lesion  at each timepoint of sampling (ie, it 
should be taken into consideration when selecting the lesion for tissue sampling that the lesion 
may shrink in response to therapy ). Since heterogeneity within tumors is an issue, it should be 
aimed at sampling within the same area of the lesion at eac h sampling timepoint. If a previous 
biopsy site is noted in the specimen to be sampled, the biopsies should be taken from near that 
site, but not from the exact site, as biopsies may alter the biology of adjacent tissue.  If the patient 
has only one target lesion, the biopsy should be taken either subsequent or at least 7  days prior to 
the screening imaging scan.  
Biopsy samples should be excisional, incisional , or core needle. Punch biopsies are allowed as 
well. Fine needle aspirates or other cytology sample s are only allowed after discussion with the 
Sponsor ’s biomarker expert. Biopsies may be done with local anesthesia or conscious sedation. 
Institutional guidelines for the safe performance of biopsies should be followed.  
Detailed instructions of the obtain ing, processing, labeling, handling, storage , and shipment of 
specimens will be provided in a separate Laboratory Manual.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  89 of 113 22 Sep 2023 Fecal Samples  
Fecal samples will be collected prior to treatment to evaluate the gut microbiome by use of PCR 
amplification of candidate gene sequences . Planned exploratory analyses are subject to changes 
in line with scientific understanding and technical development.  
Delayed -type Hypersensitivity  
Patients in the experimental arm will be asked to measure area of skin irritation on the skin of the 
anterior forearm and record it on a patient diary card (details to be explained to patient). This will 
be done 48 ±4  hours  after each DTH  test injection according to timepoints described in Table  9. 
A positive DTH test is defined as an erythema and/or induration ≥5  mm. The DTH patient diary 
card should  be delivered to the study personnel at the next visit at the study site . 
If a patient prematurely discontinue s induction therapy , no more DTH testing will be performed 
for that patient.    
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  90 of 113 22 Sep 2023 Appendix  3 Eastern Cooperative Oncology Group Performance Status Scale  
Eastern Cooperative Oncology Group Performance Status  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature ( eg, light housework or office work).  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. 
Up and about more than 50% of waking hours.  
3 Capable of only limited self -care; confined to bed or chair more than 50% of waking 
hours.  
4 Completely disabled. Cannot ca rry on any self -care. Totally confined to bed or chair.  
5 Dead.  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  91 of 113 22 Sep 2023 Appendix  4 Response Evaluation Criteria in Solid Tumors and Immune Response Evaluation 
Criteria in Solid Tumors  
RECIST 1.1 Response and Evaluation Endpoints  
Measurable Disease.  Measurable tumor lesions (nodal, subcutaneous, lung parenchyma, solid 
organ metastases) are defined as those that can be accurately measured in at least one dimension 
(longest diameter to be recorded) as ≥20  mm with chest x -ray and as ≥10  mm with computed 
tomography ( CT) scan or clinical examination. Bone lesions are considered measurable only if 
assessed by CT scan and have an identifiable soft tissue component that meets these 
requirements (soft tissue component ≥10  mm by CT scan). Malignant lymph nodes must be 
≥15 mm in the short axis to be considered measurable; only the short axis will be measured and 
followed. All tumor measurements must be recorded in millimeters (or decimal fractions of 
centimeters). Previously irradiate d lesions are not considered measurable unless progression has 
been documented in the lesion.  
Non-measurable Disease.  All other lesions (or sites of disease), including small lesions , are 
considered non -measurable disease. Bone lesions without a measurable soft tissue component, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, 
inflammatory breast disease, lymphangitic involvement of lung or skin , and abdominal masses 
followed by clinical examination are all non -measurable. Lesions in previously irradiated areas 
are non -measurable, unless progression has been demonstrated.  
Target Lesions.  When more than one measurable tumor lesion is present at Baseline , all lesions 
up to a maximum of 5  lesions total (and a maximum of 2  lesions per organ) representative of all 
involved organs should be identified as target lesions and will be recorded and measured at 
Baseline. Target lesions should be selected on the basis of their size (lesions with the longest 
diameter), be representative of all involved organs, but in addition should be those that lend 
themselves to reproducible repeated measurements. Note that pathological nodes must meet the 
criterion of a short axis of ≥15  mm by CT scan and only the short axis of these  nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis ≥10  mm but 
<15 mm) should be considered non -target lesions. Nodes that have a short axis <10  mm are 
considered non -pathological and should not be recorded or fo llowed. At Baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes: overall 
maximum of 5) is to be recorded.  
After Baseline, a value should be provided on the Case Report Form  for all identified target 
lesions for each assessment, even if very small. If extremely small and faint lesions cannot be 
accurately measured but are deemed to be present, a default value of 5  mm may be used. If 
lesions are too small to measure and indeed are believed to be absent, a d efault value of 0  mm 
may be used.  
Non-target Lesions.  All non -measurable lesions (or sites of disease) plus any measurable lesions 
over and  above those listed as target lesions are considered non -target lesions. Measurements are 
not required but  these lesi ons should be noted at Baseline and should be followed as “present” or 
“absent .”  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  92 of 113 22 Sep 2023 Response.  All patients will have their BEST RESPONSE from the start of study treatment until 
the end of treatment classified as outlined below:  
Complete Response (CR):  disapp earance of target and non -target lesions and normalization of 
tumor markers. Pathological lymph nodes must have short axis measures <10  mm (Note: 
continue to record the measurement even if <10  mm and considered CR). Residual lesions (other 
than nodes <10  mm) thought to be non -malignant should be further investigated (by cytology 
specialized imaging or other techniques as appropriate for individual cases ) before CR can be 
accepted. Confirmation of response is only required in non -randomized studies.  
Partial Response (PR):  at least a 30% decrease in the sum of measures (longest diameter for 
tumor lesions  and short axis measure for nodes) of target lesions, taking as reference the baseline 
sum of diameters. Non -target lesions must be non -progressive disease ( PD). Confirmation of 
response is only required in non -randomi zed studies.  
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD  taking as reference the smallest sum of diameters on study.  
Progressive Disease (PD):  at least a 20% increase in the sum of diameters of measured lesions 
taking as  references the smallest sum of diameters recorded on study (including baseline) AND 
an absolute increase  of ≥5  mm. Appearance of new lesions will also constitute PD (including 
lesions in  previously unassessed areas). In exceptional circumstances, unequivocal  progression 
of non -target disease  may be accepted as evidence of disease progression, where the overall 
tumor burden has increased  sufficiently to merit discontinuation of treatment. Modest increases 
in the size of one or more non -target lesions are NOT c onsidered  unequivocal progression.  
iRECIST Response Assessment  
Overall response will be assessed using immune Response Evaluation Criteria in Solid Tumors 
(iRECIST ). Immunotherapeutics may result in infiltration of immune cells leading to transient 
incre ase in the size in malignant lesions, or undetectable lesions becoming detectable. The 
criteria are identical to those of Response Evaluation Criteria in Solid Tumors ( RECIST ) 1.1 in 
many respects but have been adapted to account for instances where an inc rease in tumor burden, 
or the appearance of new lesions, does not reflect true tumor progression.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  93 of 113 22 Sep 2023 Key differences are described below.  
Comparison of RECIST 1.1 and iRECIST  
 
All responses defined using iRECIST criteria are designated with a prefix. The iRECIST 
timepoint and best overall responses will be recorded separately.  
Confirming progression  
Unlike RECIST  1.1, iRECIST requires the confirmation of progression and uses the  terms iUPD 
(unconfirmed progression) and iCPD (confirmed progression). Confirmatory scans should be 
performed at least 4  weeks but no longer than 8  weeks after iUPD.  
iCPD is confirmed if further increase in tumor burden, compared to the last assessment, is seen 
as evidenced by one or more of the following:  
• Continued increase in tumor burden (from iUPD) where RECIST  1.1 definitions of 
progression had been met in target, non -target disease , or new lesions  
o Progression in target disease worsens  with an increase of at least 5  mm in the 
absolute value of the sum  
o Continued unequivocal progression in non -target disease with an increase in 
tumor burden  
o Increase in size of previously identified new lesion(s) (an increase of at least 
5 mm in the absolute value of the sum of those considered to be target new 
lesions) or additional new lesions.  

Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  94 of 113 22 Sep 2023 • RECIST 1.1 criteria are met in lesions types (target , non-target , or new lesions) where 
progression was not previously iden tified, including the appearance of additional new 
lesions.  
If iUPD is not confirmed at the next assessment, then the appropriate response will be assigned 
(iUPD if the criteria are still met, but no worsening, or immune stable disease [iSD], immune 
partia l response [iPR], or immune complete response [iCR] if those criteria are met compared to 
Baseline). Prior documentation of iUPD does not preclude assigning iCR, iPR, or iSD in 
subsequent timepoint assessments or as best overall response providing that iCP D is not 
documented at the next assessment after iUPD.  
New lesions  
New lesions should be assessed and measured as they appear using RECIST  1.1 criteria 
(maximum of 5  lesions, no more than 2  per site ), at least 10  mm in long axis (or 15  mm in short 
axis for  nodal lesions), and recorded as New Lesions -Target (NLT) and New Lesion -Non-Target 
(NLNT) to allow clear differentiation from Baseline target and non -target lesions.  
New lesions may either meet the criteria of NLT or NLNT to drive iUPD (or iCPD). However,  
the measurements of target lesions should NOT be included in the sum of measures of original 
target lesions  identified at Baseline. Rather, these measurements will be collected on a separate 
table in the Case Report  Form. 
Progressive disease is confirmed in the New Lesion category if the next imaging assessment, 
conducted at least 4  weeks  (but not more than 8  weeks) after iUPD , confirms further progression 
from iUPD with either an increase of  at least 5  mm in the absolute value of the sum of NLT OR 
an increase (but not necessarily unequivocal  increase) in the size of NLNT lesions OR the 
appearance of additional new lesions .  
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  95 of 113 22 Sep 2023 Appendix  5 Abbreviations  
AE adverse event  
AESI  adverse events of special interest  
ADL  Activities of Daily Living  
ALT alanine aminotransferase  
ANC  absolute neutrophil count  
AST  aspartate aminotransferase  
BICR  Blinded Independent Central Review  
BRAF  Gene encoding B -Raf protein  
BUN  blood urea nitrogen  
CFR  Code of Federal Regulations  
CI confidence interval  
CNS  central nervous system  
CR complete response  
CRO  Contract Research Organization  
CT computed tomography  
CTLA -4 anti-cytotoxic T -lymphocyte -associated protein -4  
DILI  drug induced liver injury  
DNA  deoxyribonucleic acid  
DOR  duration of response  
DTH  delayed -type hypersensitivity  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic Case Report Form 
EOS  end of study  
FDA  Food and Drug Administration  
FFPE  formalin fixed, paraffin embedded  
FSH follicle stimulating hormone  
GCP  Good Clinical Practice  
GMP  Good Manufacturing Practice  
GM-CSF  granulocyte -macrophage  colony -stimulating fact or 
hTERT  human telomerase reverse transcriptase  
GOT  glutamic -oxaloacetic transaminase  
GPT  glutamic -pyruvic transaminase  
HIV human immunodeficiency virus  
HR hazard ratio  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  96 of 113 22 Sep 2023 HRT  hormonal replacement therapy  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IMP investigational medicinal product  
IRB Institutional Review Board  
ITT intention -to-treat 
iCPD  immune confirmed progressive disease  
iCR immune complete response  
iPR immune partial response  
iRECIST  immune RECIST  
iSD immune stable disease  
iUPD  immune unconfirmed progressive disease  
IWRS  interactive web response system  
MedDRA  Medical Dictionary for Regulatory Activities  
MEK  mitogen -activated protein kinase  
MRI  magnetic resonance imaging  
NE non-evaluable  
NIMP  non-investigational medicinal product  
NLNT  New Lesion -Non-Target  
NLT New Lesions -Target  
NSCLC  non-small cell lung cancer  
ORR  objective response rate  
OS overall survival  
PBMC  peripheral blood mononuclear cell  
PD progressive disease  
PD-1 anti-programmed cell death  
PFS progression free survival  
PR partial response  
RBC  red blood cells  
RECIST  Response Evaluation Criteria in Solid Tumors  
RNA  ribonucleic acid  
Q2W  every 2 weeks  
Q3W  every 3 weeks  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  97 of 113 22 Sep 2023 Q4W  every 4 weeks  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SD stable disease  
SNPs  single nucleotide polymorphisms  
SUSAR  suspected unexpected serious adverse reaction  
TCR  T-cell receptor  
TEAE  treatment -emergent adverse event  
Th1 T-helper type 1  
TMB  tumor mutational burden  
TSH  thyroid -stimulating hormone  
ULN  upper limit of normal  
WBC  white blood cells  
WOCBP  women of childbearing potential  
 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  98 of 113 22 Sep 2023 Appendix  6 References  
1. Bray F, Ferlay J, Soerjomataram I , Siegel RL, Torre LA, Jemal A. Global cancer 
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 
36 cancers in 185 countries. CA Cancer J Clin . 2018 Nov;68(6):394 -424. 
2. Ascierto PA, Sim eone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: 
real-world efficacy and safety data from an expanded access programme cohort. J Transl 
Med. 2014 May 7;12: 116.  
3. Ahmad SS, Qian W, Ellis S, et al.  Ipilimumab in the real world: the UK ex panded access 
programme experience in previously trea ted advanced melanoma patients.  Melanoma 
Res. 2015 ;25(5): 432-442. 
4. Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilimumab in Advanced 
Melanoma. N Engl J Med . 2015 Jun 25;372(26):2521 -2532. 
5. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced 
melanoma: final overall survival results of a multicentre, randomised, open -label 
phase  3 study (KEYNOTE -006). Lancet . 2017;390(10105):1853 -1862.  
6. Hamid O, Puzanov I, Dummer  R, et al. Final analysis of a randomised trial comparing 
pembrolizumab versus investigator -choice chemotherapy for ipilimumab -refractory 
advanced melanoma. Eur J Cancer . 2017;86:37 -45. 
7. Hodi FS, O'Day SJ, McD ermott DF, et al.  Improved survival with ipilimumab in patients 
with metastatic melanoma.  N Engl J Med . 2010 ;363(8):711-723. 
8. Hersh EM, O' Day SJ, Powderly J, et al.  A phase II multicenter study of ipilimumab with 
or without dacarbazine in chemotherapy -naïve patients with advanced melanoma. Invest 
New Drugs . 2011 ;29(3):489-498. 
9. Wilgenhof S, Du Four S, Van denbroucke F, et al.  Single -center experience with 
ipilimumab in an expanded access program for patients with pretreated advanced 
melanoma. J Immunother . 2013 ;36(3):215-222. 
10. Ascierto PA, Del Vecchio  M, Robert  C, et al. Ipilimum ab 10 mg/kg versus ipilimumab 
3 mg/kg in patients with unresectable or metastatic  melanoma: a randomised, 
double -blind, multicentre, phase 3 trial.  Lancet Oncol . 201 7;18(5):611-622. 
11. Robert C , Long GV, Brady B, et al.  Nivolumab in previously untreated melanoma 
without BRAF mutation.  N Engl J Med . 2015 Jan 22;372(4):320 -330. 
12. Hamid O, Puzanov  I, Dummer  R, et al. Final analysis of a randomised trial comparing 
pembrolizumab versus investigator -choice chemotherapy for ipilimuma b-refractory 
advanced melanoma.  Eur J Cancer . 2017; 86:37-45. 
13. Larkin J, Ch iarion -Sileni V, Gonzalez R, et al . Combined Nivolumab and Ipilimumab or 
Monotherapy in Untreated Melanoma. N Engl J Med . 2015 Jul 2;373(1):23 -34.  
14. Hodi FS, Chiarion -Sileni V, Gonz alez R, et al.  Nivolumab plus ipilimumab or nivolumab 
alone versus ipilimumab alone in advanced melanoma (CheckM ate 067): 4 -year 
outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol . 2018 
Nov;19(11):1480 -1492. doi: 10.1016/S1470 -2045(18)30700 -9. Epub 2018 Oct 22.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  99 of 113 22 Sep 2023 15. Larkin J, Chiarion -Sileni V, Gonzale z R, et al. Five-year survival with combined 
nivolumab  and ipilimumab in advanced m elanoma. N Engl J Med . 2019 Oct 
17;381(16):1535 -1546 . 
16. Vasef  MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnostic 
utility and clinical applications.  Am J Clin Pathol . 1999; 112(1 Suppl 1):  S68-75. 
17. Mattson MP, Zhang P, Fu W. Roles for TERT and telomerase in c ell differentiation and 
apoptosis.  Madame Curie Bioscience Database  [Internet] . 2000 -2013.  
18. Hiyama E, Hiyama  K, Yokoyama T, Shay JW. Immunohistochemical detection of 
telomerase (hTERT) protein in human cancer tissues and a sub set of cells in normal 
tissues.  Neoplasia . 2001; 3(1):17-26. 
19. Kim NW, Piatyszek  MA, Prowse  KR, et al. Specific association of human telomerase 
activity with immortal cells and cancer.  Science . 1994; 266(5193): 2011 -2015.  
20. Zanetti M . A second chance for telomerase reverse transcripta se in anticancer 
immunotherapy.  Nat Rev Clin Oncol . 2017; 14(2):115-128. 
21. de Kok JB, Ruers  TJ, van Muijen  GN, et al. Real-time quantification of human 
telomerase reverse transcriptase mRNA  in tumors and healthy tissues.  Clin Chem . 
2000; 46(3):313-318. 
22. Inderberg -Suso EM, Trachsel  S, Lislerud  K, Rasmussen  AM, Gaudernack  G. Widespread 
CD4+ T -cell reactivity to novel hTERT epitopes following vaccination of cancer patients 
with a single hTERT pep tide GV1001.  Oncoimmunology . 2012 ;1(5):670-686. 
23. Suso EM, Duelan d S, Rasmussen AM, et al.  hTERT mRNA dendritic cell vaccination: 
complete response in a pancreatic cancer patient associated with response against several 
hTERT epitopes. Cancer Immunol Immunot her. 2011 Jun;60(6):809 -818. 
24. Disis ML, Bernhard  H, Shiota  FM, et al. Granulocyte -macrophage colony -stimulating 
factor: an effective adjuvant for prot ein and peptide -based vaccines.  Blood . 1996; 88(1): 
202-210. 
25. Kaplan G, Walsh  G, Guido  LS, et al. Novel responses of human skin to intradermal 
recombinant granulocyte/macrophage -colony -stimulating factor: Langerhans cell 
recruitment, keratinocyte grow th, and enhanced wound healing.  J Exp Med . 1992; 175(6): 
1717 -1728.  
26. Kremer IB, Stevens  SR, Gould JW, DiCarlo  J, Quinby  GE, Cooper  KD. Intradermal 
granulocyte -macrophage colony -stimulating factor alters cutaneous antigen -presenting 
cells and differentially affects local versus distant im munization in humans.  Clin 
Immunol . 2000; 96(1):29-37. 
27. Lilleby  W, Gaudernack G, Br unsvig PF, et al.  Phase I/IIa clinical trial of a novel hTERT 
peptide vaccine in men with metastatic hormone -naive prostate cancer. Cancer Immunol 
Immunother . 2017 Jul;66(7):891 -901.  
28. Brunsvig PF, Aamdal S, Gjertsen MK, et al.  Telomeras e peptide vaccination: a phase I/II 
study in patients with non -small cell lung cancer. Cancer Immunol Immunother . 
2006; 55(12): 1553 -1564. 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  100 of 113 22 Sep 2023 29. Kyte JA, Trachsel  S, Risberg  B, thor Straten  P, Lislerud  K, Gaudernack  G. 
Unconventional cytokine profiles and development of T cell memory in long -term 
survivors after cancer vaccina tion. Cancer Immunol Immunother . 
2009; 58(10): 1609 -1626 . 
30. Buchbinder EI, Desai A. CTLA -4 and PD -1 pathways: similarities, differences, and 
implications of their inhibition. Am J Clin Onc ol. 2016 Feb;39(1):98 -106. 
31. Wei SC , Levine JH,  Cogdill AP,  et al., Distinct cellular mechanisms underlie anti-CTLA -
4 and anti-PD-1 checkpoint blockade.  Cell. 2017; 170(6):1120 -1133 . 
32. Ellis S, Carroll KJ, Pemberton K. Analysis of duration of response in oncology trials. 
Contemp Clin  Trials . 2008;29(4): 456-465. 
33. Perez -Garcia A, Osca G, Bosch -Vizcaya A, et al. Kinetics of the CTLA -4 isoforms 
expression after T -lymphocyte activation and role of the promoter polymorphisms on  
CTLA -4 gene transcription. Hum Immunol . 2013;74(9):1219 -1224. 
34. Doyle  AM, Mullen AC, Villarino  AV, Hutchins  AS, High  FA, Lee HW, et al. Induction 
of cytotoxic T lymphocyte antigen 4 (CTLA -4) restricts clonal expansion of helper 
T cells. J Exp Med . 2001  Oct 1;194(7):893 –902. 
 
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  101 of 113 22 Sep 2023 Appendix  7 Single Arm UV1 Cohort  
Background  and Rationale  
Patients participating in the Extended Exploratory  cohort of the study  (Appendix  2) provide 
biological sample material including PBMCs and tumor tissue to answer the exploratory 
objectives of the INITIUM study. The material is used to test for immune response in blood and 
to characterize changes in the tumor and the tumor microenvironment. The PBMCs and tumor 
tissue from patients in the experimental arm of the extended exploratory cohort is needed  for 
these analyses, as this material is used to identify changes in the tumor a nd tumor environment 
that are unique for the vaccine responders.   
As an immunological response to the vaccine is not expected in all patients in the experimental 
arm of the extended exploratory cohort , and as all patients in this arm will not be able to p rovide 
a complete set of biological sample material, 20 additional patients will be enrolled in a single 
arm UV1 cohort  and provide additional biological material to support the extended exploratory 
cohort.  This will be done to secure that sufficient mater ial is available to identify anti -tumor 
activity unique for the vaccine responders and thereby to strengthen the support from the 
mechanistical data to the clinical outcome data derived from all patients in the study.  
Design and Methodology  
20 patients at selected sites will be included in a single arm UV1 cohort. The inclusion of 
patients in this cohort will start after the 154 patients have been enrolled in the 2-armed 
randomized part of the study. All patients in this single arm UV1 cohort will receive UV1 
vaccination in combination with nivolumab and ipilimumab.  
If not described otherwise in Appendix 7, the patients will follow the same treatment schedule, 
visits and procedures as in the experimental arm described elsewhere in this study p rotocol. In 
addition, all patients in the single arm UV1 cohort will perform the biological sampling and 
procedures as described for the Extended Exploratory Cohort ( Appendix  2). The patients  will 
have to sign a separate Informed Consent Form (ICF) to enroll in this part of the study.  
As in the randomized part of the study, t his single arm UV1 cohort will consist of 3 phases: 
Screening, Induction period  and a Follow -up period. The Follow -up period includes safety, 
response, and survival follow -up visits.  The Response Follow -up visits will be performed until 
iCPD per iRECIST or until the end of study (whichever comes first). The Survival Follow -visits 
will be performed every 12 weeks from iCPD per iRECIST until the end of study.  
Patients in the single arm UV1 cohort will not be randomized and will therefore not be included 
in the data used for analysis of primary and secondary endpoints.  
Planned Timelines  for the Single Arm UV1 Cohort:  
First patient in:      H1 2022 
Last patient in:       H1 2023 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  102 of 113 22 Sep 2023 End of study:        H1 2026 
The first patient in is defined as the timepoint  when the first patient is enrolled .  
The estimated  inclusion period is 9 mo nths.  All patients in the single arm UV1 cohort will be 
followed up until death or until the end of study (EOS), whichever comes first.  
Target Population  
Patients in the single arm UV1 cohort must meet all the inclusion criteria and none of the 
exclusion criteria  as described in Section s 5.1 and 5.2. Only s elected study  sites that have the 
necessary laboratory facilities to collect and handle the requested lab samples can take part in 
this cohort.  
After the patient has signed the ICF, the site will enter information into the IWRS  which will  
assign a unique screening num ber. Once assigned, a screening number cannot be re -used for any  
reason. After a screening period of up to 28  days, eligible patients will be enrolled in the study 
using IWRS.  Individuals who do not meet the criteria for enrollment (screen failures) may be 
re-screened once. Re -screened patients should be assigned a new screening number and 
re-consent.  
Discontinuation from the Single Arm UV1 Cohort  
Patients can withdraw their single arm UV1 cohort consent at any time without this affecting 
their care and treatment.  The patient can request all samples collected under this consent to be 
destroyed. Results from samples already analyzed will not be deleted.  
Sample Processing, Shippin g, and Storage  
The study sites will use the same laboratory manual and sampling kits as applicable for Extended 
Exploratory cohort . Details regarding sample collection, processing and storage conditions will 
be provided in the laboratory manual.  
Adverse Event Reporting  
The time periods for reporting of AEs and SAEs are outlined in Figure  4.  
In the single arm UV1 cohort a ll SAEs should be reported  from the first dose of induction 
therapy until the end of study or until new anticancer treatment is initiated (whichever comes 
first).   
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  103 of 113 22 Sep 2023 Appendix  8 Protocol Version Log  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  104 of 113 22 Sep 2023 Protocol version 5.0  
22 September  2023  Changes  
Substantial 
amendment: Yes  Amended the protocol to modify  the timing of reading the primary 
endpoint at 70 PFS events reached , to the earliest of either 70 PFS events 
reached or 18 months post last patient randomized.  
 
Updated sections:  
1 Synopsis  
4.1 Overall Design  
6.2.3 New Anticancer Treatment  
Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Activities – Control arm  
7.3.2 Response Follow -up Visits  
7.3.3 Survival Follow -up Visits  
7.6 End of Study  
8.2 Safety Plan and Assessments  
8.2.1 Independent  Data Monitoring Committee  
8.3.3 Adverse Event Reporting and Follow -up 
9 Statistical Methods  
 Amended the protocol to include updated information about the 
UV1/hTERT -MM-103 study (Ultimovacs is the sponsor)  
 
Updated sections:  
2.4 Clinical Data on UV1 Vaccination  
2.6 Rationale for Dose and Administration Regimen  
2.8 Benefit/Risk Assessment  
 Amended the protocol to include non -substantial amendment version 3.0, 
dated 14 December 2022: an amendment to ensure that the blinded 
independent central review (BICR) receives the required images needed 
for determination of progression per RECIST 1.1.  
 
Updated section:  
7.3.2 Response Follow -up Visits  
Protocol version  4.0 
21 January 2022  Changes  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  105 of 113 22 Sep 2023 Substantial 
amendment: Yes  Amended  the protocol to include non -substantial protocol amendment 
version 1.0, dated 24 February 2021 : a clarification of the measurements 
that are expected per protocol in the case of severe allergic reactions 
(Adverse Events of Special Interests).  
 
Updated sections:  
8.3.3.2  Follow -up 
 Amended  the protocol to include non -substantial protocol amendment 
version 2.0, dated 07 Sept ember 2021: a clarification of prohibited 
medications during the induction period and which measurements that are 
expected in the case of discontinuation of induction therapy.  
 
Updated sections:  
6.2.1 Prohibited Medications During Induction Period  
7.2.1 D iscontinuation of Induction Therapy  
 Amended the protocol to mitigate the risk of hepatotoxicity in the study.  
Updated sections:  
Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Activities – Control arm  
8.2.1 Independent Data Monitoring Committee  
 Amended the protocol to include the single arm UV1 cohort where 
20 patients will be enrolled for collection of additional biological material 
to support the Extended Exploratory Cohort of the study.  
 
Updated  section s: 
1 Synopsis  
2.7 Rationale for Study Design  
4.1 Overall Design  
4.2 Measures to Minimize Bias: Randomization and Blinding  
8.2.1 Independent Data Monitoring Committee  
Appendix  7 Single arm UV1 cohort  - NEW  
 Name of International Coordinating Investigator updated due to change  
 
Updated section:  
Page 2  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  106 of 113 22 Sep 2023  Updated planned timelines  
 
Updated sections:  
1 Synopsis  
4.1 Overall Design  
 Table numbers corrected  
 
Updated section:  
6.1.5 Administration of Study Drug  
Protocol version 3.0  
02 November  2020  Changes  
Substantial 
amendment: Yes  Amended the protocol to reflect that from the time of 70 PFS events 
reached across both treatment arms, patients will be followed for a further 
24 months for additional survival data ; further analyses of OS data will be 
performed  at 12 and 24 months to provide evidence supportive of PFS.  
 
Updated sections:  
1 Synopsis  
4.1 Overall Design  
6.2.3 New anticancer treatment  
Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Activities – Control arm  
7.2.1 Discontinuation of Induction Therapy  
7.3.2 Response Follow -up visits  
7.3.3 Survival Follow -up visits  
7.6 End of study  
8.2 Safety plan and assessments  
8.3.3 Adverse event reporting and follow -up 
9 Statistical methods  
 Signature for International Coordinati ng Investigator added  
 Amended planned number of patients in the extended exploratory cohort 
from N = 60 to N = approximately 40   
Updated sections:  
1 Synopsis  
4.1 Overall Design  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  107 of 113 22 Sep 2023 Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Activities – Control arm  
8.5 Extended exploratory cohort  
Appendix 1 Clinical Laboratory Tests  
Appendix 2 Extended exploratory cohort  
 Text updated to clarify that Adverse Events of Special Interest should be 
reported regardless of which treatment arm the patient is randomized to.  
 
Text revised to clarify that events falling under the AESI definition must 
occur on the same day as sargramostim, UV1, nivolumab or ipilimumab 
administration.  
Updated section:  
8.3.1.5 Definition of adverse event of special i nterest  
 Text revised to allow sites to use either plasma or serum for the 
biochemistry analyses and pregnancy test.  
 
Updated sections:  
1 Synopsis (Inclusion Criteria)  
5.1 Inclusion Criteria  
8.3.1.4 Potential Drug Induced Liver Injury (DILI)  
Appendix 1 C linical Laboratory Tests  
 Text updated to reflect the planned number of study sites in Europe and 
the United States  
Updated section:  
1 Synopsis  
4.1 Overall Design  
 Text updated to clarify that unused portions of reconstituted sargramostim 
should be discarded.  
Updated section:  
6.1.1 Sargramostim  
 Text updated to clarify the visit scenario if a decision to discontinue 
induction therapy is done between two scheduled study visits. 
Clarification made on when to discontinue UV1 vaccination.  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  108 of 113 22 Sep 2023 Updated sectio n: 
7.2.1 Discontinuation of induction therapy  
 Text updated to clarify the definition of the “end of study”  
Updated section:  
7.6 End of study  
 Text updated to clarify that a brief course of corticosteroids can be 
allowed even with doses >10 mg/day prednisone equivalents  
Updated section:  
1 Synopsis (Exclusion Criteria)  
5.2 Exclusion Criteria  
6.2.2 Permitted medications during induction period  
 Text updated to clarify what is defined as “completed treatment cycle”  
 
Updated section:  
8.2.1 I ndependent Data Monitoring Committee  
 Typing error corrected from “will be stratified” to “covariates”  
Updated section:  
9.4.2.2 Secondary efficacy analyses  
Protocol version 2.1  
20 February 2020  Changes  
Substantial 
amendment: No  Text revised to clarify that all SAEs should be reported until end of study 
or until new anticancer treatment is initiated (whichever comes first)  
 
Updated sections:  
1 Synopsis  
4.1 Overall Design  
7 Study Duration and Schedule of Activities:  
Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Activities – Control arm  
7.2.1 Discontinuation of Induction Therapy  
8.3.3.1 Reporting and Figure  3 
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  109 of 113 22 Sep 2023  Clarification of when a vasectomized pa rtner is an acceptable highly 
effective contraception method  
 
Updated sections:  
1 Synopsis ( Inclusion Criteria ) 
5.1 Inclusion Criteria  
 Typing error corrected from “iPD” to “iCPD”  
 
Updated section:  
7.3.3 Survival Follow -up Visits  
 Minor typing errors corrected  
 
Updated section:  
Appendix 7 Protocol Version Log  
Protocol version 2.0  
27 January 2020  Changes  
Substantial 
amendment: Yes  Amended safety data collection. Revised to include collection of all 
serious AESIs until the end of the study, in both treatment arms, and 
regardless of the investigator’s causality assessment  
Updated sections:  
1 Synopsis  
4.1 Overall design  
7 Study Duration and Schedule of Activities:  
Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Act ivities – Control arm  
7.2.1 Discontinuation of Induction Therapy  
8.3.1.5 Definition of Adverse Event of Special Interest  
8.3.3.1 Reporting and Figure  3 
Amended to accurately describe what is highly effective contraceptive 
methods  
Updated sections:  
1 Syno psis ( Inclusion Criteria ) 
5.1 Inclusion Criteria  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  110 of 113 22 Sep 2023 The IDMC meeting schedule has been amended with an additional third 
meeting and to allow for review of patients in both treatment arms. The 
primary responsibility of the IDMC has been more clearly described.  
Updated section:  
8.2.1 Independent Data Monitoring Committee  
Text revised to align with the wording used for BRAF/MEK inhibitors in 
section 5.2 exclusion criteria  
Updated section:  
1 Synopsis ( the exclusion criteria ) 
Text revised to clarify t hat Overall Survival will be analyzed at the end of 
the study, which is defined by having reached 70 PFS endpoints across 
both study arms.  
Updated sections:  
1 Synopsis  
9.5 Timing of Analyses (new section)  
Clarification that the UV1 vaccination will be permanently discontinued if 
nivolumab and/or ipilimumab is temporarily or permanently discontinued.  
Updated section:  
7.2.1 Discontinuation of Induction Therapy  
Text revised to clarify that patients who continue with survival follow -up 
visits will be cont acted per phone (or, at the Investigator’s discretion visit 
the hospital)  
Updated sections:  
1 Synopsis (study design and methodology)  
4.1 Overall design  
7 Study Duration and Schedule of Activities:  
Table 5 Schedule of Activities – Experimental arm  
Table 6 Schedule of Activities – Control arm  
7.3.3 Survival Follow -up visits  
Text revised to clarify the timing of the biopsy sampling at screening  
Updated sections:  
7 Study Duration and Schedule of Activities:  
Table 5 Schedule of Activities – Experimental arm  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  111 of 113 22 Sep 2023 Table 6 Schedule of Activities – Control arm  
Appendix 2, Tumor Tissue Specimen  
Text revised to reflect that the patient may continue with maintenance 
therapy if withdrawing the informed consent form  
Updated section:  
7.4 Withdrawal of Con sent  
Deleted collection of respiratory rate.  
Updated section:  
8.2.3 Vital Signs  
Clarification of what is considered a clinically significant laboratory 
abnormality.  
 
Updated sections:  
8.3.1.1 Definition of AE  
8.3.1.2 Events Not Meeting the AE Definition  
Deleted and revised Clinical Study Protocol signature/declaration pages to 
reflect the signature roles required  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  112 of 113 22 Sep 2023 Declaration of the National Coordinating Investigator  
Title: A Randomized Phase II, Open-label,  Active -controlled, Multicenter Study Investigating 
the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as 
First-line Treatment of Patients with Unresectable or Metastatic Melanoma  (UV1 -202) 
This study protocol was subjected to critical review and has been approved by the Sponsor . The 
information it contains is consistent with the current risk/benefit evaluation of the investigational 
product as well as with the moral, ethical, and scientific principles governing clinical research as 
set out in the Declaration of Helsinki, as amended in  October  2013  and the guidelines on Good 
Clinical Practice.  
National Coordinating Investigator  
 
_____________________________________  _____________________  
Signature  Date  
_____________________________________  
Name (block letters)  
_____________________________________  
Title (block letters)  
_____________________________________  
Institution (block lette rs) 
_____________________________________  
Phone number  
  
Ultimovacs   Clinical Study Protocol  
UV1 -202  CONFIDENTIAL  
Version 5.0 (FINAL)  113 of 113 22 Sep 2023 Declaration of the Principal Investigator  
Title: A Randomized Phase II, Open-label,  Active -controlled, Multicenter Study Investigating 
the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as 
First-line Treatment of Patients with Unresectable or Metastatic Melanoma  (UV1 -202) 
All documentation for this study that is supplied to me and that has not been previously 
published will be kept in the strictest confidence. This documentation includes this study 
protocol, Investigator's Brochure, electronic Case Report Form , and other sc ientific data.  
The study will not be commenced without the prior written approval of a properly constituted 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC). No changes will be 
made to the study protocol without the prior written appr oval of the Sponsor  and the IRB or IEC, 
except where necessary to eliminate a n immediate hazard to the participan ts. 
I have read , understood , and agree to abide by all the conditions and instructions contained in 
this protocol.  
Responsible Principal Invest igator  of the local study center  
 
_____________________________________  _____________________  
Signature  Date  
_____________________________________  
Name (block letters)  
_____________________________________  
Title (block letters)  
____________________________ _________  
Institution (block letters)  
_____________________________________  
Phone number  
 